<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1209234181
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ADENOCOR 6MG-2ML VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ADENOSINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        6
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        153.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="FAMAR (SANOFI AVENTIS) " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            FAMAR (SANOFI AVENTIS) 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2218]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Sanofi Arabia Trading Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AVENTIS PHARMA LIMITED
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C01EB10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Adenocor contains a medicine called adenosine. This belongs to a group of medicines called &#39;antiarrhythmics&#39;.<br />Adenocor works by slowing down electrical impulses between the upper and lower chambers of the heart. This slows the fast or uneven heartbeats called &#39;arrhythmias&#39;.<br />Adenocor is used:<br />&bull; During a test. This is to help doctors find out what type of arrhythmia (uneven heart beat) you have<br />&bull; To bring your heart beat back to normal if you have a type of arrhythmia called &lsquo;paroxysmal supraventricular tachycardia (SVT)&rsquo; or &lsquo;Wolff-Parkinson-White Syndrome&rsquo;<br />In children, Adenocor bolus is used:<br />&bull; To bring your child&rsquo;s heart beat back to normal if your child have a type of heart rhythm trouble called &lsquo;paroxysmal supraventricular tachycardia&rsquo; (PSVT)</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Contra-indications :<br />Do not have this medicine and tell your doctor if:</p><p>&bull; You are allergic (hypersensitive) to adenosine or any of the other ingredients of Adenocor (listed in section 6 below). Signs of an allergic reaction include: a rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue<br />&bull; You have asthma or any other severe breathing problem<br />&bull; You have very low blood pressure (severe hypotension)<br />&bull; You have a type of heart failure where your heart is not pumping out enough blood<br />&bull; You have problems with your heart rhythm and do not have a pace maker (second or third degree AtrioVentricular block, sick sinus syndrome)<br />&bull; You have been told you have &lsquo;Long QT syndrome&rsquo;. This is a rare heart problem that can lead to a fast heart beat and fainting<br />Do not have this medicine if any of the above apply to you. If you are not sure, talk to your doctor, nurse or pharmacist before you are given Adenocor.<br /><strong>Appropriate precautions for use ; Special warnings<br />Take special care with Adenocor</strong><br />Check with your doctor, nurse or pharmacist before you have Adenocor if:<br />&bull; You have a certain type of unusual heart rhythm (atrial fibrillation or atrial flutter) and in particular if you have an &lsquo;accessory conduction pathway&rsquo;<br />&bull; You have been told that you have a heart problem whereby the electrical impulses in parts of your heart take longer than normal to discharge and then recharge (prolonged QT interval)<br />&bull; You have low blood volume (hypovolaemia) that is not adequately corrected by treatment with medicines<br />&bull; You have problems with a part of your nervous system called the &lsquo;autonomic nervous system&rsquo;<br />&bull; You have narrowing of the main arteries in the neck (carotid artery). This means that not enough blood is getting to the brain (cerebrovascular insuficiency)<br />&bull; You have or have ever had fits or convulsions<br />&bull; You have difficulty in breathing (bronchospasm)<br />&bull; You have heart disease due to narrowing of your heart valves (stenotic valvular heart disease)<br />&bull; You have inflammation of the membrane surrounding your heart (pericarditis) or a build-up of fluid around your heart (pericardial effusion)<br />&bull; You have a left-right shunt in your heart. This will mean blood goes directly from the left side of your heart to the right side<br />&bull; You have narrowing of the left main artery supplying blood to your heart (left main coronary stenosis)<br />&bull; You have had a recent heart attack, severe heart failure or you have had a heart transplant in the last year<br />&bull; You have any minor problem with your heart (first degree AtrioVentricular block or bundle branch block). These conditions may be temporarily aggravated when you are given Adenocor<br />If you get a very slow heartbeat (severe bradycardia), respiratory failure, a heart problem that can be fatal (asystole), severe chest pains (angina) or very low blood pressure (severe hypotension), then treatment with Adenocor should be stopped.<br /><strong>If you are below 18 years of age</strong><br />In children with a heart rhythm trouble called &lsquo;Wolff-Parkinson-White (WPW) syndrome&rsquo;, Adenocor bolus may cause some unexpected severely abnormal heart rhythm.</p><p>If you are not sure if any of the above apply to you, talk to your doctor or nurse before being given Adenocor.<br /><strong>Taking or using other medicines</strong><br />Please tell your doctor, nurse or pharmacist if you are taking or have recently taken any other medicines. This includes medicines you buy without a prescription, including herbal medicines. This is because Adenocor can affect the way some other medicines work. Also some medicines can affect the way Adenocor works.<br />In particular, check with your doctor, nurse or pharmacist if you are taking any of the following:<br />&bull; Dipyridamole (medicine used to thin the blood). Make sure your doctor knows you are taking dipyridamole. Your doctor may decide you should not have Adenocor or may tell you to stop taking dipyridamole 24 hours before you are given Adenocor or may need to give you a lower dose of Adenocor<br />&bull; Aminophylline or theophylline (medicines used to help breathing) Your doctor may tell you to stop taking it 24 hours before you are given Adenocor<br />&bull; Caffeine (sometimes found in headache medicines)<br /><strong>Taking Adenocor with food and drink</strong><br />Food and drinks containing caffeine such as tea, coffee, chocolate and cola should be avoided for at least 12 hours before you are given Adenocor.<br /><strong>Pregnancy and breast-feeding</strong><br />Talk to your doctor or nurse before having this medicine if:<br />&bull; You are pregnant, might become pregnant, or think that you may be pregnant. You should not be given Adenocor if you are pregnant or think you may be pregnant, unless clearly necessary<br />&bull; You are breast-feeding. You should not be given Adenocor if you are breast-feeding<br />Ask you doctor or nurse for advice before taking any medicine if you are pregnant or breast-feeding.<br /><strong>Important information about some of the ingredients of Adenocor<br />Sodium</strong>: Adenocor injection contains 3.54 mg sodium per dose (7.08 mg/2 ml vial).<br />This should be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How Adenocor is given</strong><br />&bull; Adenocor is a medicine for use in hospitals<br />&bull; It will be given to you by a doctor or nurse as an injection into your vein<br />&bull; Your heart and blood pressure will be closely monitored<br /><strong>How much Adenocor is given</strong><br />If you are not sure why you are being given Adenocor or have any questions about how much Adenocor is being given to you, speak to your doctor, nurse or pharmacist.<br /><strong>Adults (including the elderly)</strong><br />&bull; The first dose is 3mg given over 2 seconds. This is given by rapid injection into your vein</p><p>&bull; If the first dose does not bring your heart beat to normal then you will be given a second dose. The second dose is 6 mg given as a rapid injection<br />&bull; If the second dose does not bring your heart beat to normal then you will be given a third dose: The third dose is 12mg given as a rapid injection<br />&bull; You should not have any more doses after the 12mg dose<br /><strong>Infants and Children</strong><br />Adenocor bolus is a medicine for use in hospitals with resuscitation equipment available<br />Your doctor will decide if this medicine is needed, how much should be given depending on your child&rsquo;s weight, and if several injections are needed.<br />&bull; Your child will be closely monitored, including recording of his/her heart&rsquo;s electrical activity using an ECG (electrocardiogram) machine<br />&bull; It will be given as an injection into your child vein by a doctor or nurse<br /><strong>If you have more Adenocor than you should</strong><br />As this medicine is given to you by a doctor or nurse it is unlikely that you will be given too much. Your doctor will carefully work out how much Adenocor you should be given.<br />If you have more of this medicine than you should, the following effects may happen:<br />&bull; Very low blood pressure (severe hypotension)<br />&bull; Slow heartbeat (bradycardia)<br />&bull; A heart problem (asystole)<br />Your doctor will be monitoring your heart throughout the procedure.<br />As the length of time adenosine stays in the blood is very short, any side effects of too much Adenocor would quickly stop when the injection is stopped. Sometimes you may need an injection of a medicine called aminophylline or theophylline to help with any side effects.<br />If you have any further questions on the use of this medicine, ask your doctor, nurse or pharmacist</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Adenocor can cause side effects, although not everybody gets them. While you are being given Adenocor you may have some of the following side effects:<br /><strong>If any of the following side effects get worse, tell your doctor or nurse and they may stop the injection:</strong><br />The side effects normally settle within seconds or minutes after the injection is finished but you should tell your doctor or nurse if any of them happen.<br /><strong>Very common (affects more than 1 person in 10)</strong><br />&bull; Reddening of skin with a feeling of heat (flushing)<br />&bull; Slow heartbeat (bradycardia)<br />&bull; Skipped heart beats or extra heartbeats<br />&bull; A heart problem called an AV block<br />&bull; Severe heart problems which can be fatal (asystole) or uneven heartbeat<br />&bull; Shortness of breath or the urge to breathe deeply (dyspnoea)<br />&bull; Chest pain or pressure on the chest<br /><strong>Common (affects less than 1 person in 10)</strong><br />&bull; Feeling dizzy or light-headed</p><p>&bull; Feeling sick (nausea)<br />&bull; Headache<br />&bull; Unusual skin sensations such as burning<br />&bull; Feeling nervous<br /><strong>Uncommon (affects less than 1 person in 100)</strong><br />&bull; Blurred vision<br />&bull; Being aware of your heartbeat or feeling it &lsquo;racing&rsquo;<br />&bull; Metallic taste in your mouth<br />&bull; Breathing more quickly or more deeply than normal (hyperventilation)<br />&bull; Feeling pressure in your head, or weighed down in your arms<br />&bull; Feeling of general discomfort, weakness or pain<br />&bull; Sweating<br /><strong>Very rare (affects less than 1 person in 10 000)</strong><br />&bull; Severe breathlessness or problems in breathing<br />&bull; Redness, pain or swelling at the site of injection<br />&bull; Feeling uncomfortable during the injection<br />&bull; Worsening of high blood pressure that affects the brain (intracranial hypertension)<br />&bull; Very slow, fast or uneven heartbeats<br />&bull; Severe bradycardia (very slow heartbeat)<br /><strong>Other side effects</strong><br />&bull; Fainting<br />&bull; Fits (convulsions)<br />&bull; Being sick (vomiting)<br />&bull; Stopping breathing (respiratory arrest)<br />If any of the above side effects get worse, tell your doctor or nurse and they may stop the injection. The side effects normally settle within seconds or minutes after the injection is finished but you should tell your doctor or nurse if any of them happen.</p><p><br /><strong>To report any side effect(s):<br />&bull; Saudi Arabia:</strong><br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Sanofi- Pharmacovigilance: KSA_Pharmacovigilance@sanofi.com</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>KEEP THIS MEDICINE OUT OF THE SIGHT AND REACH OF CHILDREN<br />This medicine will be kept by your doctor, nurse or pharmacist in a safe place where children cannot see or reach it.</p><p>Adenocor should not be used after the expiry date which is stated on the carton and on the label. The expiry date refers to the last day of that month.<br />Adenocor should not be refrigerated.<br />Store below 30&deg;C. Do not refrigerate.<br />The product is for single use only and should be used straight away after opening. Any portion of the vial not used at once should be disposed of.<br />Adenocor should not be used if your doctor or nurse notice any particles in the solution or any discolouration before they give you the medicine. If the appearance of the medicine has changed, the vial must be thrown away.<br />Medicines should not be disposed of via wastewater or household waste. The pharmacist will dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substance is adenosine. Each 2ml vial of Adenocor contains 6mg of adenosine (3 mg per ml).<br />&bull; The other ingredients are sodium chloride and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Adenocor is a clear, colourless solution for injection.
Each pack contains 6 vials.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong><br />Aventis Pharma Limited<br />One Onslow Street<br />Guildford<br />Surrey<br />GU1 4YS<br />UK</p><p><br /><strong>Manufacturer:</strong><br />FAMAR HEALTH CARE SERVICES MADRID, S.A.U. Avda. Legan&eacute;s,62<br />28923 Alcorc&oacute;n (Madrid) Spain</p><p><br /><strong>Secondary packaging:</strong><br />Sanofi Aventis Arabia Co. Ltd, Industrial Valley Phase 1A St. KAEC,, King Abdullah Economic City, KAEC - Rabigh, 21423, Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                09/2013
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>یحتوي أدینوكور على دواء یسُمّى أدینوزین ینتمي إلى مجموعة من الأدویة تسُمّى &quot;مضادات اللانظمیةّ&quot;.<br />یبُطئّ أدینوكور الدفعات الكھربائیةّ بین الحجرتین العلویةّ والسفلیةّ للقلب ممّا یبطئّ ضربات القلب<br />السریعة أو غیر المنتظمة المسمّاة &quot;اللانظمیاّت&quot;.<br />یسُتعمل أدینوكور:<br />&bull; في خلال فحص لمساعدة الأطبّاء على معرفة من أيّ نوع من اللانظمیّة (عدم انتظام<br />دقاّت القلب) تعاني.<br />&bull; لإعادة ضربات قلبك إلى طبیعتھا إذا كنت تعاني من لانظمیةّ تسُمّى &quot;تسرّع القلب<br />الانتیابي فوق البطُیني&quot; أو &quot;متلازمة وولف باركنسون وایت&quot;.</p><p>لدى الأطفال، یعُطى أدینوكور بجرعة كبیرة واحدة (أدینوكور بولوس):<br />&bull; لإعادة ضربات قلب طفلك إلى طبیعتھا إذا كان طفلك یعاني من نوع من اضطراب نظم<br />القلب یسُمّى &quot;تسرّع القلب الانتیابي فوق البطُیني&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>موانع الاستعمال:<br />لا تأخذ ھذا الدواء وأعلم طبیبك في الحالات التالیة:<br />&bull; إذ ا كنت تعان ي م ن حساسیّ ة (فرط حساسیّة) ضدّ الأدینوزین أو أيّ مركّب آخر من<br />مركّبات أدینوكور (مذكورة في القسم 6 أدناه).<br />تتضمّن علامات الارتكاس التحسّسي ما یلي: طفح، مشاكل في البلع أو التنفسّ، تورّم<br />الشفتین أو الوجھ أو الحلق أو اللسان.<br />&bull; إذا كنت تعاني من الربو أو من مشكلة حادة أخرى في التنفسّ.<br />&bull; إذا كنت تعاني من انخفاض كبیر في ضغط الدم (نقص الضغط الحاد).<br />&bull; إذا كنت تعاني من نوع من قصور القلب لا یضخّ فیھ قلبك كمیةّ كافیة من الدم.<br />&bull; إذا كنت تعاني من مشاكل في نظم القلب ولیس لدیك ناظمة (الحصر الأذُیني البطُیني من<br />الدرجة الثانیة أو الثالثة، متلازمة العقدة الجیبیةّ المریضة).<br />&bull; إذا قیل لك إنكّ تعاني من &quot;متلازمة طول فارق كیو تي&quot;. وھذه مشكلة نادرة في القلب<br />یمكن أن تؤدّي إلى تسارع دقاّت القلب وإلى الإغماء.<br />لا تأخذ ھذا الدواء إذا كانت تنطبق علیك إحدى الحالات أعلاه. في حال لم تكن واثقا،ً تحدّث إلى الطبیب<br />أو الممرّضة أو الصیدلي قبل أن تتلقىّ أدینوكور.<br />محاذیر مناسبة للاستعمال؛ تحذیرات خاصة<br />إعتمد عنایة خاصة مع أدینوكور<br />إسأل الطبیب أو الممرّضة أو الصیدليّ قبل أن تتلقىّ أدینوكور في الحالات التالیة:<br />&bull; إذا كنت تعاني من نوع معینّ من النظم القلبي غیر العادي (رجفان أذیني أو رفرفة أذینیةّ)<br />وبصورة خاصة إذا كنت تعاني من &quot;مسار توصیلي لاحق&quot;.<br />&bull; إذا قیل لك إنكّ تعاني من مشكلة قلبیةّ تأخذ فیھا النبضات الكھربائیةّ في أقسام من قلبك<br />وقتاً أطول من العادة للتفریغ وإعادة الشحن (فارق كیو تي المطوّل).<br />&bull; إذا كنت تعاني من انخفاض حجم الدم (نقص حجم الدم) غیر المصحّح بالأدویة بشكل<br />مناسب.<br />&bull; إذ ا كن ت تعان ي م ن مشاك ل ف ي قس م م ن جھاز ك العصب ي یُسمّ ى &quot;الجھا ز العصبي<br />المستقلّ&quot;.<br />&bull; إذا كنت تعاني من تضیّق في الشرایین الرئیسیةّ في العنق (الشریان السباتي). ھذا یعني<br />أنّ كمیةّ الدم التي تصل إلى الدماغ غیر كافیة (القصور المخّي الوعائي).<br />&bull; إذا كنت تعاني أو عانیت في السابق من نوبات أو اختلاجات.<br />&bull; إذا كنت تعاني من صعوبة في التنفسّ (التشنجّ القصبي).<br />&bull; إذا كنت تعاني من مرضفي القلب بسبب تضیقّ صمّامات القلب (مرض القلب الصمامي<br />التضیقّي)</p><p>&bull; إذا كنت تعاني من التھاب الغشاء المحیط بقلبك (التھاب التأمور) أو من تراكم السوائل<br />حول قلبك (انصباب التأمور).<br />&bull; إذا كنت تعاني من تحویلة بین الیسار والیمین، ھذا یعني أنّ الدم یذھب مباشرة من الجھة<br />الیسُرى من قلبك إلى الجھة الیمُنى.<br />&bull; إذا كنت تعاني من تضیقّ في الشریان الرئیسي الأیسر في قلبك (تضیقّ الشریان التاجي<br />الرئیسي الأیسر).<br />&bull; إذا أصُبت مؤخّرًا بنوبة قلبیةّ أو بقصور قلبيّ حاد أو إذا خضعت لعملیةّ زرع قلب في<br />العام الماضي.<br />&bull; إذا كنت تعاني من مشكلة بسیطة في قلبك (الحصر الأذُیني البطُیني من الدرجة الأولى أو<br />حصر حُزیمي). یمكن أن تتفاقم ھاتان الحالتان مؤقتّاً عندما تتلقىّ أدینوكور.<br />إذا أصبحت ضربات قلبك بطیئة جدًا (بطء القلب الشدید) أو أصُبت بقصور تنفسّي أو بمشكلة قلبیةّ یمكن<br />أن تكون قاتلة (استرخاء القلب)، یجب عندئذٍ إیقاف العلاج بأدینوكور.<br />إذا كنت ما دون الثامنة عشرة من العمر<br />لدى الأطفال الذین یعانون من اضطراب في نظم القلب یسُمّى &quot; متلازمة وولف باركنسون وایت&quot;. قد<br />یسببّ إعطاء أدینوكور بجرعة كبیرة واحدة (أدینوكور بولوس) عدم انتظام حاد في نظم القلب بشكل غیر<br />متوقعّ.<br />إذا لم تكن واثقاً مما كانت إحدى الحالات أعلاه تنطبق علیك، تحدّث إلى الطبیب أو الممرّضة قبل إعطائك<br />أدینوكور.<br />أخذ أو استعمال أدویة أخرى<br />الرجاء أن تعُلم الطبیب أو الممرّضة أو الصیدلي إذا كنت تأخذ حالیاّ أو أخذت مؤخّرا أيّ أدویة أخرى،<br />وتتضمّن ھذه الأدویة تلك التي تشتریھا بدون وصفة بما في ذلك الأدویة العشبیةّ، لأنّ أدینوكور یمكن أن<br />یؤثرّ على كیفیةّ عمل بعض الأدویة كما أن بعض الأدویة یمكن أن یؤثرّ على كیفیةّ عمل أدینوكور.<br />بصورة خاصة، إسأل الطبیب أو الممرّضة أو الصیدلي إذا كنت تأخذ أیاّ من الأدویة التالیة:<br />&bull; دیبیریدامول (دواء یسُتعمل لترقیق الدم). إحرص على إعلام طبیبك أنكّ تأخذ<br />دیبیریدامول فقد یقرّر إیقاف علاجك بأدینوكور أو قد یطلب منك التوقفّ عن أخذ<br />دیبیریدامول قبل 24 ساعة من إعطائك أدینوكور أو قد یخفضّ لك جرعة أدینوكور.<br />&bull; أمینوفیلین أو ثیوفیلین (دواءان یسُتعملان للمساعدة على التنفسّ). قد یطلب منك التوقفّ<br />عن أخذه قبل 24 ساعة من إعطائك أدینوكور.<br />&bull; كافیین (تحتوي علیھ أحیانا أدویة الصداع).<br />أخذ أدینوكور مع الطعام والشراب<br />یجب تفادي الأطعمة والمشروبات التي تحتوي على الكافیین مثل الشاي والقھوة والشوكولا والكولا لمدّة<br />12 ساعة على الأقلّ قبل تلقیّك أدینوكور.<br />الحمل والإرضاع<br />استشیري الطبیب أو الممرّضة قبل تلقیّك ھذا الدواء في الحالتین التالیتین:<br />&bull; إذا كنتِ حاملا أو قد تصبحین حاملا أو تعتقدین نفسكِ حاملا.ً یجب عدم إعطائكِ<br />أدینوكور إذا كنتِ حاملا أو تعتقدین نفسكِ حاملا إلا في حال الضرورة القصوى.</p><p>&bull; إذا كنتِ ترُضعین. یجب عدم إعطائكِ أدینوكور إذا كنتِ ترُضعین.<br />استشیري الطبیب أو الممرّضة قبل تناول أيّ دواء إذا كنتِ حاملا أو مرضعة .ً<br />معلومات مھمّة حول بعض مركّبات أدینوكور<br />الصودیوم: تحتوي حقنة أدینوكور على 3.54 ملغ من الصودیوم في الجرعة الواحدة (قارورة 7.08<br />ملغ/ 2 مل). یجب أخذ ھذه الكمیةّ بعین الاعتبار لدى المرضى الذین یتبعون حمیةّ صودیوم مراقبة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>كیف یعُطى أدینوكور</strong><br />&bull; أدینوكور دواء للاستعمال في المستشفیات<br />&bull; سیعُطیك إیاّه الطبیب أو الممرّضة كحقنة في الورید.<br />&bull; سیرُاقبَ قلبك وضغط دمك مراقبة دقیقة.<br /><strong>كمیةّ أدینوكور المعطاة</strong><br />إذا لم تكن واثقا لماذا تعُطى أدینوكور، أو إذا كان لدیك أسئلة حول كمیةّ أدینوكور التي تعُطى لك، إسأل<br />الطبیب أو الممرّضة أو الصیدلي.<br />البالغون (بمن فیھم المسنوّن)<br />&bull; تبلغ الجرعة الأولى 3 ملغ تعُطى على ثانیتین بالحقن السریع داخل ورید.<br />&bull; إذا لم تعد دقاّت قلبك إلى طبیعتھا من الجرعة الأولى، سوف تعُطى جرعة ثانیة. تبلغ<br />الجرعة الثانیة 6 ملغ وتعُطى كحقنة سریعة.<br />&bull; إذا لم تعد دقاّت قلبك إلى طبیعتھا مع الجرعة الثانیة، سوف تعُطى جرعة ثالثة. تبلغ<br />الجرعة الثالثة 12 ملغ وتعُطى كحقنة سریعة.<br />&bull; لا یجدر بك تلقيّ جرعات إضافیةّ بعد جرعة ال 12 ملغ.<br /><strong>الأطفال الرضّع والأطفال</strong><br />أدینوكور بولوس ھو دواء للاستعمال في المستشفیات مع أجھزة الإنعاش المتاحة. سوف یقرّر طبیبك إذا<br />كان ثمّة حاجة إلى ھذا الدواء والكمیةّ التي یجب إعطاؤھا حسب وزن طفلك وما إذا كان من الضروري<br />إجراء عدّة حقنات.<br />&bull; سوف تتمّ مراقبة طفلك عن كثب، بما في ذلك تسجیل نشاط قلبھ بواسطة آلة تخطیط القلب<br />الكھربائي.<br />&bull; سوف یحقن طبیب أو ممرّضة الدواء في ورید طفلك.<br />إذا أخذت كمیةّ من أدینوكور أكبر من التي یجدر بك تلقیّھا<br />بما أنّ ھذا الدواء یعطیك إیاّه الطبیب أو الممرّضة، من غیر المحتمل أن تعُطى كمیةّ أكبر من التي یجب<br />أن تتلقاّھا. سوف یحدّد طبیبك بعنایة كمیةّ أدینوكور التي یجب أن تعُطى لك.<br /><strong>إذا تلقیت كمیةّ من ھذا الدواء أكبر مما یجب، قد تحصل التأثیرات التالیة:</strong><br />&bull; انخفاض كبیر في ضغط الدم (نقص ضغط الدم)</p><p>&bull; بطء ضربات القلب (بطء القلب)<br />&bull; مشكلة في القلب (استرخاء القلب)<br />سوف یراقب طبیبك قلبك في خلال الإجراء.<br />بما أنّ الأدینوزین یبقى في الدم لوقت قصیر جدًا، تتوقفّ أيّ تأثیرات ناتجة عن تلقيّ كمیةّ كبیرة من<br />أدینوكور بسرعة عند توقفّ الحقن. قد تحتاج أحیاناً إلى حقنة من دواء یسُمّى أمینوفیلین أو ثیوفیلین<br />للمساعدة على مواجھة أي تأثیرات جانبیةّ.<br />إذا كان لدیك أيّ أسئلة إضافیةّ حول استعمال ھذا الدواء، اطرحھا على الطبیب أو الممرّضة أو الصیدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل الأدویة كلھّا، یمكن أن یسببّ أدینوكور تأثیرات جانبیةّ لا تصیب المرضى كلھّم. في خلال فترة<br />العلاج بأدینوكور، یمكن أن تصُاب ببعض التأثیرات الجانبیةّ التالیة:<br />في حال تفاقم أحد التأثیرات الجانبیةّ التالیة، أعلم الطبیب أو الممرّضة وقد یوقفان الحقن:<br />عادة ما تزول التأثیرات الجانبیةّ في غضون ثوان أو دقائق بعد الانتھاء من الحقن ولكن یجب أن تعُلم<br />الطبیب أو الممرّضة في حال تعرّضك لأيّ تأثیر جانبيّ.<br />التأثیرات الجانبیةّ الشائعة جدا (تصُیب أكثر من شخص من أصل 10 أشخاص)<br />&bull; إحمرار البشرة مع شعور بالحرّ (تورّد)<br />&bull; تباطؤ في دقاّت القلب (بطء القلب)<br />&bull; تفویت دقاّت قلب أو دقاّت قلب مفرطة<br />&bull; مشكلة في القلب تسُمّى الحصر الأذیني البطُیني<br />&bull; مشاكل حادة في القلب یمكن أن تكون قاتلة (استرخاء القلب) أو عدم انتظام في دقاّت<br />القلب<br />&bull; ضیق نفس أو الحاجة إلى التنفسّ عمیقا (عسر التنفسّ)<br />&bull; ألم في الصدر أو ضغط على الصدر<br />التأثیرات الجانبیةّ الشائعة (تصُیب أقلّ من شخص من أصل 10 أشخاص)<br />&bull; الشعور بالدوار أو بالدوخة<br />&bull; الشعور بالغثیان<br />&bull; صداع<br />&bull; أحاسیس غیر طبیعیةّ في الجلد مثل الحرق<br />&bull; توترّ<br />التأثیرات الجانبیةّ غیر الشائعة (تصُیب أقلّ من شخص من أصل 100 شخص)<br />&bull; غشیان في البصر<br />&bull; الشعور بدقاّت القلب أو الشعور وكأنھّا &quot;تتسابق&quot;</p><p>&bull; طعم معدني في الفم<br />&bull; التنفسّ بسرعة أكبر أو بعمق أكثر من العادة (فرط تھوئة)<br />&bull; الشعور بضغط في الرأس أو بثقل في الذراعین<br />&bull; شعور بتوعّك عام أو بضعف أو بألم<br />&bull; تعرّق<br />التأثیرات الجانبیةّ النادرة جدا (تصُیب أقلّ من شخص واحد من أصل 10000 شخص)<br />&bull; عسر حاد في التنفسّ أو مشاكل في التنفسّ<br />&bull; احمرار أو ألم أو تورّم في موقع الحقن<br />&bull; الشعور بعدم الراحة في خلال الحقن<br />&bull; تفاقم ضغط الدم المرتفع الذي یصُیب الدماغ (فرط ضغط الدم داخل الجمجمة)<br />&bull; دقاّت قلب بطیئة جدا أو غیر منتظمة<br />&bull; بطء حاد في القلب (دقاّت قلب بطیئة جدا)ً<br />تأثیرات جانبیةّ أخرى<br />&bull; إغماء<br />&bull; نوبات (اختلاجات)<br />&bull; تقیؤّ<br />&bull; توقفّ التنفسّ (سكتة تنفسیةّ)<br />في حال تفاقم أحد التأثیرات الجانبیةّ أعلاه، أعلم الطبیب أو الممرّضة وقد یوقفان الحقن. عادة ما تزول<br />التأثیرات الجانبیةّ في غضون ثوان أو دقائق بعد الانتھاء من الحقن ولكن یجب أن تعُلم الطبیب أو<br />الممرّضة في حال تعرّضك لأيّ تأثیر جانبيّ.<br />الإبلاغ عن التأثیرات الجانبیةّ<br />إذا أصبت بأيّ تأثیرات جانبیةّ، أعلم الطبیب أو الصیدليّ أو الممرّضة وھذا ینطبق على أيّ تأثیرات<br />جانبیةّ محتملة غیر مذكورة في ھذه النشرة.<br />بالإبلاغ عن التأثیرات الجانب یةّ، یمكنك المساعدة على تزوید المزید من المعلومات حول سلامة ھذا الدواء.<br />للإبلاغ عن الأعراضالجانبیة<br /><strong>&bull; المملكة العربیة السعودیة</strong><br />المركز الوطني للتیقظ والسلامة الدوائیة:<br />فاكس : ۰۰۹٦٦۱۱۲۰٥۷٦٦۲<br />الھاتف المجاني : ۸۰۰۲٤۹۰۰۰۰<br />الإلكتروني البرید : npc.drug@sfda.gov.sa<br />الإلكتروني الموقع : www.sfda.gov.sa/npc<br />سانوفي-التیقظ الدوائي : KSA_Pharmacovigilance@sanofi.com</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یحُفظ ھذا الدواء بعیدًا عن نظر الأطفال ومتناولھم.<br />یحفظ ھذا الدواء الطبیب أو الممرّضة أو الصیدلي في مكان آمن حیث لا یستطیع الأطفال رؤیتھ أو<br />الوصول إلیھ.<br />یجب عدم استعمال أدینوكور بعد انقضاء تاریخ الصلاحیةّ المدوّن على علبة الكرتون وعلى اللصاقة.<br />یشیر تاریخ انتھاء الصلاحیةّ إلى الیوم الأخیر من الشھر المذكور.<br />لا یحُفظ أدینوكور في البرّاد.<br />یحُفظ أدینوكور في درجة حرارة ما دون 25 درجة مئویةّ.<br />ھذا الدواء ھو لاستعمال واحد فقط ویجب استعمالھ بعد فتحھ مباشرة. یجب رمي أيّ كمیةّ من القارورة لم<br />یتمّ استعمالھا على الفور.<br />یجب عدم استعمال أدینوكور إذا لاحظ الطبیب أو الممرّضة أيّ جُسیمات في المحلول أو أيّ تغییر في<br />اللون قبل إعطائك الدواء. إذا تغیرّ شكل الدواء یجب رمي القارورة.<br />یجب عدم رمي الأدویة في میاه الصرف الصحي أو مع النفایات المنزلیةّ. الصیدليّ ھو من یتخلصّ من<br />الأدویة التي لا یعود ثمّة حاجة إلیھا. من شأن ھذه الإجراءات حمایة البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ما ھي محتویات أدینوكور<br />&bull; المادة الفاعلة ھي أدینوزین. تحتوي كلّ قارورة 2 مل من أدینوكور على 6 ملغ من<br />الأدینوزین ( 3 ملغ في الملیلتر).<br />&bull; المحتویان الآخران ھما كلورید الصودیوم وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">كیف ھو شكل أدینوكور ومحتویات العلبة<br />أدینوكور ھو محلول صاف عدیم اللون للحقن.<br />تحتوي كلّ علبة على 6 قواریر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>الشركة الحاملة رخصة التسویق</strong><br />Aventis Pharma Limited<br />One Onslow Street<br />Guildford<br />Surrey<br />GU1 4YS<br />UK</p><p><strong>الشركة المصنعّة</strong><br />FAMAR HEALTH CARE SERVICES MADRID, S.A.U. Avda. Legan&eacute;s,62<br />28923 Alcorc&oacute;n (Madrid) Spain</p><p><strong>التغلیف الثانوي</strong><br />Sanofi Aventis Arabia Co. Ltd, Industrial Valley Phase 1A St. KAEC,, King Abdullah Economic City, KAEC - Rabigh, 21423, Saudi Arabia.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             09 / 2013
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ADENOCOR 6MG-2ML VIAL
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 6mg of adenosine per 2ml (3mg/ml).
For excipients, see 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection
Clear, colourless solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory by-pass tracts (Wolff-Parkinson-White Syndrome). Paediatric population<br />Rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardia in children aged 0 to 18 years. Diagnostic Indications<br />Aid to diagnosis of broad or narrow complex supraventricular tachycardias. Although Adenocor will not convert atrial flutter, atrial fibrillation or ventricular tachycardia to sinus rhythm, the slowing of AV conduction helps diagnosis of atrial activity.<br />Sensitisation of intra-cavitary electrophysiological investigations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adenocor is intended for hospital use only with monitoring and cardiorespiratory resuscitation equipment available for immediate use. Method of administration<br />It should be administered by rapid IV bolus injection according to the ascending dosage schedule below. To be certain the solution reaches the systemic circulation administer either directly into a vein or into an IV line. If given into an IV line it should be injected as proximally as possible, and followed by a rapid saline flush.<br />Adenocor should only be used when facilities exist for cardiac monitoring. Patients who develop high-level AV block at a particular dose should not be given further dosage increments. Posology Adult:<br />Initial dose:<br />3mg given as a rapid intravenous bolus (over 2 seconds).<br />Second dose:<br />If the first dose does not result in elimination of the supraventricular tachycardia within 1 to 2 minutes, 6mg should be given also as a rapid intravenous bolus.<br />Third dose:<br />If the second dose does not result in elimination of the supraventricular tachycardia within 1 to 2 minutes. 12mg should be given also as a rapid intravenous bolus.<br />Additional or higher doses are not recommended. Paediatric population<br />During administration of adenosine cardio-respiratory resuscitation equipment must be available for immediate use if necessary.<br />Adenosine is intended for use with continuous monitoring and ECG recording during administration.<br />The dosing recommended for the treatment of paroxysmal supraventricular tachycardia in the paediatric population is:<br />- first bolus of 0.1 mg/kg body weight (maximum dose of 6mg)<br />- increments of 0.1 mg/kg body weight as needed to achieve termination of supraventricular tachycardia (maximum dose of 12mg). Method of administration<br />Adenosine should be administered by rapid intravenous (IV) bolus injection into a vein or into an IV line. If given into an IV line it should be injected through as proximally as possible, and followed by a rapid saline flush. If administered through a peripheral vein, a large bore cannula should be used. Elderly<br />See dosage recommendations for adults.</p><p><strong>Diagnostic dose</strong></p><p>The above ascending dosage schedule should be employed until sufficient diagnostic information has been obtained.<br />Method of administration: Rapid intravenous injection only.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Adenocor is contraindicated for patients presenting:
- Known hypersensitivity to adenosine or to any of the excipients.
- Sick sinus syndrome, second or third degree Atrio-Ventricular (AV) block (except in patients with a functioning artificial pacemaker).
- Chronic obstructive lung disease with evidence of bronchospasm (e.g. asthma bronchiale)
- Long QT syndrome
- Severe hypotension
- Decompensated states of heart failure
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Special warnings: Due to the possibility of transient cardiac arrhythmias arising during conversion of the supraventricular tachycardia to normal sinus rhythm, administration should be carried out in a hospital setting with monitoring and cardio-respiratory resuscitation equipment available for immediate use if necessary. During administration, continuous ECG monitoring is necessary as life-threatening arrhythmia might occur. (section 4.2).<br />Because it has the potential to cause significant hypotension, adenosine should be used with caution in patients with left main coronary stenosis, uncorrected hypovolemia, stenotic valvular heart disease, left to right shunt, pericarditis or pericardial effusion, autonomic dysfunction or stenotic carotid artery disease with cerebrovascular insufficiency.<br />Adenosine should be used with caution in patients with recent myocardial infarction, severe heart failure, or in patients with minor conduction defects (first degree A-V block, bundle branch block) that could be transiently aggravated during infusion.<br />Adenosine should be used with caution in patients with atrial fibrillation or flutter and especially in those with an accessory by-pass tract since particularly the latter may develop increased conduction down the anomalous pathway.<br />Rare cases of severe bradycardia have been reported. Some occurred in early post heart transplant patients; in the other cases, occult sino-atrial disease was present. The occurrence of severe bradycardia should be taken as a warning of underlying disease and could potentially favour the occurrence of torsades de pointes, especially in patients with prolonged QT intervals.<br />In patients with recent heart transplantation (less than 1 year) an increased sensitivity of the heart to adenosine has been observed.<br />Since neither the kidney nor the liver are involved in the degradation of exogenous adenosine, Adenocor&#39;s efficacy should be unaffected by hepatic or renal insufficiency.<br />As dipyridamole is a known inhibitor of adenosine uptake, it may potentiate the action of Adenocor. It is therefore suggested that Adenocor should not be administered to patients receiving dipyridamole; if use of Adenocor is essential, dipyridamole should be stopped 24 hours before hand, or the dose of Adenocor should be greatly reduced. (see Section 4.5 Interactions with other Medicaments and other forms of Interaction).<br />Precautions:<br />The occurrence of angina, severe bradycardia, severe hypotension, respiratory failure (potentially fatal), or asystole/cardiac arrest (potentially fatal), should lead to immediate discontinuation of administration.<br />Adenosine may trigger convulsions in patients who are susceptible to convulsions. In patients with history of convulsions/seizures, the administration of adenosine should be carefully monitored.<br />Because of the possible risk of torsades de pointes, Adenocor should be used with caution in patients with a prolonged QT interval, whether this is drug induced or of metabolic origin. Adenocor is contraindicated in patients with Long QT syndrome (see section 4.3).<br />Adenosine may precipitate or aggravate bronchospasm (see sections 4.3 and 4.8).<br />Adenosine contains 9 mg sodium chloride per ml. (corresponding to 3.54 mg sodium per ml). To be taken into consideration by patients on a controlled sodium diet. Paediatric population<br />Adenosine may trigger atrial arrhythmias and thus might lead to ventricular acceleration in children with Wolff-Parkinson-White (WPW) syndrome. Also see section 5.1.<br />The efficacy of intraosseus administration has not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dipyridamole inhibits adenosine cellular uptake and metabolism, and potentiates the action of adenosine. In one study dipyridamole was shown to produce a 4 fold increase in adenosine actions. Asystole has been reported following concomitant administration.<br />It is therefore suggested that Adenocor should not be administered to patients receiving dipyridamole; if use of Adenocor is essential, dipyridamole should be stopped 24 hours before hand, or the dose of Adenocor should be greatly reduced. See Section 4.4 Special Warnings and Precautions for Use.<br />Aminophylline, theophylline and other xanthines are competitive adenosine antagonists and should be avoided for 24 hours prior to use of adenosine.<br />Food and drinks containing xanthines (tea, coffee, chocolate and cola) should be avoided for at least 12 hours prior to use of adenosine.<br />Adenocor may interact with drugs tending to impair cardiac conduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />There are no or limited amount of data from the use of adenosine in pregnant women. Animal studies are insufficient with respect to reproductive toxicity. Adenosine is not recommended during pregnancy unless the physician considers the benefits to outweigh the potential risks. Lactation<br />It is unknown whether adenosine metabolites are excreted in human milk<br />Ademocor should not be used during breast-feeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse events are ranked under the heading of the frequency:<br />Very common (&gt;1/10), Common (&gt;1/100, &lt;1/10), Uncommon (&gt;1/1000, &lt;1/100), Rare (&gt;1/10000, &lt;1/1000), Very rare (&lt;1/10000), Not known (cannot be estimated from available data).<br />These side effects are generally mild, of short duration (usually less than 1 minute) and well tolerated by the patient. However severe reactions can occur.<br />Methylxanthines, such as IV aminophylline or theophylline have been used to terminate persistent side effects (50-125 mg by slow intravenous injection).</p><p><img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4RESRXhpZgAATU0AKgAAAAgABAE7AAIAAAAYAAAISodpAAQAAAABAAAIYpydAAEAAAAwAAAQ2uocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAE11aGFtbWVkLCBVc21hbiAvU0EvRVhUAAAFkAMAAgAAABQAABCwkAQAAgAAABQAABDEkpEAAgAAAAM0MAAAkpIAAgAAAAM0MAAA6hwABwAACAwAAAikAAAAABzqAAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAMjAyMTowNjoxNCAxNDo1Mjo0OAAyMDIxOjA2OjE0IDE0OjUyOjQ4AAAATQB1AGgAYQBtAG0AZQBkACwAIABVAHMAbQBhAG4AIAAvAFMAQQAvAEUAWABUAAAA/+ELKmh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8APD94cGFja2V0IGJlZ2luPSfvu78nIGlkPSdXNU0wTXBDZWhpSHpyZVN6TlRjemtjOWQnPz4NCjx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iPjxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iLz48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOnhtcD0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLyI+PHhtcDpDcmVhdGVEYXRlPjIwMjEtMDYtMTRUMTQ6NTI6NDguNDAyPC94bXA6Q3JlYXRlRGF0ZT48L3JkZjpEZXNjcmlwdGlvbj48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOmRjPSJodHRwOi8vcHVybC5vcmcvZGMvZWxlbWVudHMvMS4xLyI+PGRjOmNyZWF0b3I+PHJkZjpTZXEgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj48cmRmOmxpPk11aGFtbWVkLCBVc21hbiAvU0EvRVhUPC9yZGY6bGk+PC9yZGY6U2VxPg0KCQkJPC9kYzpjcmVhdG9yPjwvcmRmOkRlc2NyaXB0aW9uPjwvcmRmOlJERj48L3g6eG1wbWV0YT4NCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgPD94cGFja2V0IGVuZD0ndyc/Pv/bAEMABwUFBgUEBwYFBggHBwgKEQsKCQkKFQ8QDBEYFRoZGBUYFxseJyEbHSUdFxgiLiIlKCkrLCsaIC8zLyoyJyorKv/bAEMBBwgICgkKFAsLFCocGBwqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKv/AABEIAxkCOAMBIgACEQEDEQH/xAAfAAABBQEBAQEBAQAAAAAAAAAAAQIDBAUGBwgJCgv/xAC1EAACAQMDAgQDBQUEBAAAAX0BAgMABBEFEiExQQYTUWEHInEUMoGRoQgjQrHBFVLR8CQzYnKCCQoWFxgZGiUmJygpKjQ1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4eLj5OXm5+jp6vHy8/T19vf4+fr/xAAfAQADAQEBAQEBAQEBAAAAAAAAAQIDBAUGBwgJCgv/xAC1EQACAQIEBAMEBwUEBAABAncAAQIDEQQFITEGEkFRB2FxEyIygQgUQpGhscEJIzNS8BVictEKFiQ04SXxFxgZGiYnKCkqNTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqCg4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2dri4+Tl5ufo6ery8/T19vf4+fr/2gAMAwEAAhEDEQA/APpGiiuf8fXM9n8NvEt1ZzSQXEOk3UkUsTlXjYQsQykcggjIIoA3JoIbhAlxEkqg5CuoYZ/Gof7LsP8Anxtv+/K/4Vy2t+GND0LQr3VbmfxJLDZQtPIkXiS+DFVGTjdcKvT1IpmgeG9H1/QbTVUXxVYx3cYljhu/EV6JAp5UkJcsBkYOM555weKab6CaXU6z+y7D/nxtv+/K/wCFH9l2H/Pjbf8Aflf8K4i/0vRbLxMuhx2/i68u5LJ71DB4ku9jKrBSuWulw2WGMgA+vBrcHgPSMf8AH34gH/cx6h/8fp3dri5Y3tY2/wCy7D/nxtv+/K/4Uf2XYf8APjbf9+V/wrnbvwfo1tG2y48RXFx5bSR2sXia9Ek23qF3XAHcDJIHIyRU6+BNJZATdeIVJGSp8SX+R7cT0uZ9w5V2Nv8Asuw/58bb/vyv+FH9l2H/AD423/flf8Kxf+ED0j/n88Qf+FHqH/x+j/hA9I/5/PEH/hR6h/8AH6OZ9w5V2Nr+y7D/AJ8bb/vyv+FH9l2H/Pjbf9+V/wAKxf8AhA9I/wCfzxB/4Ueof/H6P+ED0j/n88Qf+FHqH/x+jmfcOVdja/suw/58bb/vyv8AhR/Zdh/z423/AH5X/CsX/hA9I/5/PEH/AIUeof8Ax+j/AIQPSP8An88Qf+FHqH/x+jmfcOVdja/suw/58bb/AL8r/hR/Zdh/z423/flf8Kxf+ED0j/n88Qf+FHqH/wAfrD0HwnZXuteJoLnUPEDxWOppBbr/AMJFfjYhs7aQjibn55HOTk846AUcz7hyrsdt/Zdh/wA+Nt/35X/Cj+y7D/nxtv8Avyv+FYv/AAgekf8AP54g/wDCj1D/AOP0f8IHpH/P54g/8KPUP/j9HM+4cq7G1/Zdh/z423/flf8ACj+y7D/nxtv+/K/4Vi/8IHpH/P54g/8ACj1D/wCP0f8ACB6R/wA/niD/AMKPUP8A4/RzPuHKuxtf2XYf8+Nt/wB+V/wo/suw/wCfG2/78r/hWL/wgekf8/niD/wo9Q/+P0f8IHpH/P54g/8ACj1D/wCP0cz7hyrsbX9l2H/Pjbf9+V/wo/suw/58bb/vyv8AhXE694TsrLWvDMFtqHiBIr7U3guF/wCEivzvQWdzIBzNx88aHIweMdCaTTtL0bUfFWpaEtt4ugl05EeW5l8SXXlOHzs27bstyATyoxjnHGTmfcOWPY7f+y7D/nxtv+/K/wCFH9l2H/Pjbf8Aflf8Kxf+ED0j/n88Qf8AhR6h/wDH6zfEXh7QfDXh2+1m7l8TTwWMJmljt/Ed8XKjrgNcAdOetHM+41FN2SOs/suw/wCfG2/78r/hR/Zdh/z423/flf8ACuX03wvo2p+cY28UwLEU2vPr+oKsoZFfKHz+QN2CfUEdqvf8IHpH/P54g/8ACj1D/wCP025IXLHsbX9l2H/Pjbf9+V/wo/suw/58bb/vyv8AhXHeIdG8P+G4rGW8k8UTJe3sVkpg8RXx8t5DtVm3XA+XPXGT7Vr/APCB6R/z+eIP/Cj1D/4/Rd2uHKuxtf2XYf8APjbf9+V/wo/suw/58bb/AL8r/hWL/wAIHpH/AD+eIP8Awo9Q/wDj9H/CB6R/z+eIP/Cj1D/4/S5n3DlXY2v7LsP+fG2/78r/AIUf2XYf8+Nt/wB+V/wrF/4QPSP+fzxB/wCFHqH/AMfo/wCED0j/AJ/PEH/hR6h/8fo5n3DlXY2v7LsP+fG2/wC/K/4Uf2XYf8+Nt/35X/CsX/hA9I/5/PEH/hR6h/8AH6P+ED0j/n88Qf8AhR6h/wDH6OZ9w5V2Nr+y7D/nxtv+/K/4Uf2XYf8APjbf9+V/wrF/4QPSP+fzxB/4Ueof/H6P+ED0j/n88Qf+FHqH/wAfo5n3DlXY6SivP7vwnZRePtK01NQ8QC0uNMvZ5Y/+Eiv/AJnjltVQ587IwJX4Bwd3PQY3P+ED0j/n88Qf+FHqH/x+kUdJRXN/8IHpH/P54g/8KPUP/j9H/CB6R/z+eIP/AAo9Q/8Aj9AHSUVzf/CB6R/z+eIP/Cj1D/4/R/wgekf8/niD/wAKPUP/AI/QB0lFc3/wgekf8/niD/wo9Q/+P0f8IHpH/P54g/8ACj1D/wCP0AdJRXN/8IHpH/P54g/8KPUP/j9H/CB6R/z+eIP/AAo9Q/8Aj9AHSUV561h4ci8cR+FrhvFUN3Nam5gnfxFe+TMoOGCkXJbcOeCo6HFSaJpPh/XtT1a0sm8UhNLuPs0tzJ4jvRHJJtDFUxcluAwySoHPGaFrt/XT8w2O+orkU8IaQ+qy2O/xQvlwpL9oPiDUPKbcWG0N5/LDbkjsCPWpJfB2gw3EEEuo68stwSIkPiTUMvgZOP3/AGFAHVUVzf8Awgekf8/niD/wo9Q/+P0f8IHpH/P54g/8KPUP/j9AHSUVzf8Awgekf8/niD/wo9Q/+P0f8IHpH/P54g/8KPUP/j9AHSUVwl7ovh+w8UaZoc0nigz6nHM8My+Ir4xr5YBYN/pG4HBGMAitf/hA9I/5/PEH/hR6h/8AH6AOkorm/wDhA9I/5/PEH/hR6h/8fo/4QPSP+fzxB/4Ueof/AB+gDpKK5v8A4QPSP+fzxB/4Ueof/H6P+ED0j/n88Qf+FHqH/wAfoA6Siub/AOED0j/n88Qf+FHqH/x+j/hA9I/5/PEH/hR6h/8AH6AOkorm/wDhA9I/5/PEH/hR6h/8fo/4QPSP+fzxB/4Ueof/AB+gDpKK5v8A4QPSP+fzxB/4Ueof/H6P+ED0j/n88Qf+FHqH/wAfoA6SiuS8O2K6R4+1vTba71Ca0XTLCdY73UJ7rY7y3asVMrsVyI0yAcfKK62gAooooAK5v4j/APJLPFf/AGBbz/0Q9dJXN/Ef/klniv8A7At5/wCiHoAi+I2i614k8F3ei+HxZiS+Ainku7h4gkWfm27UfJIG3tjOecYPL3fwy1S58ZNrqnT4j9utpEjErnZDBAVjH+rAZvNbPP8ACoGR0r1GijYOljxnS/hHr0d3Hc6wNFuLh7iymurhJpDJMYWeSRyTFy7SMOePkG3gVbufhj4huNMh80aNNqEszHVJZp5iNTQCQx+adnQOyHy8YAXbuIwK9booeqsO+tzyCX4P3c5skntNGljsbfT7aAvIxaNIX3zFSYjtZzxkduKS9+Emu6xFqDard6e1zeE28sySOzXED3KyM7kpwyxoESMAqpyQ3PHsFFVzO9/V/fuTa34fhseYWXwz1CB9O82PTSbbWp7+SRp3lHlPxtEbR8vsCDduBU5IJGQfT6KKV9LBbW/9d/1CiiikMKKKKACub8L/APIxeM/+w1H/AOm+zrpK5vwv/wAjF4z/AOw1H/6b7OgDpKKKKACiiigAooooA5vxR/yMXgz/ALDUn/pvvKym0rxlZeMNe1XS7HRJItSjhihafUpVaIRhgHZBbkEndnbu7da1fFH/ACMXgz/sNSf+m+8rpKOoHl8Xw11mO41J5ZtPuRdCRZDLI4/tEPcLIGuAqDmNAY1GXBBwQFytZ9/8JtduPCdtpIn0y5+z2uoWsMdxK6xwec5MMqYjOGVfk24GAxwccH2CinfS39f1qC0d/meOXHwt8RXF2Z2sfD+06pHfGI3cmGUWvkupPkdWb5jxz3qjH4LvrPxN4Vg8R6M2r3GmWttEZYGllhZ42cbg7WrKMAqxBkhyRzvwK9xop8zTv6fgrCaureVv1POfFngDV9Z8W/2tZHT5l+02M8b3UzpJbrBJueNMIw2v16jkcg8EVbb4ZalHBqUd4dPvEuItjRyPxqEglMizz5iIDj5VwVkGB9APUKKlaK39f1/w+4+t/wCtDz3RfAWsWHxGXX73UlltltkjjjgkEYjxEEMWwxMzR5G8fvRg/wAJOSfQqKKbdxBRRRSGFFFFABRRRQBzd9/yVPQv+wLqX/o+xrpK5u+/5KnoX/YF1L/0fY10lABRRRQAUUUUAFFFFABRRRQBxXijwrrOt+JLbULA2Vo+nzW8tpdNO5kO0uJkaMJgBo5GA+Y8gZx2xpfh/rd9a65YahaaM1nqWqfa4w13LLtj8kRfMhiClhtVhncMk9CoavTqKOlv66f5Id9b/wBdf82eNX/wr8TXdn5bJok07adptvJNLdy7pJbaTezk+ST8wyoPXH5VNH8KNemisjcTaXaz2n9ppBJDI0htVuTuiaMmNfmjORjjAOQe1ev0U22738/xEtPw/A8Vu/g/r8mhaZaQrpc81vHerL9rvMrGZ4giiLy7VQFDDft2jB7nrWvc/DnX7zVLHUrhdIe6htTbXJNxKxuUa0MTIzGM/L5mG2gBcZO3dnPqdFJ6pr+v61BaPQ8Z0b4U+J9P0eSxuP7FaDy7APZrcyNDetApWRZcwjAcEc4b7i5BFdLZ/D2/tPiNZ64t8y6daW0cMFslz80AWMoYvmiZpEOd3+sTkAkEgY9BoquZ3v8A12FZWseU3nwx16fxLLe215ZQebLqBOorM4uttxGFj+XZjMeNoG77oGMdKtaf8Nr+3tIxNbaOCl+l1BZBi9vZYVFLx5jGWbaznCodzcMOS3plFSvd2/qxTd/x/E4fwN4J1Pwz4g1u/wBU1Frw38rMriZSJAXZgXjESkOobbkyPkADgAAdxRRR0SF1bCiiigAooooAKKKKACiiigDm7H/kqeu/9gXTf/R99XSVzdj/AMlT13/sC6b/AOj76ukoAKKKKACub+I//JLPFf8A2Bbz/wBEPXSVzfxH/wCSWeK/+wLef+iHoAP+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GK6SigDm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GK6SigDm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GK6SigDm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GK6SigDm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GK6SigDm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GK6SigDm/+E80j/nz8Qf8AhOah/wDGK5/w5400uHXvFjva64RNq0bqE0C+YgfYbVfmAhJU5U8Ng4wcYIJ9Erm/C/8AyMXjP/sNR/8Apvs6AD/hPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABiqXhC+1GXxB4sTVtZuLy107UBBbpPHCiwoYUkPKIpPLkZJPAHfJKwfErSbuO4azs7+4ZIvOt0jSMm8i8zy/Mj+fAUOMEyFMdTxzR281f8AUNrlz/hPNI/58/EH/hOah/8AGKP+E80j/nz8Qf8AhOah/wDGK5Xxf8UI5fh+9/4Ue+hvp9POoRSiGI/ZkWQIfMDkjlsrhQ3cjA5q2nxNg026u4tRtNVvHbUZrWKNILdfJMdsspXPm/MGXcwY884IGBTtv/XkHb+ulzf/AOE80j/nz8Qf+E5qH/xij/hPNI/58/EH/hOah/8AGKzV+KWjzeINK0iysdQu5tViimheJYgqpIpcMQ8gYqFByyqwB4zkgVU8W+OJrbxRpWmaPNcQrBrFva6lN5cRhdZI2cxZbLBtoVsqABnr2otZ2fe342Do2u1/1F17xZZXuteGZ7bT/EDxWOpvPcN/wjt+NiGzuYweYefnkQYGTznoDW5/wnmkf8+fiD/wnNQ/+MVnw/FDSbqzmntLDUJykcc8USiFWuIJGZVmUtIFVCVb75VunHIzcsPiHoOo+NZvC1vMw1KFCzKxTG4KrMmN24EBhyVAPIBJBALPYHpuSf8ACeaR/wA+fiD/AMJzUP8A4xR/wnmkf8+fiD/wnNQ/+MV0lFIDlm+IugrdR2rRa4LiRGkSI+Hr/eyqVDMB5OSAXUE9tw9RUv8Awnmkf8+fiD/wnNQ/+MUX3/JU9C/7Aupf+j7Gsj4hS65p91pFxpPiS90+K+1O2sHt4Le2ZVRydzAyRM278ce1HVLvp94dG+xr/wDCeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wnNQ/+MVDL4sh8P6xp3h7VBqN9dXP7uO/aGJEmk2M4U4K/MVU8quwHgkdKzbn4t6TZ+FYNfudJ1aKzuCvk+YkKb8qx+80oQY2kYLAk4ABJGTzDyNj/AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8YrBvPjN4etHubd4Lpb+3sGvGs5GiEgIi83yiockNs5zjb1GcjFWLX4s6ANQstL1VnsdRns1uZonaM+STEZNpCuW5UEggEdASCQCf1+f+Qf1+X+Zrf8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/Cc1D/4xWH4X8Z3ureJvEk04vP7Mt7C0vbSznjhWSNXSQnBXruCggMxIz26CXw78UIdat7M3Oh6laSXFjHfu+InjjgdmAclZCdo288Zwc464bVt/6/qzDfVf1t/mjX/4TzSP+fPxB/4Tmof/ABij/hPNI/58/EH/AITmof8Axis23+Kej3JtlisdR33UsCRIVi3MkysYZf8AWcI2w/7Q7qKrv8XdHB0RIdL1WebWkR7eFFhVxucoAQ0o3EEEnZu2jk4BFFne3yFdb/M2v+E80j/nz8Qf+E5qH/xij/hPNI/58/EH/hOah/8AGKxPAXjabUdSutE1qa4uL77bf/Zrh441R4YJgm35MfMAy9V59TXf0uifceza7Hnd5400tviTo1wLXXNkek36EHQL4OS01mRhPJ3EfKckDA4BI3DPQf8ACeaR/wA+fiD/AMJzUP8A4xRff8lT0L/sC6l/6Psayda8QapoHxQ01Lm+Z/D2oRrbSQvEm23uG3mNg4UNhvLK4YkZYUdbB0bNb/hPNI/58/EH/hOah/8AGKP+E80j/nz8Qf8AhOah/wDGKwNN8Z39k3inU9Y+3ahb2ep/ZbaxtIYgIIxCkmSzbcH5jku+M4A5IBB8UbGPUJ7nytUubGZNOFvElvCoX7UXCSBjIGIJwpBAKleAQc07N/h+OwPT8fwN/wD4TzSP+fPxB/4Tmof/ABij/hPNI/58/EH/AITmof8AxisY/FfTWutPZbK6SxuLG6vbm4k8sfZUt22OGAfkhsj5d3bGeSIx8ZvD0unW95a2t/dxzC5z9nMD+WYEEjqxEuCdhyNpI7ZB4pAbv/CeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wAJzUP/AIxVa6+I2mWuqW9kbHUJPtdu09tOsaCOciLzdi7nBJ2D72NmcjdkEVUsPixomo6eLi3stQE0gtjb2brEJbn7QpaMJ+825IVs7mGNp7YJdmHS5qf8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xVbT/iVoGo+LYvDaPNDqUsQfyZwqMjFBJ5bIW3hgpyfl29RnIxWHqvxHWDxzYeVc3FtoNuuoJfvJFGY52t0UlkPMnytuH8OT0B60gOl/wCE80j/AJ8/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/GKq23xEsbrYkWl6l9o+1LbTW5EIa3LKrqzHzNpBVlIClmPI25BAseG/iBoPivWtR0vSLgyXGnk+ZlkIcBihYAMSAGUjDBT0IGCCXZ7B0uO/4TzSP+fPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/wAYrpKKQHLN8RdBW6jtWi1wXEiNIkR8PX+9lUqGYDyckAuoJ7bh6ipf+E80j/nz8Qf+E5qH/wAYovv+Sp6F/wBgXUv/AEfY1ieMm1608Y+HrfT/ABTqFla6zfPbyQQ29qywosDPlTJCzZLJySSMHAAo62Dpc2/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GKq3Pju10XVjol/a6lc3kNpJMLnyY0W7MUYdwgLjnBzkgJnIDcECjqfxb0rSdFstTu9H1gR3+DbR+XCrSqURwVLShWJ3gBQSxIbCnBo32A2P8AhPNI/wCfPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/xisLUfjHoFoutwW8c01/pFo9xJbb4skpjenDkgqWAOQAedpbBqSP4v+G0vLqx1BprW8sbM3NzExjYqVRXeMBHYlgGH+yeQGJBw7MDZ/wCE80j/AJ8/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/GK5/RPHF/FY+N9V1iK7kt9Gn8yCylSFZYY/s6SGMlDtOCx53N9TV63+JloiEarpGpWjW9hDf3kpWJooI5EdtxKyE4zGw4BOSPWi36fjqG+3n+H/AA5pf8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/Cc1D/4xWY3xT0tGSJ9L1MXJeSN7bEJeJkg88Bv3u354+VIJHY7TSf8AC0tKn1rStItNP1OW61aCKaEosI8pZELhmDSBiFAOWVWUHjOSBSaaA1P+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GKxvhj41m8Q6XBp+sSzz6ulu9y9xJHGizx+fJGCAmORswflH413tNqwHN/8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFdJRSA5v/hPNI/58/EH/hOah/8AGKP+E80j/nz8Qf8AhOah/wDGK6SigDjfDmr22s/EnX7izjvI0XSdOQi8sprV8+denhJVViOeoGOozwa7Kubsf+Sp67/2BdN/9H31dJQAUUUUAFc38R/+SWeK/wDsC3n/AKIeukrm/iP/AMks8V/9gW8/9EPQB0lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc34X/AORi8Z/9hqP/ANN9nXSVzfhf/kYvGf8A2Go//TfZ0AMT4eeHo9QnvUTUhNcXAupx/bF35csgIwzR+btbG1RgjGABjAxUw8C+HR52NPYedKkp/wBIl+QpJ5ihPm+Rd/zbVwpOcjmuRuviJrttpPifU4E0zULfRb+SxEdtG29PmjCyPmXbtVXfdkr93qozirD8SfEt5reg2IPh3TxfxRyTG4uopS6lnBaPbcjOQgKhPN+98xGORbJry/FX/IHpe/n+B2Nx8OPCt1psdhLpjC1ihkgWOO6mT927bmQlXBK7uQDwDjGMVDL8L/Ck7FpbO9Z2ne4LHVbrcZHTy2bPmZyU+X6V5zB8VrrQ/DlmdPn8Pqs1vqtywAkKvLDMxXbmYkCTJOMnrxxxU8fxr1p76OxtrbSNSka6RftFvKkULK0UbrFuknAWQl3UNuOTGcIeQKUW3Zf1r/mG34/kdxB8PG07X7O50XV57DTbSOKNbJZblm2RjATJn8tlI4+eNzgnBHGNe/8ABOganq41O8s5DdieK43x3UsYMkYIRyqsFJAJGSORwciuM8OfFK61L4iDw9e3GkvHJfX1oi24Kyr5IRkJzIwOQzg4HJXjHIr1Glq0pd9Q6tfI5+DwL4etoLiK3spIluMBil1KGVRuwiNuzGg3NhFIUbjxyat2HhrStL1Sa/063e2mnULKkU8gifAADGLds3YAG7bnAAzWrRSB67hRRRQBzd9/yVPQv+wLqX/o+xq9r3hjS/Eq2i6vHcSCzmE8Hk3k0G2QdG/dsuSO2c4qjff8lT0L/sC6l/6Psaq6r4o1G28f2mg2wsoIXt1uP9LDb70bmDpAQwAdAAxBBzuH3RzR1QdGal54Q0TUNWXU7uzZ71XSRZRcSKVZFZVIAYAHa7D3zzWVqngCF/DenaP4cvJNKh06UyQ75rmTAIYEb0njl/iP/LTHbBHFcXN8Xdai08XEi6TADdWccjSxsFtTNKySW0n73/XRqocnjjqg4NaOg/FDUtebRo4P7Kja6Exkkk3bLxopjG0UBDnbJsHmAHdkEDplg7af12v/AF+A37r1/q/9f5nX23gbSEimN6s95Pd2v2a+ke5lC3a7duZIw21m28biC2P4qsW3g/RLS6Fxb20qP9mW1cfapSs0artAkUtiQgcBnBPvXmtv8Ydbn0e3vrq30nS1m1eGyP2t0Yxq4bejKs5ZHTaCS4XIP3FpkPxT1vULW11i3vdKt4B4autQaGSFmjmuI5NpUHzR02g4ySAxHcED63/rRv8AL8ws72/re35r8D0vSPBmhaFNcS6baSRtcW6W0vmXUsoaJM7Vw7EAAMQMdBx0pNI8FaDoV0lxplpLE8dmLFQ93NIogDFgm1mK4BJxxnt0rj9V+Iet6TZ6PctLo1yt6ILh0hily1vLJGm4Nv2rt8z72XzgfKBzWVN4x1IeL1TV59NuxD4oltLWyaN454gtq2xkPm4O7IGGUgl89xg1vr/XR/n+ZKs1p/Wl/wBPyPQI/AHhqKzNrHp7rH50cykXUu+No8+WEfduRVyQFUhQCQBgmsqb4bi2vrA+HdWuNJsbSIRC3Sa5ZgA7P8rCdVPLHiRJFHQADIPKH4u6wtjZzTPo0Cz3tpDLPJGwjh84OZID+9/1sW0bjx15Va3/AAj8Qb3xN/wjk7XGmJBqVu/nQwxs8jTLvDbD5nyqNqn7r9cEqdu52d/R/jYNLW/rc6DTPh/4c0fWk1bT7S4jvUeZ1ka/ncAynMh2M5X5iATx1ANdJXkviT4k69aT+JLPTzp7C2067ns5YYZC8UkDqjKxZvnOH3cKoX/bHJ9N0aWWbQ7GW4uIrqWS3RmnhUqkhKg7gCzcH6n60lrFPp0/H/Ib0lZ7/wDDf5mRff8AJU9C/wCwLqX/AKPsat6h4T0bVbyW51K3luXlMRZJLqUxgxNvQiPdtUhhnIAzk5zk1Uvv+Sp6F/2BdS/9H2NdJS63A5tPh/4cSe5l+y3MjXVz9rmEuoXEitLtK7sM5A+UlcDgjA6AYqn4W+EigT7BdBVW3VQupXIAEH+pAxJxt6j356111FGwbnM2nw78L2UMMUOmFo4Y54VWa5llykxzKrbmO4MecNnnkYNMvPhx4a1CztLW9t76eKzSWOAPqt0SiSLtdd3mZIK8YJOBwMV1NFAHMj4eeGR5WLCUNCoWN/ts+5QITDw2/P8Aqztz9D1ANQWvwu8JWVvLBbadOqSJDGc6hcMyCI5i2MZMoV5wVIIya62ind3uHSxlWvhvTLLWpdVtIporuZAkzLcyhJcDAZ03bWbAA3EFsd6oy+APDU2qHUJdOZpy8zlTcy+WTKu2X93u2YYdRjBPPXmujopBdmBB4J0C2tPs8VnLsMvmuXu5meVvl4dyxZ1wijaxIwoGMDFXdK8P6dok1y+lxSQC6kMskX2iRogxOSVjLFUySSdoGTya0qKd2AUUUUgObvv+Sp6F/wBgXUv/AEfY1d1bwvpWuanp+oajHcPc6bJ5tq0V5NEI26E7UYBuMjkHgkdCapX3/JU9C/7Aupf+j7Gs7UPF+qQeNL/SrW3tDHY2n2hbOXcLm/BjY7oCDghXCoQV75yOAVe2o7X0NW78D+Hr7UJ765sXNzOZGklS5lQ5kiET42sMZRQOMdAevNUNb8CG8stItNC1KTSoNLjMMa+bcsTGQoxvjnjfI2j7zMPVTgY42b4t6vDb2LvNoqR3F9HbtePGwhw8DSMg/fffiYBGyeSeinitPw58TNS8RXGmNDDp8KTaXHfSW7bjJesQ4kW3IbGY2VQVIJ+bkrjmrWT8v8rivez7/wCdjrl8EaIbS/t7mCa4TU4vLvle4kCXBIwzmMMEV2xyygE+tOTwVoKG8xZyFL6DyLqJrqVo512hcuhbaW2gDeRuOOteXr8aNebS9Pu7mPRNNF3cTxk3Lq+0LbmQAqlwSjK4CMH2ltynahOKnuPinrXk6hrcF5pdvaRaBZX8FrcxMyvJLIQ+GEi5wRt78lfQ7nZ3/rzDRW/rqkek2XgnQdPs9StYLSV4dVQJercXc03nAJs5LsTnaACRycDNOtfBuhWc9xLFaSO1zZJYTCe5llWSBAQqFXYjgE84ycnnk1y2o+ONb0nxTpGmXEmkXMdzcQx3IgilDCOdpBFIGLYUfIox8+STyvy55ez8e6umo2d1qZ07VL9bjWBb2MUbxXMZhB2xr+9IO4KOCmcEY55K1d7/ANW/4DDsl5fj/wAMekt8PvDT2SWr2EjIkxnEjXcxlLlPLOZN+9hsO3BJG3AxgCs5fh69pr1pc6TrFxY6bbRRRCzSa5LbIxgLu8/YwI4y8btgnDDgjj734vavaQ2h+1aD5U11NAL9omEE4W184NGPO42P+7b5jk91PFdb4V8bXXiLUtMYzWC2t/pqXS20UbNMrlVZiX34Cgtt+5jP8eflp2f9ej/QHpv/AFr/AJmpoHgDw74Y1Bb3RbS4gnWA24aS+nlAjLlyu13I+8SenUmukrwW88a6h/wmN14lt10xNWttBvQtoYWLRiK5T91KA4Zm2gtkbQA2cY69JH8TdWvr+2stOvtBMl1rc+mwyPG7K0Yt/NifAl5+YgEjhsjGKEnJL+utvzB2Tf8AXS56tRXhk/xUvPD4u47W78OCVr/UxcHbIQ8kMYdWAM/G4/KR34xjpXS6Z8RdY1vx5pmm2U+gw6bdQRXDrJMrXDo0IkOwecrFsnHEbKACdxOVCiuZK3l+Im7Xv5/g7Hp1FFFIZzdj/wAlT13/ALAum/8Ao++rpK5ux/5Knrv/AGBdN/8AR99XSUAFFFFABXN/Ef8A5JZ4r/7At5/6Ieukrm/iP/ySzxX/ANgW8/8ARD0AdJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXN+F/+Ri8Z/wDYaj/9N9nXSVzfhf8A5GLxn/2Go/8A032dAHSVk3vhnS9Q1RNQu452nUKCq3cqRSbTld8SsEfBPG5TitaigAooooAKKKKACiiigAooooA5u+/5KnoX/YF1L/0fY1qa1rmn+HdMbUNXmaC1V0RpFieTBZgq5CgnGSBnpWXff8lT0L/sC6l/6Psa5f4n+HvE2u3E8el2t1f2TWkP2eCC7SJEmW4V5DIruofKAbSc4KnpnJOqQ+jPTKbJIsUbSSHCqMnAz+nevMbzTdci1zV77Xb3VtL8PXFncCaf+1CTbuJEMMiCN/3Y27uEUcDD7up6jRINW03wQLme3m1PV5bdHltxfPiVggXEbSNhMgbuwyTnrmj7N/66i62NrSNZsNcsPtmmTGWEO0bb42jZHU4ZWRgGUg9QQDV1HWRFeNgysMqynII9a4S28K6nb/C7XNG0/wC1W894lw9hDcXI8+AyLkK8qsdzbyx3bj15JrO8P6B4wsPEGk7jew2MCwh/PvvMijtxb7XgZPNbdL53zB8H5eN+PlppXdvT+vl/XS50v6/h/n/Xl2Oo+MtB0rxRYeHb+/Eeraipa1thE7FxzzlVIXoepHStyuKn0LW5fic2qWt5rFpZqkQYfa4ZLGeMA7kMJHmLJn+Lke/8NdrSXw3B72CiiigAooooA5u+/wCSp6F/2BdS/wDR9jXSVzd9/wAlT0L/ALAupf8Ao+xrpKACiiigAooooAKKKKACiiigAooooAKKKKAObvv+Sp6F/wBgXUv/AEfY10lc3ff8lT0L/sC6l/6Psa43xhpHjW58X6lLolvrb6dK9h5RtdWSJNqs32napmUrlCB0GWGeoDUdUh9Gz1aq1hqNrqcMktjL5qRzSQOdpGHRirDkdiCM9K8rXR/iBJomlKkOsQ3llcmQmXVo23RfawQj4kPmHyCRl2YfLjAOCamo6J8QX06BLSz8QCRJ9U+7rSBvLkB+y7j9o52krjklcH8X0v6h5f11PZg6mQoGXeACVzyAehx+Bp1eP3fhrx5K2s6jZx3lvqF9ZacozfZ4Qf6REqrMoV85IYMo+Y4dSSajTRviNZ+IrWZV1u/ijbT98zX8UUbBCwuN0P2lgCUZQQMgspPXBp21tfrb+vIm+l/K/wDwPU9korx7U9D+IJXVWso9aK3L20sEa6whdHS5bzcMZVChodvyqFXkDGQav6PpPjea40xNbTWIbGG7usrFqUYmQGYPA8jCQ+bH5e5CpLHn7p4IUVf+v6+Q3oepUVw/gbTPF9n4g1ufxXeyywTSt9njIDREb2KtGfOYr8hVSvlxjgH5jlj3FLog6tBRRRQAVkyeGNKl1o6rJFObkushX7XL5LOoAVzDu8ssMDDFc8DnitaijzDyCiiigDm7H/kqeu/9gXTf/R99XSVzdj/yVPXf+wLpv/o++rpKACiiigArm/iP/wAks8V/9gW8/wDRD10lc38R/wDklniv/sC3n/oh6AOkooooAKKKKACiiigAooooAKKKKACiiigArm/C/wDyMXjP/sNR/wDpvs66Sub8L/8AIxeM/wDsNR/+m+zoA6SiiigAooooAKKKKACiiigAooooA5u+/wCSp6F/2BdS/wDR9jXSVzd9/wAlT0L/ALAupf8Ao+xrpKACiiigAooooAKKKKACiiigAooooA5u+/5KnoX/AGBdS/8AR9jXSVzd9/yVPQv+wLqX/o+xrpKACiiigAooooAKKKKACiiigAooooAKKKKAObvv+Sp6F/2BdS/9H2NdJXN33/JU9C/7Aupf+j7GukoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAObsf+Sp67/2BdN/9H31dJXN2P8AyVPXf+wLpv8A6Pvq6SgAooooAK5v4j/8ks8V/wDYFvP/AEQ9dJXN/Ef/AJJZ4r/7At5/6IegDpKK5v8A4SjV/wDoRPEH/f8A0/8A+SqP+Eo1f/oRPEH/AH/0/wD+SqAOkorm/wDhKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KoA6Siub/AOEo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqgDpKK5v8A4SjV/wDoRPEH/f8A0/8A+SqP+Eo1f/oRPEH/AH/0/wD+SqAOkorm/wDhKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KoA6Siub/AOEo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqgDpK5vwv/AMjF4z/7DUf/AKb7Oj/hKNX/AOhE8Qf9/wDT/wD5Krn/AA54j1SPXvFjJ4L1yUyatGzIk1jmI/YbUbWzcgZwA3y5GGHOcgAHolFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVABff8lT0L/sC6l/6Psa6SvO7zxHqh+JOjSnwXriuuk36iEzWO9wZrMlh/pO3A2gHJB+YYB5x0H/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVy83i/UbdVafwTrsSswRS9zpwBYnAHN11J7VJ/wlGr/APQieIP+/wDp/wD8lUAdJRXN/wDCUav/ANCJ4g/7/wCn/wDyVR/wlGr/APQieIP+/wDp/wD8lUAdJRXN/wDCUav/ANCJ4g/7/wCn/wDyVR/wlGr/APQieIP+/wDp/wD8lUAF9/yVPQv+wLqX/o+xrpK87vPEeqH4k6NKfBeuK66TfqITNY73BmsyWH+k7cDaAckH5hgHnHQf8JRq/wD0IniD/v8A6f8A/JVAHSUVzf8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVAHSUVzf8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVAHSUVzf8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVAHSUVzf8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVAHSUVzf8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVAHSUVzf8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVABff8lT0L/sC6l/6Psa6SvO7zxHqh+JOjSnwXriuuk36iEzWO9wZrMlh/pO3A2gHJB+YYB5x0H/CUav8A9CJ4g/7/AOn/APyVQB0lFc3/AMJRq/8A0IniD/v/AKf/APJVH/CUav8A9CJ4g/7/AOn/APyVQB0lFc3/AMJRq/8A0IniD/v/AKf/APJVH/CUav8A9CJ4g/7/AOn/APyVQB0lFcvL4v1GDZ5/gnXY/McIm+504bmPQDN1yfapP+Eo1f8A6ETxB/3/ANP/APkqgDpKK5v/AISjV/8AoRPEH/f/AE//AOSqP+Eo1f8A6ETxB/3/ANP/APkqgDpKK5v/AISjV/8AoRPEH/f/AE//AOSqP+Eo1f8A6ETxB/3/ANP/APkqgDpKK5v/AISjV/8AoRPEH/f/AE//AOSqP+Eo1f8A6ETxB/3/ANP/APkqgDpKK5v/AISjV/8AoRPEH/f/AE//AOSqP+Eo1f8A6ETxB/3/ANP/APkqgAsf+Sp67/2BdN/9H31dJXG+HL+51H4k6/LeaTeaU66TpyiG8eFnYedencPKkdcc45OeDx0z2VABRRRQAVzfxH/5JZ4r/wCwLef+iHrpK5v4j/8AJLPFf/YFvP8A0Q9AGzqepwaTZ/abqO6kj3BcWtpLcvk/7ESs2PfGK5nXp31Lx7pmgXd5dWWm3FhLcgW1w9tJcyq6AJ5iFXG1WJ2gjOeeARXY1T1PR9M1u0+y6zp1pqFvuDeTdwLKmR3wwIzR1T/r+uodDlr3xgug38mn2NudTtbIRy3lxNfZlRZpmRRGu0+btYEEFlwAANx4rOf4n6lDZzXE3hyACGC6nYLqROUtp/Klx+668gr68g7cZPX/AGDw5eatFD9k0ufUNJRTEnlxtLZqw+XA6xggcYxnFVD8PfBhMhHhLQg0gIcjTIctk55+XnnmnfuPT8v+CctqHjW/1bSfs91p/wDZskyySwTWOpO7Bre5SN1bCIQpJGOoYEggdDrDxlfDU73T9P0VLnUVvZ0WF9SKpKkSRElGZMK5WRcR4C5DEt1NO0fwZ4N0mOfw5Omm6nd3ObmeC+gtTPKm/cCyIi7kVjwSvHTPStibwt4VjRluNC0dVnuVmIeziAkn/hbkcvycHrRpf+u/9InXr/Wj/wCHOY1n4g6rD/adtpmm2Lz2zQeRP9skMcivcCFgzeTtDqeCFLgdzxgpp3xQuNThm2eHpoWkmS3s5JmmigmkZyhVpnhCrgrnKeZwRjniut/4RXw8fPzoOmf6SGE/+hx/vdxBbdxzkqCc9SB6UHwp4eP2vOg6YftwAu82cf8ApAH9/j5vxzSXS435HP8Ah/WNRsvh/a3UVrJqMwu7iN/PvXk8qNZpBuMpV3cBVABwSeM4GSMSy8aS6fp/iiOGJ9RjsvtV8puNSlUvFtVtsEm1iQMtyCNmUwOeO9/4RnQf7NbTv7E077C0hla1+yR+UXPVtuMZPrVc+CfCp8zPhnRz5pdpM2EXzl/vE/LznAz64p395t/1sC6X6MzLbxneP4o/sqXSIktReLZi6W9Lvua389TsMY7Ag/NwcdcnHX1iReC/C0FzHcQ+GtIjnidHjlSwiDIyjCsDtyCBwD2rbodgCub8L/8AIxeM/wDsNR/+m+zrpK5vwv8A8jF4z/7DUf8A6b7OkBx2r+Mb5/EusLbz6rZhNKlEUUunzxRwbZgpm3PGFY7ctuyR0A75bd3l1Dqmq6T/AG1qEOm6VDdT2tybuQyNJHDbsoaUnMgVpHO1iQehBAxXpwhsbqeSUR280qqbeR9qswHUoT6dDiqw8OaILG2sho2ni0tJBLbwfZU8uFx0ZFxhT7iiOiXp+bvf5dAXxN/1stPmYGv+M9R0GCyK6RFdtNpk19MWujCY/JVGdcbG6hzjnqMHA5FG9+I2p28E6WvhsXV/FcCIW0d1I+9DEsqt+7hdskOoPy7VPV8c11ereGNA1+SOTXdD03U3iBWNry0jmKA9QCwOKw9Y+F3hjVVhWHTrTTVjcO6WunWjLNgYG9ZYnBwMgEAEAnBGTQ9f68/8gVkkjqbGW4msIJb2BLe5eNWlhSQyLGxHKhiBnB74H0qeobO0hsLGC0tV2QwRrHGvooGAKmpu19BLbUKKKKQwooooA5u+/wCSp6F/2BdS/wDR9jWhf6nLZ3RSDyrttoP2WMN5q+/G4YPQZCj3rPvv+Sp6F/2BdS/9H2NdJQBy0SXcnjLxDbWd7PbvNptrJF50jzR28rGddyxlsD7q5C4Bx681Qs9WuvDHgXUbj7K2oXWmXJimEupTSLOcrlkklMjDhvuE4DArnvXTy+HtFnvrm8n0ewkuruLybid7VC80fHyOxGWXgcHjgU6fQtIutHGk3OlWU2mgACzkt0aEAHIGwjbwR6U/6/r+vyB6/wBeVv6/4LOUf4hXtvNOl7ocSCFrqLMd/u3SwqHwMovyspHzdQeMHqWxazrHirRJE1LTZ9DXE8n+j3dxHJJGiYBy0cMkeXcY4BIQ9q1br4ceEprCW2tfD+l6ezo6rcWdhAkkW4YYqShAJHByCCODmpdD8C6FoWiXGlx2Vvc291/x8rLZwIs49GjijSPH/Aee+alq8WvL8e/9f8EFdO/n+BS0WyOp/DvQLM37m6kgtL1nupWnkk2NHKxJZtxyeM54yPYV19Zek+GNA0CWSTQtD03THlAWRrO0jhLgdiVAzWpVyldtr1JinGKi+gUUUVJQUUUUAc3ff8lT0L/sC6l/6PsawvEetamnj6OJ1f8AsXT2tBJFBfNBLJLPIVVyqrmRFIUbNyg5bIbAFbt9/wAlT0L/ALAupf8Ao+xrWmsNJu9Ygubi0s59Ss03QyyRo00CtkZUn5lBwRx1xTWkkw6M5zWvG99pPiO502PRYriGFrNfP+27C32l2jX5PLOCHXnn7pznPynPtviNq1/qFlaWHhlJnkkMV2/2yQpbFZXjc71gZdo8tmBkMZYEYBOcdRf+DvDOqaib/U/Duk3l4cZubixikkOOnzFSeMViyfCrwu2vQ6lDYW1skW0izhsLURZBJ3AmIyIcnJ2uucUK2lwl1sZdnr15p3xAWKZ7ic6xaW8iRXN1ItvBvmmIxwyo3lqoAAG9lAJGc1t+HPFGq+I9XvbafQRZ6bCrBL4XMuZTuIAUGFVPAzuR2AyOSc417rwvoF7fm+vND02e8ZVU3EtpG0hCkFRuIzwQCPQgVneGvAeleF9Sur+yZprq53BpZLe3jfDNuILRRoz8jq5Y+/JpK1rPz/4AN63Xl/wTmdI8c32kaZp+mXNgLye4TZY3E2pM/mnzvLxO7IWj5IwfnLYPfio9V8d3Ot2kVvZ2bWU9nfWovXXUmjMbm88nbHtUechKODnaMEcE5A74+HNEMV7EdG08x6g268Q2qYuT6yDHzn65qK48J+HbyGCK70DS547aPyoElso2EScfKoI+UcDgccU4u1m+4bPT+v6/ryoaB4n1DV9WuNOutLtrW4sWkS+WO9aTyTx5WMxLuDqS2eMAd+2DF8StVbUzp0vh+yS73SQhBqjlROswQRk+RxuQmQHk4B4712+naaunrMTcTXU0z75J5ggZuyr8iqMAcDj65JJK/wBj6Z9r+1f2dafaPO8/zvIXf5u3ZvzjO7b8ueuOOlIO5w+i/EqfxFLYsPD11bWdzeQpFcySTwqyuHIILRKHYFPmRWZcMDuPSqOseMNf1dR9m0WSwtbXU7QQ3iX88YuS1ysfln9yqurKSSVaReR1PTuW8HeGWuGuD4d0nz2nFwZfsMW4yjpJnbncMn5uvNY+l/C3wzp91cXF1Y2+qPM5fN7Y2pKnO7JKRKXOf4nLN155OWtJJ/P8v6/qwPrb+txvhvxbq+veKWtJ9OtbWzjsfMlC3RkdZhPJEQP3Y3LmI4OV4wcc4HZ1m6d4b0PSJFk0nRtPsXRWRWtrVIyqscsAVA4JAJ9cVpUaWDqc3ff8lT0L/sC6l/6Psav3OqTW98YYRFe/OAYYA3mRcfxYyvPX5igqhff8lT0L/sC6l/6Psa6SkBycVrfXd14ssNO1GW3meaPyJZ5JJlgLQqTtG8FRyeFK4JyMVBb69NoXw/ivbewe7kguxaSRTajJKXJuPJLrNJvZhk5AY9OMjFdBJ4Z0GWS8kl0TTne+Km7ZrSMm4KnKlzj5sHpnOKmvtF0rU9NGnalplnd2Ixi1uLdZIhjp8pGOO1C0X3D0OLl+Jd9bI/2jw/EJP9IijWO+L75oZliZcCLcVJdSpUMx5ATOMrdapq/iXwldz6lZXGhPDZXFz5VrezRycArCxbZE652u20gHhc9wNTUfhl4RvtNa0t9B0zTjnKT2enW4dORnG6NlwcYIIII4NXtL8F6Hpnh19F/s+1ubKXmaKa0hCTHrlo0RY+vOAoGecZpNXi11GmlJNdyK2sBe+GtFs470iaIW12TcStNJIEKsclm3HJ43EnrXR1maR4a0LQGlbQdF07TDMAJTZWiQ78dM7QM4yevrVu11CzvZLiOyu4Lh7aTyp1ilDmJ8Z2sAflOCODzVt3bt6/1+BnFWX4FiiiipKCiiigAooooAKKKKAObsf+Sp67/2BdN/9H31dJXN2P8AyVPXf+wLpv8A6Pvq6SgAooooAK5v4j/8ks8V/wDYFvP/AEQ9dJXN/Ef/AJJZ4r/7At5/6IegCx4vuru08PSNpzagly8iRpJp8KySIS2MkNHJ8vqdjEDnFcBbeJ/GMd1bS3h1wuIdPMtouhuYXlYstypcQZCgBWyCMH2+WvWJZGjj3JE8pyBtQgHk4zyQOOv4d+lQanqNvpGl3OoXrFbe2jaSQgZOAM8e9C0HurHBeDrzV7nxBqN1qy6qt3NpEO57zS2ijhmV5S8SFUAdVLrt5YsOQzdRXvda8VrZQpbza4ETz0W9XSRJJc3ChPKRozCCkLEuC+xeV++Bhj6FpGpHVdOS6exu7BizK1veRhZEKkjnBII4yCCQRgg1JLfRRzvbx5muVjEvkIRuKk4zyQOuep7Gm9/6/r+tbhfr/Xb+vwseSWdhrVz8Rlv7uXXYSuuo0uNMBhRGstp2SNBzH5i+WSGxtCtkEhzu3Vzrul+PryRbrXJLW41W1QQx6b51v9maA7jvWEkAPnJ3DGBnrz6PRRfby/4H+Qnrf0PPDq+vxae7Nd61PJb3Iy0eklWusj/VoGg+VAT1YY6fvOGNYes+IfH1jcva6eusXTpJdxSO+mfIEE8ZikWRLdgW8lnxhXBIxtZuD6/RS63Hf+vvMXwhc6nd+FLGbXG3XzIfNbynjLfMcEq8cbA4xn5F5zgAYraoopt3dyVogooopDCub8L/APIxeM/+w1H/AOm+zrpK5vwv/wAjF4z/AOw1H/6b7OgDiNT8R+LEmuktLrxEvktqHllPD7OJCjK1uufs+CDllyOo755qXR7rxEPFm06l4kS21C+nkkjk0cCKOPyUaMh2txsOfkwzcYwRuya9Tjdn37onj2sVG4j5h6jBPH1wfamQXcFy0y28iyGCTypMfwtgHH5EULRfL+mEtfvPNdN1jxbJvv5ZfED2lveRMLObToxNPBKpUqf9HTBjkwTtzhckswIIZLqXjuy8SahY3V1ePZW9nJ5VxHYtK82IcrKgjtDH5nmZG0yYI48vOCfU6KOlg6nkcHiTxdJtgluPEKQ+Sksl4vh9vNSdolKwhDBgx794YgErwCyg5FqTW/GttqkEF62pRPJcI0nlaV9ot4o5LMkjdHFkhLgY+9ux1JBBr1KinfVsI6I4mbVNcHgdZrdtWM6XYhnu2sQboQBsNLHD5S7jjoDH6kKwxmr4P1HxPf8AiYwa3c6mlpHaCaLztMEKT4lkVS7mMBXaPynZAQQeyjctdlpWqpq0Vw6W81ube5kt3SbbnchxkbWIweo5zzyB0q9Qn1/rb+mHdf1v/SCiiikBzd9/yVPQv+wLqX/o+xrpK5u+/wCSp6F/2BdS/wDR9jXSUAFFFFABRRRQAUUUUAFFFFABRRRQBzd9/wAlT0L/ALAupf8Ao+xrnPFuueIrPxVdWmmT60lrmwaNrXRzcRqGlZbgBxCwOIyrdcgjjuK6O+/5KnoX/YF1L/0fY10IkYzmPynChQwkyNpOTx1zkY9Mc9aFumPo0eMQar4uOrtf/b/FCsz2luqtoJ2TRC6lWRnU2+VPlbXyNnLemAOgnuvF11rWr6fpuoa5DFHaS/Zri6sYR/pETJgK32YJskBPJZ8842lcV6It3A97JaLKpuIo1keMdVViQpP1Kt+VTU7/AK/18hdfu/r5nmOrax41TU9KuNK+3Jp98wmKXdm26H5lHkyLFbSMo2At8xQhm5fA21nQeJvGCskTzeIpkmeZbiZtAKvaxLc4SSP9wFZzEc7SGzgYXPB9foo2E1dWPKbjW/GtpZxzzSazIJYC0Pk6SHZgl0AGkRYiUd4Dkqcd9oU8V0dtqfiA6P4h+xre39/bxF7Jrqz+zxu5DERorIhOPl6lhyBvznHZ1QtdWjutbvtMFvNHLZJFIzvt2SLJuwVwxPVWByB07jmjpYezucFpWq+KLnxHp1q2oa82lzzSKLq50URSMoiDHzf3AEeHyqsQoYE8NgNXplFFArBRRRSGFFFFAHN33/JU9C/7Aupf+j7GsjWdT8TReMHgtTfx26zRCGKCxElvLbFR50rS+WSsqndtXcM4HytnjXvv+Sp6F/2BdS/9H2NdJSDoePad4l8XyQWsF/deJES4toZLu8Xw63m2kn7wMqJ9nwwLCHI2scMxGByu/pGq+MX+I4s9RLHSBGArGzljSZfKB8wYgIR/MyCrzjA42ZwT6FRV31uD1ON0fVdan+It9azrqn9kGKUILy0CpHKjIBsdYVGxlYkEyOTg/dKkVhz3HjqHxFNYx3ury2v2t7QXP2K32hZFDxTKRDjEY3IxPGccZr06ip7egPqeKjxD8UBpUxnjnSXz0WYrZymS2+V92zFiyuhYRj5FmIG75wCCNvwzqmuf8J9crf2moQ215LC080GmzrFJMLVFILSwjEW5X+YFSGVQeDg+n0VSdgeuwUUUVIBRRRQAUUUUAFFFFAHN2P8AyVPXf+wLpv8A6Pvq6Subsf8Akqeu/wDYF03/ANH31dJQAUUUUAFc38R/+SWeK/8AsC3n/oh66Sub+I//ACSzxX/2Bbz/ANEPQA7xvot7rugw2+lQWU11De290gvZWjQeVKrnDKjkEhSvT+I/Q+et8LdeOi3timieGE+2W9zFIBeyFS0lz5seR9m5EYyF9zxivZKKabX9eVgeqszyc/C7WV1u9vbeazhjmjAigjnVYgnyH7K6i2DtD8m0HzMAE4QcgrqXwsmml+1aZ4b8NwT/AGWFIY3uXYWkqXBkJikMBIUqxAwFxgADHT1eihO1vIOjXc8p1T4Zazf2+sIItHa4vIrlftTzuHvTK4ZBP+6OBD/ARuPyjGzmtDT/AARq1terL/ZGh26xaj9ptgl48q20bCPzCsZgA3koTkFT85+brn0aihNrYJe9uFFFFIAooooAKKKKACub8L/8jF4z/wCw1H/6b7Oukrm/C/8AyMXjP/sNR/8Apvs6AOI1P4Z61fTXRXSPDpRm1AwF7yQFPtDK0b4FvwVZS2OxOQc1b034a3dv4qh1O50Lw6Fa6muLmZJWaVxJEoCEeSN4EgJ5YZ64B4G7e+O/IkXy4m8u+vJrDT3jtZZ8SxK++STZ/DvTGOOAWLAZ2r4f+INhq+iaRLc3It9QultxPH9hnCB5I9+FJGApAbDkleCMk8U0rR9LL7wnro/NnLL8NdcjWN20jw1P/wATBL2S0E5ggz5LxyIoS24DblJyCTyCTxTdO+GWv2kljNLp/h8y2cdoWP2yR/OlhdgzEmDI3RPtzycKF6dPSIPEul3Giy6ss8iWMQy0s1vJHkcYIVlBYHIwQDnIxnNU/wDhO/D3lQyfbJh5pI2mzmDxYbb+9XZmL5ht+cLk8daXW3oDd467f0zk9P8Ah9rVrpUFpHFpNhcJZS2j3sEzysq7WEaxqYlKD5snD4HIAJO4VdT+F95c2ZbStC8O6bPPZT2s9vHcyNCrM8ckbofJGMNGTt2gKWLDJzntk8daDI2yKW8lk2zMIo9NuWciKQRyAKI8kqzAYxnnOMc1VPxH0AX4gL3flNZpdrOLGchg7lFQAJkuSCNv3ieACcgNNppr+t/+D/w4NaWf9bHO6p4I8S6uhFxZaBGy6hJewy/aGklibcjJtdrclc7WDbQDyCG7V0/grw3L4ft9QN5Zafb3F1fTzK1m5fMTyM6qSUUjBdvlAI5J7mr9h4p0jU7m3gsJ5ZpLiLzVxbSgKuSMOxXCNlWG1iG+U8cVmn4haLFfana3QvYn0+6FqQLCeQzN5YclAqEsACScZwBuOAQSLTRdv8l/kLdf15/5s6miorS7gvrOG7s5knt50EkUqHKupGQQfTFS0thnN33/ACVPQv8AsC6l/wCj7Gukrm77/kqehf8AYF1L/wBH2NdJQAUUUUAFFFFABRRRQAUUUUAFFFFAHN33/JU9C/7Aupf+j7Guc8W+BdV1vxVdX1pp2iz2s5sGJurl0kLW8rOxIELD5lcpnd09jiujvv8Akqehf9gXUv8A0fY03xL4rXSdRsLCymja7lu7dJ4ntZJQIpH2ffXCxvzldxOdpwp6hr4lbuF7RfocDF8JtVF0tzJonhnzVntmjZbl91tHFcvIURvs+RmNlj4xwoHTAq/rXw01a8vdXlsNN8PRRXkBt4oo2+zqQssbRSPsgLb1VWGSzYwu3bk12sfjfQ5Jkh8y9jke6W0CS6bcxlZGGVDboxtBHRjhT2Na+nahb6rp8N7ZGRoJl3RtJE8ZI9drAEflyOaE3v8A1qhNJ6P+rf1+B5PefC3W9RguYZNJ8O2a3DXfMV5JL5SyoDGgBt1yFlG/tg/MOa2rHwPrMOoNdzabocczamb1HS5eRbcOsfmFUaAAuSh+YFSdxORkg+j0UJ2/r+uwNJ/meZJ8OL2OO1m/svRH1G0u1eS7a4kzqEeySNnlHlEJIRJk43btoBbGMVbX4e+JT4fGj39j4dmg+xWdkxedpuIQ4LqsluVVvnBXIb7uO+R6vRS6Nd/0Kcm3c4jwX4PvtF1S6vNYtNNEz2ltDHc20zSyF44tkjHdGuCcDnJJAGa56f4X6w9hLEsGjyzfug7tO6/2iyTpJ9omPlHbLtUqMbvvn5gMCvWKKbd5cxKSS5UeZaN8PtVtNUEmoaZopto5pGsTBeyiTS1MruDDiEDkSBSnyghBkkHAs+DvAmseGfDet2U0lnd3V7Ftj+0SLJbzuFI3yRpbx4LZG7JkJ7scc+iUUX0a7j63Ob8C+H7rwzoMun3aWsa/aZJoo7VhsjV8NtAWONQASQAF6YPUmukooobuJKxzd9/yVPQv+wLqX/o+xrpK5u+/5KnoX/YF1L/0fY10lIYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc3Y/8lT13/sC6b/6Pvq6Subsf+Sp67/2BdN/9H31dJQAUUUUAFc38R/+SWeK/wDsC3n/AKIeukrm/iP/AMks8V/9gW8/9EPQB0lFVNT1ODSbP7TdR3Uke4Li1tJbl8n/AGIlZse+MVx3jyC6uNe0YWEOtXMk8FwPI03VHs8EBSjsDKikKTznJwehxik3YZ3lFecT/ETVPDVtNF4h0mK5Gm7be6u7a6JeaX7J5+5YvLHBwwPzccYz2H+KOoQ6XJd3Phk25SzurnZcTzQeZ5ARiFEturFWWThio5BGMc1dtbIEm7K256PRXCSfEDVP7UmsofD9u5W9ksonbUSodxbi4Un90doKEg9SCBgMDkVrX4py39jDf2WiRtaXAaOEyXu2Tzxb+fsdBGdqbRjeCT324OaTTSv5XFueiUVwdv48ubq60xL/AEiK0FzcIN66k22NXtXmVmxGA3CsCp4HB57bfhHxPL4lgvjcWcdrLZXAhPkyvJHIDGrh1Z44yQQ45249CRzRyu7XYN0n3OhooopAFFFFABXN+F/+Ri8Z/wDYaj/9N9nXSVzfhf8A5GLxn/2Go/8A032dAED+CvOkMJvZLW2t72S+spLTaJY3mWQSowdGUrmRiD1+bHbJpWvwwgs3szF4k1vFkLdYlYWpG2BWVAf3GTw7Z7nNNvPiFeW2pX1rBpVncrbSQrHNHfSBJFefyTljBtDqxGVUsBzlgetd/iTqcJvTP4ftAunIz3fl6mWOEk2P5f7kbzyCM7cnIO0jlxu7W6/p/kEurf8AV/8AM6BvBdhPoOp6RqFxc31vqbFpvOEa7eBgKqIqADA/hOe+a567+GH9l6O6eErjbeMiRSRSiC0guUEm8eYIbfAK5bBRVJzyTVtfHmqS7YoNCtPtM15cWkCy6kURzAX3kt5Rx8qggYJJJBwF3GG1+It9qLRi00S2WO5tRd273GpGPehi37DiI4kz/AM/L82SOCr2Vx2v7pZu/hnZ3l8bz+2tWtGaSaTyYJITGvnOkkifNESyl4wcNnqR0OKbcfCnQ7nTBp81xdtarbLbLEUgKBUlMsZ2mPb8hYgAjaRwwaqtl8QNQdbWK20CNoZFs0jeTU2Zs3EW5NxMZJwwwxJJx83J+WkX4l3k4gW30m0L3FtORi9kbyZ442cxyYh2hTsODu3EHOzGcEvdT8v0JjLne+/6v/M3tM8FWmlNpgtby4WHTQ3lwRW9tAjk55YRRLj7x4XapPJBpl54FtbnUrnULfVNSsbue5+0rLbtFmFjEsThQ0bAhlVcht3IBGDXKQ/EPUdXtH0W70a6WY6f/pd/YPcbYJWtvNVhIsSqqkFRnerBjgKR81b+n+K9Tj1Kx0abTbd5rm2t5bWZ75t1xEV/fSMPK+VkwOMnJdeRmqafM1/Wv/Dfd5BdWT/r+tTqdM0620fSrbTrBCltaxLFEpOSFAwMnvVqiik3d3Gc3ff8lT0L/sC6l/6Psa6Subvv+Sp6F/2BdS/9H2NdJSAKKKKACiiigAooooAKKKKACiiigDm77/kqehf9gXUv/R9jSaz4JttX1N71dV1KwaR4ZZY7R4wkjxMCjkOjHIxjggEdeQCFvv8Akqehf9gXUv8A0fY10lHmHSxxH/Cu4bPSrrTrOea8j1N4/tlxdzLHLHs+7MhiiBeXhRliPug5yDntYokhhSKJQkaKFVQMAAdBTqKdwCiiikAUUUUAFFFFABRRRQAUUUUAc3ff8lT0L/sC6l/6Psa6Subvv+Sp6F/2BdS/9H2NdJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc3Y/wDJU9d/7Aum/wDo++rpK5ux/wCSp67/ANgXTf8A0ffV0lABRRRQAVzfxH/5JZ4r/wCwLef+iHrpK5v4j/8AJLPFf/YFvP8A0Q9AHSVSuNG0y61S31K6060mvrUEQXUkCtLED1CuRlep6GrtFAGPP4Q8NXV+97c+HtKmu3kErXEllG0jOBgMWK5JHr1pB4O8MrYJYjw7pItI3Z0txYxeWrMMMQu3AJHBPcVs0UeQHPf8IB4NMxlPhLQvMIwX/s2HJ4x12+nFWYvB/hqHd5Ph3So91ubZtljGMwnrGfl+5/s9K2KKAMGPwL4ShmSWHwtosciMrK66fECpUYUg7eCBwPStHTtG0zR42j0jTrSwRgAy2sCxA4GBkKB0FXaKACiiigAooooAK5vwv/yMXjP/ALDUf/pvs66Sub8L/wDIxeM/+w1H/wCm+zoAra74T8LavJJpANlpmoXZ+0yCzitxczqsiuxIdG3KWVN3HOBk1ZXwLoq69Z6l5Efl2NuILSw+ywfZ7fBzvQeXuVvcMB7VgeE7PWLHx1qDXJvpDdXFzJf/AGizCwqu/wD0YxTbAX+TAKhmAwchT1wbrxP4uSa+igu/EZeMX/lY8OORmN82wDfZ8NvGQTzxjo3zETsl94+W7a87f19x6W/hXw89hLYvoOmNaTTfaJbc2cZjeX++Vxgtx1PNU4dG8F+I0mmt9N0HVVWciZ0ghnAlChSGIB+YLgc84wOlcZaeIPEWreK5UGqalbWcqtFBaNpbpG0rIAAXa2wuw7mP78txgquCKbZalqWheIPEsVraapZ6askslrKumSeW7x2saDeZEAKZjO0qyglcEkMuXbv2v91hb7dzr73wd4B0yEX+o+HPDdnHCUAuJ7GCMIchVG4rxzgD8Kv2fg7wxp7o9h4c0m2ZPutBYxIV4YcYX0Zv++j6muK0l9f1v4deJoNT1C+1HUZIGWG1nsjA8SmPgDdbW5csQxzsx0AJwSSbV/FgtdyXOtLpsk8v2e+XRwbw4jQxpJB5WVjLmRdxRThVyRncR6Atdjrbnw74MW8tLK80fQhcyQPBawS2sO9ogPmRFIyVAPIHHNX7HQrXT7wTW+Viii8m1tVjjSK0j4ysYVQQDtBOSenGBxXnoufE+q+I9KTW/wC1tNu1nZSLPTRJbWm61ZVlWYxsCS7EHcSo4BA6t1/guTWrrT5LjX7qaSVD9lEbrEFZoiUeYbFH32BOM4AAwBzTtb+v6/p+pKd/6/r+kdLRRRUlHN33/JU9C/7Aupf+j7Gukrm77/kqehf9gXUv/R9jXSUAFFFFABRRRQAUUUUAFFFFABRRRQBzd9/yVPQv+wLqX/o+xrpK5u+/5KnoX/YF1L/0fY10lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN33/JU9C/7Aupf+j7Gukrm77/AJKnoX/YF1L/ANH2NdJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc3Y/8AJU9d/wCwLpv/AKPvq6Subsf+Sp67/wBgXTf/AEffV0lABRRRQAVzfxH/AOSWeK/+wLef+iHrpK5v4j/8ks8V/wDYFvP/AEQ9AHSVkax4jh0m8t7GKzutS1G5RpIrKzCeYyKQGcl2VVUbhyWHXAyauanZT39n5Nrqd1pkm4Hz7VYmfHpiVHXB+maxNZ0XVk8TWfiDQDaXFzDaPZzWt9M0KSozKwYSKj7WBU/wkHPbFHVX/r+mHTQ37O5N3bCVrea2O5lMc6gMMEjsSMHGQQeQRU9cFr3gvWNb8QQajN/ZruY4Qs7O4l0xkkLs1v8AKd28EK2SmdvOR8o5ST4WeIfsl1DFpHhuLfBdpE66hNkPLP5sL4+zcGLLBcdCSRtzT06jt28j1rWdVTRdMe+mt5p40dFZYNu4BmC7vmYDAzk85x0B6VbjkZ2kDRPGEbarMRhxgHIwTxzjnB4PGME+OeHfBur3miy3ek6Np+lSL59usM3n2jXKtciRTIGgBCoqkJhWzv8A4ORW3J4B1W4vr17zS9EurG41Ga5/s9ryREIkWMeduEOVmUxkggH/AFjfMCMktrb+v6tqTe/9ev8Awx6NdXUFlbtPdSLFEpALN6k4A/EkCpTwDxn2ry3UPhpqepXGsS3FhoBW/MbCFeI5TFcCRGk/cZLMm5WZi5z04JAh074Xazp0Woq0lldrcSxs1vPOqwXyK5by5US2DDg7dzNLwACMcUlrYbPSdE1aPW9Kjvorea2DO8bQz7d6MjlGB2sy9VPQmrkztHEzpE8zDoiEAn8yB+tcJF4L1IeD9OspbPSGvtM1Q3kCea5h8sysxUOY9yHY5XAU9MZweOf0/wCF2sWeh6jbyaT4ca7f7L9kdblwqmJ8lj+4+QlVUDAPQDOAKfUnU9eoryqf4fa+upXtzZ6H4W/0u6unk8+5dxJFLs+Rl+z4PKliDkAnOG72NF+HjaXOjeJNL0q/0y202a2fYGnlkBmZ0HkrAqkBGKgL0JIVcUul/wCtv6RWvT+tf6Z6bXN+F/8AkYvGf/Yaj/8ATfZ1F4E8Opoej73iQTSARRObfypBax5WBGB5BCckHuzcDpUvhf8A5GLxn/2Go/8A032dNqzA6SmSyNHHuSJ5TkDahAPJxnkgcdfw79K80m+FJ/4SSW5t7fSE057t8weRhntJgGnjb5eT5i5UZwAT9Kow/C3XLFb0wtYXs0l7bXMUlxdLGriKcS7mVLXcr7coGLyHB64GKUdWr/8ADA+p3mqQ6H4UjvPEkehQfamKi5uLO2iWeQFguWYlSwGcnnOBwD0q5rep6daWk0Ooxfao2hMk1usQkzDkK7Fe6jdyOTjOAa8ltPCF9q+q+JXtPD1ul/d+bEt3fCa2CKZgxG42YLblHUSzYwANqnje07wVfaBrl1rUvh7Rz+6uILSGwkaWWLzXDIFzCoUZZw3ICgk85NLWy9P+GXzDVN+v/Dv5Hoek6Zpek6ekGh2NpZWh+dY7OFY4znnICgDmrteb+KfhxqWseHvDmnWt+JF0q2EE0bzLF5jbUAlV2hm2uu04IUN8xwy95tQ+Gzzw6zbaeun2cV3/AKVaTJEPNiunRUlYnZgBlXrgk+Y2Rjg1K2oLZHfXFvDd20lvdRRzQyqUkikUMrqRggg8EEdqaI47Kx2WlsBHDHiOCEKvAHCqDgD0HQV5n4f+G50i5M3iPSdNu9MTT5YpYw4upMmQuFSKO1iUoAWwoXI3EAc10/gjw7/YehvIsMRuZF8qBnh8hvs0eVt4343DC4JyMgs3A6Uns/67iT1LNx4yhg8MW2urpOpz200JnkSKOMvbxgZZn+fBx6KWJ5wDiugilSaFJYjuR1DKfUHpXGxaT4ot/A9ho40/SJ5VUxXsbanLGjx88K4tyfm7/KMDIB712FuJFtohMqLIEAdYz8oOOQM9qfcfY5++/wCSp6F/2BdS/wDR9jXSVzd9/wAlT0L/ALAupf8Ao+xrpKQBRRRQAUUUUAFFFFABRRRQAUUUUAc3ff8AJU9C/wCwLqX/AKPsa6Subvv+Sp6F/wBgXUv/AEfY10lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN33/JU9C/7Aupf+j7Gukrm77/kqehf9gXUv/R9jXSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN2P/JU9d/7Aum/+j76ukrm7H/kqeu/9gXTf/R99XSUAFFFFABXN/Ef/klniv8A7At5/wCiHrpK5v4j/wDJLPFf/YFvP/RD0AXfEviO18L6Wl9ew3EyPcRW4W2geVsyOFB2oCe/pz0HJFUU8f8Ah+TThfpLfG03mNpv7LutsTBirBz5fyYKkHdjHfGRWprmiw69potJ557fbPFOksBXejxuHUjcCOqjqDXOXPwysLzQU0m71jVJrdZp5mL+Qd7TMXJK+VtyrncpABU98cU1br/S0/4IPy/rf/gFvVviJoOlxXf7y5uZbVlRo4bOZt5MgjOxghDgMQDtzg8HnAq1qXjDSdIvHTULqWFEhikdPsE7MBK+xG3BcY3cEYyCRnFVz4HgOmXmnDWNTFlcSieODMJFtIJBLujJjz98ZwxZecAAcUmveBotf1J7ybWtUtWeGKEx2wg2/u5RKrfPExzuHPOPal2Aytc+JEMV7pkGhyoqXSTTyz32n3OxUikVHjOFBjfJI+YHBCgr861u/wDCc+Hxb20xu5gtw5jVTZzBoyG2HzF2ZiAYgZcKMkCsW4+FWn3rsNR1vVryFxcq9vMLbYwncSODthB++qsOe2ORkG/pPw/stCFodI1G7sntwyu1tb2sIuEJztdEhCcHkFVVuvPNNW0/r+ugS/ukemfEfRdSkuGaa4s0tVnMkd1p86Fwkwi3I7KFb5uNi7mywHBBBsS/EXwzBFG8t5cKHWRtp0+43J5ZAkDr5eUK7gSGAIByeOaot8MNOkvJZpNX1V4n80x2xaAJAZJhOWQiLfkSAMMsemORxS3fwztLvez67q6TzRXEdzOv2fdc+cqq7NmEgHbGgG0KBt6UlbS/9f1/Xk/teV/wOms9asb++uLS0kkkktziRvIcR544DkbWPIzgnFXqxtN8OLp2qC/fUry7lFuLfbMIlUjIJYiONdzHA5Occ4Ayc7NMlXCiiikMK5vwv/yMXjP/ALDUf/pvs66Sub8L/wDIxeM/+w1H/wCm+zoApaL49s3S/g1+6jhu7O4uVJjtZUR4o5vLBUncGflAVVicsOBkVbf4h+GordppLy4RUhlnkDWFwGjWIgSBl2ZVl3KSpAbBzjHNZ8vwwsbicvc65q8qedPOsRNuAryyLKSCIg3yuisvPBXnIyKkvvhpp2oWTxT6pqYuJxOt1eK0IluRMio+/wDd7RwiY2quNo98i2V+34/1/Xavd5vK/wCH9f130Y/HWgzXHkRT3UkomaAqun3Bw6/eB+TgDg56YIOcEVS8a+Lp/D93p9jYmGKe6WSVri8tZpLeOOMAsGeMfJnP3jwvUg0+LwFFHpdzYtruqypc3JuZJXW2EmSFBCkQjaML1XDDJwQcYteIvB1p4murd7+9vI4YYZYGtoTGEmWQYbcShcHAGCrDGKO39f1qQvP+v6QyPx94el8hRc3IlnlaFIW0+4WTzAm/aUMe5SV+YAgbh0zT9W1q+0/xXpNmrW62V6zRsJLeTcTtJyJshFOcAIQWbJIxg1Wt/AVvDqdlqMus6pc3lrc/aGmmMGbgiMxKr4iA2hGYDbtPzEkk81rXeifbtXhvLrULt7eAq6WGIhCJF6SZ2eYSPQvt9qel1/X9f16hrZ+n4/1/XQ1KKKKQwooooA5u+/5KnoX/AGBdS/8AR9jXSVzd9/yVPQv+wLqX/o+xrpKACiiigAooooAKKKKACiiigAooooA5u+/5KnoX/YF1L/0fY10lc3ff8lT0L/sC6l/6Psa6SgAooooAKKKKACiiigAooooAKKKKACiiigDm77/kqehf9gXUv/R9jXSVzd9/yVPQv+wLqX/o+xrpKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm7H/AJKnrv8A2BdN/wDR99XSVzdj/wAlT13/ALAum/8Ao++rpKACiiigArm/iP8A8ks8V/8AYFvP/RD10lc38R/+SWeK/wDsC3n/AKIegDpKKKKACiiigAooooAKKKKACiiigAooooAK5vwv/wAjF4z/AOw1H/6b7Oukrm/C/wDyMXjP/sNR/wDpvs6AMx/iA8mo3+mxabG06TRw2jm7dIp/MaRAWk8v5SDE+dm/HAzuyBl6F421Sy0nTrMaYt+phtybmfU2aQ+dNJEoJKMWwyDLbjkEnqMHt28L6A8dwjaHprJdZ+0KbSPE2W3Hdx83zc89+arHwP4TLBj4X0YsDkE6fFx8xb+76kn6kmheYPrY56Hx5fyt58ehw+fItkjRtqb7B50skXA8rAKuvUDLKRnGAtPsvHF7e29xe22iBplsrWcxm/kZFV3lD5CxnG0xt8yqSwK5wBxt/wDCA+D/ACTD/wAIpoflNjKf2bDtOCSONvqSfxNSw+CvCtvC8MHhnR4opE2OiWESqy5J2kBeRkk496fQOpztj431uTXbuCbTdNlsDcOLe5TUWGyNIY5SSPKwRtcnO7qccDmoo/HmtalJb/YdItIwkl1FdxS3kse4xwh12MYA2CHHO0e2RgnrW8K+Hn1Q6m+haY1+RtN2bOMy427cb8Z+7x16cU0eEvDgtVth4f0sQKSVi+xR7QSmzpjH3Pl+nHSk9Vby/EFo1c5mL4gziCP7Lo6vb+T5cTS37GQzi2+0bGBQnZt48zJJP8OOansPHt7eMol0WG3VLxLe5la8Zo4VeOKRDkRcsRKBghVypG/kZ6BfCnh1N2zQdMXdbfZDizjGYP8Anl0+5/s9PaorPwX4W090ew8NaRaskglVoLCJCrjowwvBHrVXXNf+txJNJL+v6/ryNuiiipGc3ff8lT0L/sC6l/6Psa6Subvv+Sp6F/2BdS/9H2NdJQAUUUUAFFFFABRRRQAUUUUAFFFFAHN33/JU9C/7Aupf+j7Gukrm77/kqehf9gXUv/R9jXSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc3ff8lT0L/sC6l/6Psa6Subvv8Akqehf9gXUv8A0fY10lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzdj/wAlT13/ALAum/8Ao++rpK5ux/5Knrv/AGBdN/8AR99XSUAFFFFABXN/Ef8A5JZ4r/7At5/6Ieukrm/iP/ySzxX/ANgW8/8ARD0AdJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXN+F/+Ri8Z/wDYaj/9N9nXSVzfhf8A5GLxn/2Go/8A032dAHSUUUUAFFFFABRRRQAUUUUAFFFFAHN33/JU9C/7Aupf+j7Gukrm77/kqehf9gXUv/R9jXSUAFFFFABRRRQAUUUUAFFFFABRRRQBzd9/yVPQv+wLqX/o+xrpK5u+/wCSp6F/2BdS/wDR9jXSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc3ff8AJU9C/wCwLqX/AKPsa6Subvv+Sp6F/wBgXUv/AEfY10lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzdj/yVPXf+wLpv/o++rpK5ux/5Knrv/YF03/0ffV0lABRRRQAVzfxH/wCSWeK/+wLef+iHrpK5v4j/APJLPFf/AGBbz/0Q9AHSUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzfhf/kYvGf/AGGo/wD032ddJXN+F/8AkYvGf/Yaj/8ATfZ0AdJRRRQAUUUUAFFFFABRRRQAUUUUAc3ff8lT0L/sC6l/6Psa6Subvv8Akqehf9gXUv8A0fY10lABRRRQAUUUUAFFFFABRRRQAUUUUAc3ff8AJU9C/wCwLqX/AKPsa6Subvv+Sp6F/wBgXUv/AEfY10lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN33/JU9C/7Aupf+j7Gukrm77/kqehf9gXUv/R9jXSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN2P/JU9d/7Aum/+j76ukrm7H/kqeu/9gXTf/R99XSUAFFFFABXN/Ef/klniv8A7At5/wCiHrpK5v4j/wDJLPFf/YFvP/RD0AH/AAsfwR/0OXh//wAGkH/xVH/Cx/BH/Q5eH/8AwaQf/FVs6lqun6NZm81i/tbC2UhTPdTLEgJ6DcxA5rkvG13rUWs6UNCvtaaG5gmL22kJYszbApD5uVxj5sEBueMDrSbsNK5qf8LH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFVkaT8R7f+xLCS/gubyf7PE+oXNrEqx2jO5jXzAzKwJZWBCqcYJOBzTpPivo9tpbX2oWF/YR7VMQumt4/OJdkKhjLsXDKQS7KOmCab0diU7o1f8AhY/gj/ocvD//AINIP/iqP+Fj+CP+hy8P/wDg0g/+KpLnxzp0PgmHxVbwTXenSxCUmKWBCiYOSTJIq8YIwGJ9M1TX4l6UJ7gXNjqNrb27ujXUqRmMssImAAVy3zRnI+Xtg4OAXZ3a7BfRPuXf+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qqei+Ib+e08U3V/DqSCxnzDaSpbieFPs8cmxSp2HliQWY9cE1OPHVhFdQ2wtr+ePdDDJebY/LjmlVWjjf5gQzBl5C7QWGSKX/A/Eb0Jf+Fj+CP+hy8P/wDg0g/+Ko/4WP4I/wChy8P/APg0g/8AiqzLb4k2fl26/wBlazMJYoZjK6W/yLNK0ahtsg5DjbwD1B5GSN7wlrsviXwvZ6tPYy2DXSbxDKyE4zwcqzDBHvn2FMCp/wALH8Ef9Dl4f/8ABpB/8VR/wsfwR/0OXh//AMGkH/xVdJRSA5v/AIWP4I/6HLw//wCDSD/4quf8OePvB8GveLJJ/FmhxpcatHJCz6lCBIv2G1XcpLcjcrDI7qR2r0Sub8L/APIxeM/+w1H/AOm+zoAP+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4quUl8W69Z6xrol1FCIkuBaQyxRm3bbIqI0LKAzFMkSq7HDYxgVLca/r8eqajoceskSaTFcXJvpIIi9yI4oHVHUKFAzMQxUA4AwQeaOl/K47O9jpv+Fj+CP+hy8P/wDg0g/+Ko/4WP4I/wChy8P/APg0g/8Aiqj1bxzb6JBZvd6Zfzm6sZL4m1WNgiRhTIDudTkB89OcYHOAaOpfFHS9L0+e6utN1FTDcCBom8hGJMYkVgXlVfmUjC7t5JxtzxQ9P6+Qlqk11NL/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iq3bG5N5YQXLW8tsZo1cwzbd8eRna20kZHsSKnptWdg3Ob/AOFj+CP+hy8P/wDg0g/+Ko/4WP4I/wChy8P/APg0g/8Aiq6SikBzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVXSUUAed3nj7we3xJ0a6XxZoZt49Jv43lGpQ7FZprMqpO7AJCMQO+0+hroP+Fj+CP+hy8P/wDg0g/+Kovv+Sp6F/2BdS/9H2Namoar/Zjb7qFTbnhXSVd5PcbDjP0Ukn0oAy/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iqzPEWpa9ol9d3Nlqf2u3eykkNvPbosdk5ZVhYEAMc5bIdjnaSNuMVPB4mn0HSdcfWWutXXRbtIWnijjE0qPHG+4qNi5BkP3QOBwCerWv9edgLn/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVVYfEOxEsqT6VqkBh+0Bt8UbfPCNzRja5JJXDA9MdweKp2/jOTxfoby+H1vdKGZv8ASybabKxpktGyNLGw3si5Of4vSpbsr/MFq7fI1f8AhY/gj/ocvD//AINIP/iqP+Fj+CP+hy8P/wDg0g/+KqGwg1DW/hpphnuftt/c21vcPNcBE3MSrn7igDHIGB6fWuqqpJxbT6ExkpRUl1Ob/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qukopFHN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVdJRQB53eePvB7fEnRrpfFmhm3j0m/jeUalDsVmmsyqk7sAkIxA77T6Gug/4WP4I/6HLw//AODSD/4qi+/5KnoX/YF1L/0fY1Zvri8h8ZaXBDeSLbXNtceZbFEKFl2FXzjdn5iMbse1AFb/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iqXQ31e21XV4L6+k1a0hWN4ZWijjcSkMZIl2hVKjCYzkjcQWOKzbT4n6ddRwS/2Rq0MUyW8u+SOLCRzOY0c4kJxvG0gZPcArzT62DU0f+Fj+CP+hy8P/wDg0g/+Ko/4WP4I/wChy8P/APg0g/8AiqzI/H8ev3t/ouiWeoW13Ewg+2t9nZYXZ9mdokZlYAM4V0HC8jBGYvDvjxV8F3N9qZutRk0sMt5dKIU3OJCApGUCkLtYsQqAHO7g4XS4dbGx/wALH8Ef9Dl4f/8ABpB/8VR/wsfwR/0OXh//AMGkH/xVZlx4xn1fwjYa/osGoWUbanDCIGFu7XcZlEbAEM67WycMGGcA5x1mi+Jmlytxp+pAQsEv2MceNPYyNEBL8/Pzowym8ADJOMGnZ/18v8xX/r7/APIu/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVYlz48mh1+a+trHVrvR4tOmmEEUdvify5UUzREsGwAzAhmGQAQp6neuvGEFtolxqw0y+mtILkQF4jCd6kgGUZkA2AnBJweCcY5pdL/ANb2C+tv62uM/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qsmf4saRaWEl3d6ff28cUz28hmktkCSq+wIzGbaC3JBJ24GSRxmS3+Jekz6Xf6zDHfyWdtb20wU+QEZZSwDK+8Acghi7BRtz05J0uPZ2NL/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrndO+I8lz4gF21jqv9kXlpbGGB0tj5DSTyRCQsjnKMQmMM3XIAGTXWeEten8SaAmo3OnTaezyyIsUrIxKq5UH5GYdvbkHjGKdna4PR2/rucreePvB7fEnRrpfFmhm3j0m/jeUalDsVmmsyqk7sAkIxA77T6Gug/4WP4I/6HLw/wD+DSD/AOKovv8Akqehf9gXUv8A0fY1p3mrf2fcql3CBHK22Jo5AzN65Q4J+i7jSAzP+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qsnWNQ8QaTqN1DBqxuobhraESyW8aixllnWPCYUbvkYthyxBC5OGxV638USaR4ZuLvV1udSNlqJsGmt40EkgMojVyuVXPzLu2jrnA7ULVX/AK/rVfeD0dix/wALH8Ef9Dl4f/8ABpB/8VR/wsfwR/0OXh//AMGkH/xVZ8nxO02CGWS50rVIBEkzESLCMtDIEkTPmbQVLAliQmDndwcQTeLrrxP4Um1DQDf6Mkdrc3IndbeR28vhCuDKhVmDEHuE44INJuyuUou9vka//Cx/BH/Q5eH/APwaQf8AxVH/AAsfwR/0OXh//wAGkH/xVOFle6l4X0Utcfa7lJLW5lnuNqM2CGY/IoGSMjAAHNdFVNWun3M076o5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKRRzf/AAsfwR/0OXh//wAGkH/xVH/Cx/BH/Q5eH/8AwaQf/FV0lFAHN/8ACx/BH/Q5eH//AAaQf/FUf8LH8Ef9Dl4f/wDBpB/8VXSUUAc3/wALH8Ef9Dl4f/8ABpB/8VR/wsfwR/0OXh//AMGkH/xVdJRQBxvhzW9K174k6/daHqdnqVumk6dG0tncLMisJr0lSVJGcEHHuK7Kubsf+Sp67/2BdN/9H31dJQAUUUUAFc38R/8Aklniv/sC3n/oh66Sub+I/wDySzxX/wBgW8/9EPQB0lYus+E9L16+hu9QN+J4YzHG1rqdzbBVPXiKRRz3PU4HpVPx7rqeHfDsN9NLp8cP2+1il/tBcx7GmUMR8ygMoJYE5xtzivN9V+KNzqPhHVoZPEnhyOSazujDJb5BHl3HlDgzHPmIcrjpjPzZwBK/9eVxv3Vdnpp8CeG99qyad5QtY1jRIZ5I1ZVYsodVYCTDEsN4OCSRyarRfDXwzCqhLe++RNkZbVrpjGN5fKky/K24k7hgjPWuE0rx1deHLq70TS9P0uLTbNCyNE6Ksasyk3Sx/aGkMB3s21UCqq4DkcibV/HGrWd489/4i8K3GnCxhl2CFngu1a5MbMjGcAELsJ++FJA56l7tef8AX9f8OL7Lfb/gHpF74X0vUdPtLO9juJorNt8LPeTeYDtKnMm/c2QxB3E5zzWWPhn4WB+azu5FLl2jl1O5dHJj8s7laQhvkG3kdK5TVPijqlpb6xcQTaODZxXLi2ljfzLLynAjM58wBhMPukBfvDG8ZrQ0/wCIktzerA+s+H50i1H7JK1qd7z7hGUEcfm5BG9gSN/3D8o5wJNv1CXu7+h0K+DLbTtL1C28OTNZS6iFW4mvJZ7zcAuwnDy8Ns43Z7DIbAFWB4N0X7ZBdvbSNcQxogYXEiq5RdqOyBgrOB0YjI7EVu0UgOSX4Y+F0iWNLfUAqokYA1i7+6khkUf63s5JFdDpWlWmiabFYabG8VtFny0aVpNoJzgFiTjngdAOBxVyind7AFFFFIArm/C//IxeM/8AsNR/+m+zrpK5vwv/AMjF4z/7DUf/AKb7OgCxH4M0CO7u7gWG5rxZFlR5naMeZzJtjLbULHlioBJ5OaY/gjQJLGK0ks5Hiidn3PdSl5CwAYSOW3SBgACrkggAEHArnbv4gahpz3Ih0GGby2vpJd2qPwLYpuK5iP3lbIUYAPHQ7qdpvjbxBPr81nPo+nvbTX09vbTDUWUxrHGr/Ovk9MEnIYnJxjHNC2TXa4SutX3t8zotf8G6L4mkifV4rpzDC8C/Z7+e3HlvjepETqCDgZznpWHqfwytnnim0C/uNOl3hrh5ry9laUBAgw6XMbKdoA+8QcDIOBhlp8RLya5/f6VYx2Ud4tvNerqEnlqske+KRS0C7wx+XI4yRgtziOH4k6jLq17p/wDwjMnm2UDmaRZJ2hSZYRLsaXyNgQghd2d2f4MYNGyb/ruPsv67HdWdubSxgtzLJMYo1TzJWLM+BjJJ6k+tTVwEfxI1CVo7ZNBt1v5YPtaRPqJWMwCJZD+88r/WYbGzGOCdwGcLb/Eq4uriBLfQxItxciGFRd4lYNZm5Q7CgAYgbSM4B5yaqzbYo6pWO+orkrvXry+0iwh2rZXV7qC2NybaVnNt8pZhuZEIJC4BKjG4H0rmpPE3iH+0bW/NpEzWl7qNtHapqcqxzxQof9Z+7xuBTgkMcnqMmp9f62/zQa6f13/yZ6lRXFWfjS5lsLy+j0lEiivmS4kmv3McUQiRxJnyzt4ZcqAFBDEt3Pag5GRyKbTQk09jm77/AJKnoX/YF1L/ANH2NdALeFbhrhYYxMy7WkCjcR6Z64rn77/kqehf9gXUv/R9jXSUhmIfB+jvf3V3Kl5M14GE8U2oXEkLbl2n90zlBxxkKMdqJPCGjS+HZtEeC4NlOweYC8mEsjZBy0u/zCeByW6DHStuijyA4y++F+hzWMyWLX0N0/mtHPcald3Cq8i7WZlab5sgY659CDzV3RfBy2Wi3Nlq1/dahJdKUllW7ulKof4UaSeSROnOJPyrpqKPIDF0PwlpPh1w2mLefLEIYxc6hcXKxoMfKgldgg4H3cdB6VtUUU7thawUUUUgCiiigDm77/kqehf9gXUv/R9jWneaFY32r2mp3AuPtVmrrC0d3LGoDfeyisFbOB1B6Csy+/5KnoX/AGBdS/8AR9jVDXvGN3o3iO6tLfSY7poxYorPqDRhluJniB2bCAVYfiD1GAKErtIfRs3NK8L6boy3AsWvyLhSr/aNSuJ9oJJO3zHbZySflx+lY0fws8KxQmKO31EJsSMKdZvCAqNvRRmXgK3IA6GsKL4k6+2sS50Kxazja1t5IxqLB45ZbmSAlf3OHG5O5XgA9TgaV54+1W2u9StYdEsbuexs3uwYNRlMbiNlWVC5t8b1z0Xd0525FOzv/XQV/wBPxLnhnwNLod5JPfatLeqN4giSS5RIw2edjzyIGAJAMaoBk8dMMufhrpUWj3FpoLzWE8yInnT3dzcABJfNGQZlbO4nDKysMnBFVtQ+I9xZ61bWNvob6gly3mRy2LzT7oN4QyYSEgEMW4YquFzuycVBF8S78mKO40G3inu5pLe0A1ElHljuPIIdjENi5IIIDE5xtzjIk3awrpXZ0dj4UhXwv/Y+sXM+oqzCR5WuJwysCCCjvK8q4IyP3hIPQ0n/AAgvh0T20o08q9uoUbbiUCUBi480bsS4Ylv3m7kk9TXP/wDCzLrY7NokCmJPnBvz99boW8gX93ggE5U/xdCFrafxe1lpOtXurWAtm0qFrg20cxeVovm2sQVULnaehZevPBou9/600Gt+Ud/whGm2V3Jf6En2PUGV0V5pZ5oFWRgZF8jzVXBxnAwA3OOudCLw7pkfhZfDptlbTBa/ZTDnaGj27SOMY49K5y08c6rceIINGl0K1S7eQpI0epF4l/diVSreUNwKk54BBA4IO6u3pdLAnrdGCfBPh/yLmJLAxi5MTO8U8iODEoWMq4YMhAHVSD+dZ2rfD2zurS5/sm7ubS+ufID3N1eXdxlYmyn/AC3VgevzKytyeeTnr6KAOPt/hrpDQKdXn1G+vGREln/tW8QNsfeoAMzEBW5GWYj1rpNL0q00ay+yacjxweY8gRpXkwWYscFiSBkngcDsKuUU7sDm77/kqehf9gXUv/R9jXQJbwxzSSxwxpJLje6qAz46ZPeufvv+Sp6F/wBgXUv/AEfY10lIDATwVoqNd7kvpRd7vNSfU7mVQSwYsitIRG2QCGUAjHBFTXPhLR7rw6uhywTCwVxJtju5Y3Lht+4yKwctu+Yktknk1s0UeQHDan8KtFuLEJpUt5aXkcjSw3FxqN5OEZnV3JXz1JLFQchgQQCCCM1r6f4Pt4vDk+lardXV99qQJcyi7uFZl/uq7StKq8njzD94jOOK6KijpYOtzI0XwvpmgSM+n/bWZoxGDd6hPdbEHRV8122j2GM4HoK16KKd2wCiiikAUUUUAFFFFABRRRQBzdj/AMlT13/sC6b/AOj76ukrm7H/AJKnrv8A2BdN/wDR99XSUAFFFFABXN/Ef/klniv/ALAt5/6Ieukrm/iP/wAks8V/9gW8/wDRD0AdJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXN+F/8AkYvGf/Yaj/8ATfZ10lc34X/5GLxn/wBhqP8A9N9nQBPJ4G8JzSPJL4X0WR5Gd3ZtPiJZn++SdvJPc96mg8JeHLa8iu7bw/pcNzD/AKqeOyjV4/lC/KwGR8oC8dgBXAJ4g8fJqOtC8guEgjmCqkFlJK8EXnhfMgH2cJIfKJbb5kx3Y+XqtRt4j8VpbPPBfa1exZljiaHSVkJaG82Heqw5VmizkEDODtANNapeYPS7PRoPDOg2tvJb22iadDDJt3xx2kaq21ty5AGDhiSPQ80t34a0LUL572/0XTrm6kiMDzzWiO7RkYKFiMlSCRjpXm97feKdU1KZFn8R2+nJqFrLCW05fNQCZ1kXAtgNgxGw+/xyWIyBJo+t+OptN1CXXpruzlikjbybfTZpZQw3740P2TYUOEwR5uPm+f5gQlqr/wBdP8x2s7f1/Wh3S+B/CaIyJ4X0ZVYoWUafEASn3Cfl/h7enarN54Y0HULv7Vf6Jp11cfL++mtI3f5c7fmIzxk49MmuS8WP4kj17TNQ0U6oGGkXB+zJbpJGZsxHbJ8hAbbuIG5QWQAHkg7vgu71S7sbw6nLeXFulztsrnULT7LcTRbFJLx7ExhywB2LkAHHc1br/W9ibmjJ4d0ttHOmW1pHZWofzI1s0EXlSBtwddowG3c59etQXHg7w3euZL/w/pd3KzMzyz2MTs7MAHYkr1YAAnvitqipGYsHgvwvaw+TbeG9Ihi8wS7I7CJV3jGGwF6jAwfatqiigDm77/kqehf9gXUv/R9jXSVzd9/yVPQv+wLqX/o+xrpKACiiigAooooAKKKKACiiigAooooA5u+/5KnoX/YF1L/0fY1avvDXhjVdVebUtF0m91DYjO9xaRSS7QflJJBOMg4+lVb7/kqehf8AYF1L/wBH2Nc54t1zxFZ+Krq00yfWktc2DRta6ObiNQ0rLcAOIWBxGVbrkEcdxQtWkPo2dUvgbwkgQJ4X0VRGwZANPiG0g5BHy8HJJ+tXotB0eC/lvYNKsY7uYsZLhLZBI+7G7LAZOdq59cD0rySDVfFx1dr/AO3+KFZntLdVbQTsmiF1KsjOpt8qfK2vkbOW9MAauta74tsr3V49Pn8QvBDAVt5JNJWZvPSWMfIsdsAyOrMc7mz82Nm2nb9SW7XfoehT+GtCubezgudF0+aGxx9kjktUZbfHTYCPlx7Yqqvgbwkm7Z4X0Vd6NG2NPiG5WOWU/L0J6jvXnd54k8YywXK6TdeInlLXa2xl8PNFlUQSRMS9uACWynOAR23fNW1Y6/4gm1BneXXGgGplYbd9HaJpoXWMrucwYVFzJySrcDLZGCWuDdv67fodlc+FvD95bQW93oWmzwW0Zigils42WJDjKqCMAHA4HHApdNtNAtrm/s9It9NinypvoLVI1bJX5fMVeeV6bu1cMmq+KvLtbya/1sN9rWLULBdEGLbckgPlP5RMsYfyyGG7HJZiDgZtjrniCfTprhrfxFBrVzp1hFJcJpDxfvx5u/dvt3ULuZQxVDjdkYAJB0b/AK1Kas7HpNr4V8PWMlq9loOmW72bM1s0VnGhgLfeKYHyk98da1q4jwXqevarql02rzalGkdpbSLb3Omm3j814v3ih2jUsAwzgEkEnPGAOen17xslhLL5mspMPKN0i6Pv+yzeegaOHEJ86IxFyW+YjaPmBOKGnzcpKd1c9YorzLRtd8T3mqC3urrWoUt5pEtnn0JhHqAErjEzeUvl/J5RDDYuSfvYKiz4O1rxZN4b1u58Ux3huYIt8UNvauLhH2nekYe3jRwCBtx5vuzcZLaNj62PRKK5vwLe6teaDL/bxunuYrmREkuoDE8kXBQkeVECcEZwg5BHUGukoasJO5zd9/yVPQv+wLqX/o+xrpK5u+/5KnoX/YF1L/0fY10lIYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc3Y/8lT13/sC6b/6Pvq6Subsf+Sp67/2BdN/9H31dJQAUUUUAFc38R/8Aklniv/sC3n/oh66Sub+I/wDySzxX/wBgW8/9EPQB0lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc34X/5GLxn/wBhqP8A9N9nXSVzfhf/AJGLxn/2Go//AE32dAHSVU07SdO0iGSLSdPtbGOWQyyJbQrGHc9WIUDJOOteWeJ/CGoWUmq6vdaPp10Ly5gKW+n2ryF2S6V1kdI4C2fLLhmJfGOPvYqufAU5186XBothBNc2rS/akt5hBpmZtyC3l8nazpklVJTG44wOKI628/8Ahwlon/XzPZqDwDxn2rzE/De9+wOJNJ0G5c6lczvZTzP5FzDIzNHvbysq0ZcsF2suckEE5EC/DTVbaVHGnaDqbeQLeZr2Zx9oPkbPPYeS2JSSVzlvk75Jo6f1/X9eo+tj1KJ2khR3iaJmUExuQWQ+hwSMj2JFOd1jjZ5GCqoyzE8AV5Db/DXxBHdWzzaN4bl2fYhLIdRlDOIYvLkGPs3O9Tg88gAHI6S6f8MtdM1odUs/D8aQW81o32Zy7SQSRyKI3ZoAzhCyYXcFxn5cgGnLrYmLbtdHptzqkUGhSarBHJdwJbm4VIdoaRdu75dxAyR6kVYtbhLyzhuYgwSaNZFDdQCMjP515NZ/CvW9P1GK8tf7PUx2HkxW8N2sMcL+QY2jz9lZ2jZiXOHQbjnYSMne0zwhC/iq2mn0+2iaG1gOrKtoxjnuYgPIdJXRfMxuckgZBVM4IxTsuZrp/wAOGtl/Xb/gnoFFFFSM5u+/5KnoX/YF1L/0fY10lc3ff8lT0L/sC6l/6Psa6SgAooooAKKKKACiiigAooooAKKKKAObvv8Akqehf9gXUv8A0fY1qatq6aOlq81vPMlzdR226Hb+6MjbVZtzD5ckDjJ56day77/kqehf9gXUv/R9jWP4o8H6vqfihdTsINJu9kttJDLfSuktsIpAzxptRhtfqeRyACDwVFugezsd5RXlCeA7zTrCc3VjpkOqz3sN3pjadZmWG1ulHzkhYUEcbBRlmOTkgsSFz6XpOl2ui6TbadYRLFBboEVUUKPc4HcnJPuadtBdS5RRRSGFFFFABRRRQAUUUUAFFFFAHN33/JU9C/7Aupf+j7Gukrm77/kqehf9gXUv/R9jXSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN2P/JU9d/7Aum/+j76ukrm7H/kqeu/9gXTf/R99XSUAFFFFABXN/Ef/klniv8A7At5/wCiHrpK5v4j/wDJLPFf/YFvP/RD0AdJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXN+F/wDkYvGf/Yaj/wDTfZ10lc34X/5GLxn/ANhqP/032dAE8GoarPret6ej2ZNssL2jGJ12hw2RJ8x34K5425zj3qvYeJpLHwzqGpeK3hjTTZ5Ip7qzgkMciIceYsYLsBzgjJwVbnAqy/hpjqWrXsWtalBJqcKRFYxDi32ggNHmMnPJ+8WHPTpiGXwgLjwfeeHrzWtSuIbtDE1yy26yohABVQsQQDAP8BPJ56UAul+4R+PfDck7Q/b3R1MgbzbWWMKY13sCWUAHZ8wHVl+YZHNULrx1Fqmm3Q8JyN9tt9/mHUdNuI1iCxeYco4jLcFBweN6nuM0rz4ZSNDPPb+JtXuL1pZLpDcNbxo8zQeRljHAGA2cfLj161P4W8DXWmeHbvT9QuVtGuInhjWxFuRbh/vshS2hUlsKfmjPI6miWsXbe34jWjVy/bePNJXw5aalqEs2ZUQP9msp5Q0hj3sIwisXCjdkrkLggkEGmah4zhtJNG1CORm0XUIJZGI0+dp+FDKwUDcBjOQU6c5AFYGrfC+eHw9BpOg3bXtqtys0lvqUluka4j25VfskqEk4YhkPzcgqSc9XdeGH1HS9OhvNUu4byyTabu08tGcFdrqQUK4I9FUjqNtOVndxIimkkxB468Nm68j+1EH7syCYxuISAm8gS42FgnzbQ27HOMVnaP48trq+vI7+SRYW1JLOxZdNuI2+aJHCyhgSjZcjc2wHjikk+F+hSRvbGW9XTTuZNOWVRDFIYzGZVO3eG2k8btuTnGeaSfwLINPvrIajd6mmrTRveT39wkckBRQBLF5UQy/yJwSoGMjuC9P69UUr21/r+v67nVadqFvqunw3tkZGgmXdG0kTxkj12sAR+XI5qzTYokhhSKJQkaKFVQMAAdBTqn0A5u+/5KnoX/YF1L/0fY10lc3ff8lT0L/sC6l/6Psa6SgAooooAKKKKACiiigAooooAKKKKAObvv8Akqehf9gXUv8A0fY10lc3ff8AJU9C/wCwLqX/AKPsa6SgAooooAKKKKACiiigAooooAKKKKACiiigDm77/kqehf8AYF1L/wBH2NdJXN33/JU9C/7Aupf+j7GukoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAObsf+Sp67/2BdN/9H31dJXN2P/JU9d/7Aum/+j76ukoAKKKKACub+I//ACSzxX/2Bbz/ANEPXSVzfxH/AOSWeK/+wLef+iHoA6SiiigAooooAKKKKACiiigAooooAKKKKACub8L/APIxeM/+w1H/AOm+zrpK5vwv/wAjF4z/AOw1H/6b7OgDBf4k6jFrUmly6HZLcrNLbBRqbkeeMGJGPkfKJEO4HnoRiorf4mT6payyf8I7dR2q3ltCk7Szwq4e4ERIcwqpZWwdqsysp5Yciu0tbbQdUZtQsodOvG+0b2uYUjkPnRgpncM/Ooyueo5FQz+D/DN1JcPc+HdJme6cSXDSWMbGZh0ZiV+Yj1NEdGr/APDg+pxXiDxfreq6brkFto81jaWILR6lDezRs7pMFVQREqNuwc7JHAHDc5Wrn/CSa/ruvXGk/ZoNLjtrWeSWeC+Z3SaOQBWXMQDr0ypwCGbOcDOlY/C/w3a6hfXV7aQ6ob1mMiXtjakctvIJWJWfkA/vC2MCrGo+G/B2k2paW10rQ1uJDEbiGOG1aQyEBkD4By+ADg5NLt/Wonu/60/4Jmat8R5tL0Xw/cQ6Fdaheaxafa/ssEcrMqqqFgBHG53fOMAhV9WWn33xAvdMtdTmvdGgDabK3mwx3jvIYSiGOQL5Ocs0iqV7YbBYjFdVqGh6Tq1rFbarplnfW8LBoorm3SRUI6EBgQCKhn/sCPVvsVz/AGamo38Hl+RJ5YmuIUz8u08ug3HjkDJ9apu97eY1olf5nNaT4513Wbn7Lb+F0guTavOEvbqa3DFX2YAktw+05Uhiozk5AxzreGfEE3izTZppbJLW38tYnMV2zOs+P3seQi42H5dwOcg8DFWrbwloWm7pNF0mw0m58loI7qxs4Y5IlJzhTtIxnnBBGeoNW4bOz0vR3hndTbKrvcS3G0B85Z3fgLySSeAOewpO3KwV7nIraXGp/DHTSup6mmo/ZcWjw3siyST4+RnbOXxjJDkqRksDjjuLcsbWIyOsj7BudejHHUVz9p4d8Ea7oNqlho/h/UdIjZmtlhtYZbdSSdxTAKg5znHeuijjSGJY4kVI0AVUUYCgdABTfUN7HO33/JU9C/7Aupf+j7Gukrm77/kqehf9gXUv/R9jXSUgCiiigAooooAKKKKACiiigAooooA5u+/5KnoX/YF1L/0fY10lc3ff8lT0L/sC6l/6Psa6SgAooooAKKKKACiiigAooooAKKKKACiiigDm77/kqehf9gXUv/R9jXSVzd9/yVPQv+wLqX/o+xrpKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm7H/AJKnrv8A2BdN/wDR99XSVzdj/wAlT13/ALAum/8Ao++rpKACiiigArm/iP8A8ks8V/8AYFvP/RD10lc38R/+SWeK/wDsC3n/AKIegDpKKKKACiiigAooooAKKKKACiiigAooooAK5vwv/wAjF4z/AOw1H/6b7Oukrm/C/wDyMXjP/sNR/wDpvs6AOEt9W8S6Xd38WjwayyXV3fOYZNGkCQ/6SrCVHaIbmMTSkBmKsVUAZ4M+o6z42ttKmuLO41ueJre8jspBpCmeV1VHgeWLycoxPmryqqQBwCRXq7EqpIUsQM4HU1T0fVI9a0e31CGGWBJ1z5U23ehBIIO0kZyOxIoWiXkv6/r/AIBXN73N53/r+v1OAttZ8SS2dzfPf6+Vhv3SKz/sQxyTx4UqBut+BliNx2jA5YYLVP8AEmHUp9a0r+y4b66dLS7ItFsBPayyFBsWVjGyrnkcsv1Gc16EJGNw0ZhcKqhhKSu1iSeBznIwOoxyME84BIxuGjMLhVUMJSV2sSTwOc5GB1GORgnnB2/roSlY80s9U8Uzappdsl/rp064vmiN3PoojmMRgJJkXyAI9su0KxVQQTkMBmuj1xWuPGGkpYrePPbzLLPGbFvszoQVMhn2BfMUE7VDnryvQjpYLuC5knSCVXa3k8uUD+BtobH5MD+NE13DBNFDI486fd5Ufd8DJx+FO+zFbp8jgvFj+IrLxjdXekz6qbc6dAoS2s1mRB55E7J+7OZVQhgpOW/utjFathJNqHgW5XxWNSngkleNJUtZYbuaHfiN2jhUOj+uFXpkheQOsicyQo7xtEzKCUcjKn0OCRn6EinUtlb+t/6/q1qvd3/raxleGxfDQ4hqbyvKHkCNOoEjRbz5Zcf3tm3Pv15rVoopsRzd9/yVPQv+wLqX/o+xrpK5u+/5KnoX/YF1L/0fY10lIAooooAKKKKACiiigAooooAKKKKAObvv+Sp6F/2BdS/9H2NdJXN33/JU9C/7Aupf+j7GukoAKKKKACiiigAooooAKKKKACiiigAooooA5u+/5KnoX/YF1L/0fY10lc3ff8lT0L/sC6l/6Psa6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooA5ux/wCSp67/ANgXTf8A0ffV0lc3Y/8AJU9d/wCwLpv/AKPvq6SgAooooAK5v4j/APJLPFf/AGBbz/0Q9dJXN/Ef/klniv8A7At5/wCiHoA6SiiigAooooAKKKKACiiigAooooAKKKKACub8L/8AIxeM/wDsNR/+m+zrpK5vwv8A8jF4z/7DUf8A6b7OgDmX8A642oatdPFo80V9PHK9i8jCG62SSHEmIs5ZGTJPmHKAcrgDPj+GuuLJavNpXh6Z4Etoy5vZQSIp5Gb/AJYE/NHJs5PQkZI6+tUULSwPW/meSRfDnX0sxFJovhuTb9i2xG+k2H7PLI2M/ZuMo4QccDI6cVY074ea3FpNza6hpuhyF7K2gjRLxmRpIHkKFw1sQVCuoAKnG0egNep0U76WDrc8yi+HN7D4ul1IaN4cdZHkla73MkrM0CKAYxFyolTd/rO+eoqG0+Gd/DZxLd6XoN40cty8cEsn7uFZoFUqhFuAAJAeijIOSS2c+p0UnqreVgWjVvU8vT4day6lrq30eWf7EYmna4dmlH2byfsrZi/1G/8AeZ55/gzzRonw/wBbsponu9N0KLydQjuoBFdvMkA8uNJGCNbjLsYywYFSC5+bru9QoquZ3v8A1vcSSSsv6/r+tAoooqRnN33/ACVPQv8AsC6l/wCj7Gukrm77/kqehf8AYF1L/wBH2NdJQAUUUUAFFFFABRRRQAUUUUAFFFFAHN33/JU9C/7Aupf+j7Gukrm77/kqehf9gXUv/R9jXSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc3ff8lT0L/sC6l/6Psa6Subvv+Sp6F/2BdS/9H2NdJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc3Y/wDJU9d/7Aum/wDo++rpK5ux/wCSp67/ANgXTf8A0ffV0lABRRRQAVzfxH/5JZ4r/wCwLef+iHrpK5v4j/8AJLPFf/YFvP8A0Q9AHSUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzfhf/AJGLxn/2Go//AE32ddJXN+F/+Ri8Z/8AYaj/APTfZ0AdJRRRQAUUUUAFFFFABRRRQAUUUUAc3ff8lT0L/sC6l/6Psa6Subvv+Sp6F/2BdS/9H2NdJQAUUUUAFFFFABRRRQAUUUUAFFFFAHN33/JU9C/7Aupf+j7Gukrm77/kqehf9gXUv/R9jXSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc3ff8lT0L/sC6l/6Psa6Subvv8Akqehf9gXUv8A0fY10lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzdj/wAlT13/ALAum/8Ao++rpK5ux/5Knrv/AGBdN/8AR99XSUAFFFFABXN/Ef8A5JZ4r/7At5/6Ieukrm/iP/ySzxX/ANgW8/8ARD0AdJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXN+F/+Ri8Z/wDYaj/9N9nXSVzfhf8A5GLxn/2Go/8A032dAHSUUUUAFFFFABRRRQAUUUUAFFFFAHN33/JU9C/7Aupf+j7Gukrm77/kqehf9gXUv/R9jXSUAFFFFABRRRQAUUUUAFFFFABRRRQBzd9/yVPQv+wLqX/o+xrpK5u+/wCSp6F/2BdS/wDR9jXSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc3ff8AJU9C/wCwLqX/AKPsa6Subvv+Sp6F/wBgXUv/AEfY10lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzdj/yVPXf+wLpv/o++rpK5ux/5Knrv/YF03/0ffV0lABRRRQAVzfxH/wCSWeK/+wLef+iHrpK5v4j/APJLPFf/AGBbz/0Q9AB/wi+r/wDQ9+IP+/Gn/wDyLWXPDNbeI7bQpvHvigX91E0sSrplq0bIv3j5os9gxxnLDqvqM9bqUeoy2ZXR7q1tbnIxJdWzToB3GxZEP/j351xXjmw1+81uN9H0nULgpot5bre2d1DBsnl8sx7S0yuMGLqOm4cnnB118/yKik3Yv6rpt1omnve6j4/8RRwoQPks7KRmJ6AIloWY+wBqe00HUL6zhu7Tx/r0sE8ayRyLBp+GUjIP/Hr6Vx9zoXiW9gggm0bxCywatBdQyS6xGWjTyAJCWFzkgSZO3nAPyjHFN0fQPHcVi0XiB9au4XmH2iKyvFgm37SPOila7clN2CUPlDphMZWnbe/9bf1/WkN7f1/X9fPs20DUlkCf8J74hZi+whLawbacZ+bFr8vHc4HI9RUv/CL6v/0PfiD/AL8af/8AItckPC+uW3iyWaG0157W91cSXM8esbFa2az8skqJxhll5+VcjaNvRRTNX8N+NG8N2yafPqS3VtMLWcLqMksl1AgcJMP9IiAdmZWOZFOFwdw+Whqy/r+v68iv6/P/AC/Ludh/wi+r/wDQ9+IP+/Gn/wDyLR/wi+r/APQ9+IP+/Gn/APyLWzpSXUejWaahI0t0sCCZ3QKzPtGSQrMAc9gSPc1boas7Ep3Vzm/+EX1f/oe/EH/fjT//AJFo/wCEX1f/AKHvxB/340//AORa6SikM5v/AIRfV/8Aoe/EH/fjT/8A5Fo/4RfV/wDoe/EH/fjT/wD5FrpKKAOb/wCEX1f/AKHvxB/340//AORa5/w54c1STXvFip401yIx6tGrOkNjmU/YbU7mzbEZwQvy4GFHGck+iVzfhf8A5GLxn/2Go/8A032dAGGt1Ab68tT8StfR7JJHmeSzskj2x8SbZDZhH2kgNtJ2ng4pj31vHYxXcnxI8RpHK7IFfT7QSIVALF0NnuQAEEswAAIJIBqk/hPX59W1wRaattFdC4bMkyNbysZFaPyQGLxlgo83KqC3IzUtxoGvyapqOuR6Kxl1aK4thYvNCHtRJFAivIwcqRmElgpY4IwDzQtl6fj2+f4bsqy5ref9f112OmHhjViAR488QEHoRBp//wAi0v8Awi+r/wDQ9+IP+/Gn/wDyLXP+NtJ8RqunQ+HrbWrsQ6XPbu+nailuvn4TyWZXmTOGUkkA8ccgkVyniW713TbVrPVZ9a0iK8vFe1kuNYhWRswKHVW+2R9JNxC+YAMjCMMhR+X9a2/4JK2TZ6X/AMIvq/8A0PfiD/vxp/8A8i0f8Ivq/wD0PfiD/vxp/wD8i1r6KFXQrEJ9p2/Z0x9rcvN90ffYkkt6nJ571dptWdhJ3VzhNZ0zXtO1bw/aweONcZNS1B7WYvb2BKqLWebK4tuDuiUc54J+o1/+EX1f/oe/EH/fjT//AJFo8Uf8jF4M/wCw1J/6b7yukpDOb/4RfV/+h78Qf9+NP/8AkWj/AIRfV/8Aoe/EH/fjT/8A5FrpKKAPO7zw5qg+JOjRHxprjO2k37CYw2O9AJrMFR/o23B3AnIJ+UYI5zfvLSew1O2sLr4geJFnuSFj22NmyAnoGcWhVCSCBuIyRgZrRvv+Sp6F/wBgXUv/AEfY03xFZXuo69pS2Vleo1nOk4v/AD0Fsq7h5iNGX3M5QEA+WcbuGHNC3SDozOsIH1TULiysfiJ4glntywcfZLJVO07W2sbQB8NwSpODwcGn3No9nqZ0+5+JGtxXQtXvGjaGw+WFCAzk/ZcAZI6+/oarab4f8RQ6hAtslvpzaXDdQQ3l1ELiO586ZHDCNJFbAVMHcV+Y8AgZNDV/BHiq/wDEF1JNqGm3Vvd6Xe27zJYtCQ0hj2Rkmdj/AADkLgBCCMtmmrO1/P8AWwzZ0mxuNctWuNN+IPiKREfY4ezso2U4B5V7QMMggjI5BBHBFX/+EX1f/oe/EH/fjT//AJFrG1HTfEF74T8UXVrp15Y6pqKItla295HHPGyIFVjIsgUfNk/f+6BnrtrnLhfF+mtc6i+n+I7W0imuHLXerwOsVs1r/EBO/wAwn+YEKxUcDA+WjTUSTaR2OpaTfaTYvd3vjzxIIlIGIrKyldiegVEtCzH2ANZ6fa7zwtFr2leOfElzaTFDEZbOzgLqzhdwD2YbHORxyOnBzWV8PRcXmkz36y6prPku8679QS4SR/L2JHCTdzqOshO6QfMRnA246DwTDqX/AAi2l+Htf8LXVpHZ2Ucc013NbSRu6BQAgjkcnkZyQvSnbf5f8ELpq5of8Ivq/wD0PfiD/vxp/wD8i0f8Ivq//Q9+IP8Avxp//wAi10lFSBzf/CL6v/0PfiD/AL8af/8AItH/AAi+r/8AQ9+IP+/Gn/8AyLXSUUAed3nhzVB8SdGiPjTXGdtJv2Exhsd6ATWYKj/RtuDuBOQT8owRznTl027g1aHTZvH3iNbmaF5owbKy2MqkBvn+ybcjI4zn2q7ff8lT0L/sC6l/6Psal1VL7/hMtGnt9MuLm1ihuFmuI3iCxFgu0EM4Y52noD1FAGPpEEmuSXMem/ELxG8lswEqS2NnEwB5VgHswSpwcMMqcHBNaf8Awi+r/wDQ9+IP+/Gn/wDyLTNFN7eahq19qPh7UNOuJ4liDSz2+ZI03bEQxSsQfmYksV5bjpxwNjpvju3tYGk0vxQbiCG0JMuswOrzJL++OPtJypiOMHgkZI3fNT0vYdtGd1e6HqGn2M15d+PfESwwIXcra2LnA9FW0JJ9gCT2qLStLvNa0uHUNO8f+IpLacEoz2djG3BIOVa0DA5BGCBXIeCJpdf8UXsrX2p36LKXeI6ks0EQSQuFKC5fa5YIADFD8oPyj5qZGPEfh7wPrB1y1vtLUov2a4bUYolgVrg5jISfaGw27zNyEhtpdNoNLpf+v6/rsLeVjstQ0u80sW5vfH3iNBczpbxlbKycb2OFBK2h2gnjJwMkDPNXP+EX1f8A6HvxB/340/8A+Ra5jSdPutU+FUAs21TU51vo7pjNfhpZ1WZXIhl+0SKF2jC/vj05bOTUEWg+Nori2DSam4BVrGT+0wVsR57My3QL/wCkfuii5xJyp5H3zXL08/0Qr9f66/8AAOi/su8GtDST4+8Ri8MBuAhsrIKyBgpIf7JtJBIyM5GRxzVz/hF9X/6HvxB/340//wCRa4u50XVjqF1ceJZNS0qN7S5hl1r+2RHDHM0sbQtGFlDRoQoXaAMkYIOdx6OXRtavvh3PL5l5Hr1wBfLBFqMyBZQAVhDFhtQgBSOAckkZqfs3/rf/AC/rUet7f1sv1NH/AIRfV/8Aoe/EH/fjT/8A5FqMeHNVad4h468R7kUMSbWxC4OejfZME8dAcjjPUVx9x4X8cDSbxbe41ASxTq0CnVJZWmgkIeSMfv0JZD8isZEOAcMAeauoP4k0Dwzqz67PqtvHJBYxx311fxQgyBiJMAXf7vIKg4lTdtJ3gnJOgdbHZR6Zdy6zPpSeP/EX2y3hSeSM2dkAEYkKQxtNp5UjgnGOatJ4b1SVd0fj7XnXJGVh08jIOCP+PX1GK860rTNfmFtqek2PiS+C29qEvTq0OZyty7ygk3b74zG5Cgsy++RmvRvAWj3Gh+FUsryC6hnW4mZhc3RuC2ZCQwYu2ARg4yO+QCTVW0E3rp/WhgXnhzVB8SdGiPjTXGdtJv2Exhsd6ATWYKj/AEbbg7gTkE/KMEc56D/hF9X/AOh78Qf9+NP/APkWi+/5KnoX/YF1L/0fY1fudLnnvjLA0Vj84ZpoWYyS8fxDhcjp8wcVIzlzIq/bvM+IviOMWABmMlhZqCCcAoTZ/vATxlN3PHXir+naRe6tYpeWHj/xDJC+QC1rYoykHBVla0BVgQQQQCCMGs7UdD1XUdS1HUbTTL23UTW0xtb25idrt4JlcGIiRhGpVSApKjc2So5JfqWl68PAt01lZX0eqXWpi9FrY3ccUsSGZWZS/mKhPlg5G4gk45HNC2u/62/4PpbXcOtv62/r+kbH/CL6v/0PfiD/AL8af/8AItZ+sWVxoNkbrUvH3iVYgCT5NhZzNgDJO1LMtgAZJxxXDau/izRdLku7y28QafaMbiGWa81qErDE0yGDJ+08EKXUsGVucGRRhl3/AA7Z3l38Pb24to9U1eeSynht/tF7HM0zzHko7XEieWAIwP3p4B5LZynflbRSS5kn3NSW11E6VYajaeNvEctvezQxp5trZQsFkYKG2tZhh1BwQK1v+EX1f/oe/EH/AH40/wD+RaPD73eo2FtZa14ZutPjsoYir30tvJvlXGCgikfpjOTjtgenSVckk3b+kZxberOb/wCEX1f/AKHvxB/340//AORaP+EX1f8A6HvxB/340/8A+Ra6SipKOb/4RfV/+h78Qf8AfjT/AP5Fo/4RfV/+h78Qf9+NP/8AkWukooA5v/hF9X/6HvxB/wB+NP8A/kWj/hF9X/6HvxB/340//wCRa6SigDm/+EX1f/oe/EH/AH40/wD+RaP+EX1f/oe/EH/fjT//AJFrpKKAON8OWFzp3xJ1+K81a81V20nTmE14kKuo869G0eVGi44zyM8nnpjsq5ux/wCSp67/ANgXTf8A0ffV0lABRRRQAVzfxH/5JZ4r/wCwLef+iHrpK5v4j/8AJLPFf/YFvP8A0Q9AHSUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzfhf/AJGLxn/2Go//AE32ddJXN+F/+Ri8Z/8AYaj/APTfZ0AWx4s0JGC3Wt6TEzyMkSi/Q79r7D1xyGIUgZwTjrUVj448MahJLFba7p/mwzPC8TXUYcMjBW+XOcZIH4j1Fc1q/wAOda1NZlj8RafCJWvPvaS7lUuHRiAftA+ZdnXvnpV1PA2ppeGZdctVULfBMacd6NcsGLZMpHysP7vIOPehbK/Yel/n/n/wDeTxf4akUNH4h0plMBuAVvYyPKBwZPvfdzxu6ZqSXxRoEDzJPrmmxtBKIZle7jBjkIyEbJ4YgEgHnisDTvAU9jJaSHV98kN5LPOywv8Av45NrPES8jEAuitnJwBtx3rO/wCFX3dtcXkum61AjzXiXMLXltcXHlhZjNsKm5CY3n+BU4z1JzT7E62Owk8T6BD5Pm65pqefAbmLddxjzIQMmReeUA53Dij/AISjQPJMv9uab5YkSIv9rjwHcBkXOerAggdSDkVymmfDW6tLe3tr3WoLiBSjziKxMbu8e7yyjGVti4bBHzZ5wVyRS2Hw71SxsZLddftjIVt1iuF090kh8qPy8qRN1KjvkZzkMDtoVuv9f1/XYNbm14o/5GLwZ/2GpP8A033ldJXNeJ+PEXgzv/xOZOf+4fd10tIYUUUUAc3ff8lT0L/sC6l/6Psa6Subvv8Akqehf9gXUv8A0fY10lABRRRQAUUUUAFFFFABRRRQAUUUUAc3ff8AJU9C/wCwLqX/AKPsa6Subvv+Sp6F/wBgXUv/AEfY10lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN33/JU9C/7Aupf+j7Gukrm77/kqehf9gXUv/R9jXSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN2P/JU9d/7Aum/+j76ukrm7H/kqeu/9gXTf/R99XSUAFFFFABXN/Ef/klniv8A7At5/wCiHrpK5v4j/wDJLPFf/YFvP/RD0AdJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXN+F/wDkYvGf/Yaj/wDTfZ10lc34X/5GLxn/ANhqP/032dAHSUUUUAFFFFABRRRQBzfij/kYvBn/AGGpP/TfeV0lc34o/wCRi8Gf9hqT/wBN95XSUAFFFFAHN33/ACVPQv8AsC6l/wCj7Gukrm77/kqehf8AYF1L/wBH2NdJQAUUUUAFFFFABRRRQAUUUUAFFFFAHN33/JU9C/7Aupf+j7Gukrm77/kqehf9gXUv/R9jXSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc3ff8lT0L/sC6l/6Psa6Subvv+Sp6F/2BdS/9H2NdJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc3Y/wDJU9d/7Aum/wDo++rpK5ux/wCSp67/ANgXTf8A0ffV0lABRRRQAVzfxH/5JZ4r/wCwLef+iHrpK5v4j/8AJLPFf/YFvP8A0Q9AHSUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzfhf/AJGLxn/2Go//AE32ddJXN+F/+Ri8Z/8AYaj/APTfZ0AdJRRRQAUUUUAFFFFAHN+KP+Ri8Gf9hqT/ANN95XSVzfij/kYvBn/Yak/9N95XSUAFFFFAHN33/JU9C/7Aupf+j7Gukrm77/kqehf9gXUv/R9jXSUAFFFFABRRRQAUUUUAFFFFABRRRQBzd9/yVPQv+wLqX/o+xrpK5u+/5KnoX/YF1L/0fY10lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN33/JU9C/7Aupf+j7Gukrm77/AJKnoX/YF1L/ANH2NdJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc3Y/8AJU9d/wCwLpv/AKPvq6Subsf+Sp67/wBgXTf/AEffV0lABRRRQAVzfxH/AOSWeK/+wLef+iHrpKo63pUGvaBqGkXjSJb6hayWsrREB1V1KkqSCM4PGQaAL1Fc3/wgekf8/niD/wAKPUP/AI/R/wAIHpH/AD+eIP8Awo9Q/wDj9AHSUVzf/CB6R/z+eIP/AAo9Q/8Aj9H/AAgekf8AP54g/wDCj1D/AOP0AdJRXN/8IHpH/P54g/8ACj1D/wCP0f8ACB6R/wA/niD/AMKPUP8A4/QB0lFc3/wgekf8/niD/wAKPUP/AI/R/wAIHpH/AD+eIP8Awo9Q/wDj9AHSUVzf/CB6R/z+eIP/AAo9Q/8Aj9H/AAgekf8AP54g/wDCj1D/AOP0AdJRXN/8IHpH/P54g/8ACj1D/wCP0f8ACB6R/wA/niD/AMKPUP8A4/QB0lc34X/5GLxn/wBhqP8A9N9nR/wgekf8/niD/wAKPUP/AI/Va1+GuiWlzezR3viAteTCZ/8AioL1cERpH1WUFuIxyxY9s7QoAB1tFc3/AMIHpH/P54g/8KPUP/j9H/CB6R/z+eIP/Cj1D/4/QB0lFc3/AMIHpH/P54g/8KPUP/j9H/CB6R/z+eIP/Cj1D/4/QB0lFc3/AMIHpH/P54g/8KPUP/j9H/CB6R/z+eIP/Cj1D/4/QAeKP+Ri8Gf9hqT/ANN95XSVyV18NdEu7mymkvfEAazmMyf8VBetkmN4+rSkrxIeVKntnaWBs/8ACB6R/wA/niD/AMKPUP8A4/QB0lFc3/wgekf8/niD/wAKPUP/AI/R/wAIHpH/AD+eIP8Awo9Q/wDj9ABff8lT0L/sC6l/6Psa6SuSk+GuiSarBfm98QebBDJCo/4SC9PDshPzGXcP9WOAQD3BIUrZ/wCED0j/AJ/PEH/hR6h/8foA6Siub/4QPSP+fzxB/wCFHqH/AMfo/wCED0j/AJ/PEH/hR6h/8foA6Siub/4QPSP+fzxB/wCFHqH/AMfo/wCED0j/AJ/PEH/hR6h/8foA6Siub/4QPSP+fzxB/wCFHqH/AMfo/wCED0j/AJ/PEH/hR6h/8foA6Siub/4QPSP+fzxB/wCFHqH/AMfo/wCED0j/AJ/PEH/hR6h/8foA6Siub/4QPSP+fzxB/wCFHqH/AMfo/wCED0j/AJ/PEH/hR6h/8foAL7/kqehf9gXUv/R9jXSVyUnw10STVYL83viDzYIZIVH/AAkF6eHZCfmMu4f6scAgHuCQpWz/AMIHpH/P54g/8KPUP/j9AHSUVzf/AAgekf8AP54g/wDCj1D/AOP0f8IHpH/P54g/8KPUP/j9AHSUVzf/AAgekf8AP54g/wDCj1D/AOP0f8IHpH/P54g/8KPUP/j9AHSUVzf/AAgekf8AP54g/wDCj1D/AOP0f8IHpH/P54g/8KPUP/j9AHSUVzf/AAgekf8AP54g/wDCj1D/AOP0f8IHpH/P54g/8KPUP/j9AHSUVzf/AAgekf8AP54g/wDCj1D/AOP0f8IHpH/P54g/8KPUP/j9AHSUVzf/AAgekf8AP54g/wDCj1D/AOP0f8IHpH/P54g/8KPUP/j9ABff8lT0L/sC6l/6Psa6SuSk+GuiSarBfm98QebBDJCo/wCEgvTw7IT8xl3D/VjgEA9wSFK2f+ED0j/n88Qf+FHqH/x+gDpKK5v/AIQPSP8An88Qf+FHqH/x+j/hA9I/5/PEH/hR6h/8foA6Siub/wCED0j/AJ/PEH/hR6h/8fo/4QPSP+fzxB/4Ueof/H6AOkorm/8AhA9I/wCfzxB/4Ueof/H6P+ED0j/n88Qf+FHqH/x+gDpKK5v/AIQPSP8An88Qf+FHqH/x+j/hA9I/5/PEH/hR6h/8foA6Siub/wCED0j/AJ/PEH/hR6h/8fo/4QPSP+fzxB/4Ueof/H6AOkorm/8AhA9I/wCfzxB/4Ueof/H6P+ED0j/n88Qf+FHqH/x+gDpKK5v/AIQPSP8An88Qf+FHqH/x+j/hA9I/5/PEH/hR6h/8foALH/kqeu/9gXTf/R99XSViaJ4TsNA1W9v7GfUJZb2GGGQXt9LdYETSFdrSszD/AFrZGccDAByTt0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFMmmjt4HmncJHGpZ2PQAdTVCz8Q6df2AvLeWURmYW5WW2kikWTIG0xuocHkdR0OenNAGlRWVD4m0ibQG1r7X5VgrMrSXETxFWVyhUo4DA7gRjGSav2d1HfWcN1AJBHMgdRLE0TYPqjAMp9iAaAJqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAIrqV4bSWSO3luXRCVhhKh5Dj7qliACfcge4rlvDGiXtsyfa7e5t7NLqW7t7e7nWWaIsiqFkcM29stK2dzdV5OK66ihaB0seaT+HtW1Hwvape6LqSfY9cub2SwhvYoZ7iN3lZGSRJdoKmVW5dTlD7Z7nw7b31p4csYNWlaW8jhCyuz72J92/iOMAnuea0qKdxvV3/AK3uFFFFIQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcZ/wse0/58Jv++xR/wse0/wCfCb/vsUf8K4tP+f8Am/74FZviPwfaeH/Cuq6z9omuP7OsprvyeE8zy0L7d2DjOMZwaANL/hY9p/z4Tf8AfYo/4WPaf8+E3/fYrm/+EG8W/wDQN0X/AMHcv/yHR/wg3i3/AKBui/8Ag7l/+Q6AOk/4WPaf8+E3/fYo/wCFj2n/AD4Tf99iub/4Qbxb/wBA3Rf/AAdy/wDyHR/wg3i3/oG6L/4O5f8A5DoA6T/hY9p/z4Tf99ij/hY9p/z4Tf8AfYrm/wDhBvFv/QN0X/wdy/8AyHR/wg3i3/oG6L/4O5f/AJDoA6T/AIWPaf8APhN/32KP+Fj2n/PhN/32K5v/AIQbxb/0DdF/8Hcv/wAh0f8ACDeLf+gbov8A4O5f/kOgDpP+Fj2n/PhN/wB9ij/hY9p/z4Tf99iub/4Qbxb/ANA3Rf8Awdy//IdH/CDeLf8AoG6L/wCDuX/5DoA6T/hY9p/z4Tf99ij/AIWPaf8APhN/32K5v/hBvFv/AEDdF/8AB3L/APIdH/CDeLf+gbov/g7l/wDkOgDpP+Fj2n/PhN/32KP+Fj2n/PhN/wB9iub/AOEG8W/9A3Rf/B3L/wDIdUYvDfiabX7vSF0rSRcWtrBdOx1qTYVlaVVAP2TOcwtnjuOvOADsv+Fj2n/PhN/32KP+Fj2n/PhN/wB9iub/AOEG8W/9A3Rf/B3L/wDIdH/CDeLf+gbov/g7l/8AkOgDpP8AhY9p/wA+E3/fYo/4WPaf8+E3/fYrm/8AhBvFv/QN0X/wdy//ACHR/wAIN4t/6Bui/wDg7l/+Q6AOk/4WPaf8+E3/AH2KP+Fj2n/PhN/32K5v/hBvFv8A0DdF/wDB3L/8h0f8IN4t/wCgbov/AIO5f/kOgDpP+Fj2n/PhN/32KP8AhY9p/wA+E3/fYrm/+EG8W/8AQN0X/wAHcv8A8h0f8IN4t/6Bui/+DuX/AOQ6AOk/4WPaf8+E3/fYo/4WPaf8+E3/AH2K5v8A4Qbxb/0DdF/8Hcv/AMh0f8IN4t/6Bui/+DuX/wCQ6AOk/wCFj2n/AD4Tf99ij/hY9p/z4Tf99iub/wCEG8W/9A3Rf/B3L/8AIdH/AAg3i3/oG6L/AODuX/5DoA6T/hY9p/z4Tf8AfYo/4WPaf8+E3/fYrm/+EG8W/wDQN0X/AMHcv/yHR/wg3i3/AKBui/8Ag7l/+Q6AOk/4WPaf8+E3/fYo/wCFj2n/AD4Tf99iub/4Qbxb/wBA3Rf/AAdy/wDyHR/wg3i3/oG6L/4O5f8A5DoA6T/hY9p/z4Tf99ij/hY9p/z4Tf8AfYrm/wDhBvFv/QN0X/wdy/8AyHR/wg3i3/oG6L/4O5f/AJDoA6T/AIWPaf8APhN/32KP+Fj2n/PhN/32K5v/AIQbxb/0DdF/8Hcv/wAh0f8ACDeLf+gbov8A4O5f/kOgDpP+Fj2n/PhN/wB9ij/hY9p/z4Tf99iub/4Qbxb/ANA3Rf8Awdy//IdH/CDeLf8AoG6L/wCDuX/5DoA6T/hY9p/z4Tf99ij/AIWPaf8APhN/32K42Xw34mh1+00htK0k3F1az3SMNak2BYmiVgT9kznMy447Hpxm9/wg3i3/AKBui/8Ag7l/+Q6AOk/4WPaf8+E3/fYo/wCFj2n/AD4Tf99iub/4Qbxb/wBA3Rf/AAdy/wDyHR/wg3i3/oG6L/4O5f8A5DoA6T/hY9p/z4Tf99ij/hY9p/z4Tf8AfYrm/wDhBvFv/QN0X/wdy/8AyHR/wg3i3/oG6L/4O5f/AJDoA6T/AIWPaf8APhN/32KP+Fj2n/PhN/32K5v/AIQbxb/0DdF/8Hcv/wAh0f8ACDeLf+gbov8A4O5f/kOgDpP+Fj2n/PhN/wB9ij/hY9p/z4Tf99iub/4Qbxb/ANA3Rf8Awdy//IdH/CDeLf8AoG6L/wCDuX/5DoA6T/hY9p/z4Tf99ij/AIWPaf8APhN/32K5v/hBvFv/AEDdF/8AB3L/APIdH/CDeLf+gbov/g7l/wDkOgDpP+Fj2n/PhN/32KP+Fj2n/PhN/wB9iub/AOEG8W/9A3Rf/B3L/wDIdH/CDeLf+gbov/g7l/8AkOgDpP8AhY9p/wA+E3/fYo/4WPaf8+E3/fYrm/8AhBvFv/QN0X/wdy//ACHR/wAIN4t/6Bui/wDg7l/+Q6AOk/4WPaf8+E3/AH2KP+Fj2n/PhN/32K5v/hBvFv8A0DdF/wDB3L/8h0f8IN4t/wCgbov/AIO5f/kOgDpP+Fj2n/PhN/32KP8AhY9p/wA+E3/fYrm/+EG8W/8AQN0X/wAHcv8A8h0f8IN4t/6Bui/+DuX/AOQ6AOk/4WPaf8+E3/fYo/4WPaf8+E3/AH2K5v8A4Qbxb/0DdF/8Hcv/AMh0f8IN4t/6Bui/+DuX/wCQ6AOk/wCFj2n/AD4Tf99ij/hY9p/z4Tf99iub/wCEG8W/9A3Rf/B3L/8AIdH/AAg3i3/oG6L/AODuX/5DoA6T/hY9p/z4Tf8AfYo/4WPaf8+E3/fYrm/+EG8W/wDQN0X/AMHcv/yHR/wg3i3/AKBui/8Ag7l/+Q6AOk/4WPaf8+E3/fYo/wCFj2n/AD4Tf99iub/4Qbxb/wBA3Rf/AAdy/wDyHR/wg3i3/oG6L/4O5f8A5DoA6T/hY9p/z4Tf99ij/hY9p/z4Tf8AfYrm/wDhBvFv/QN0X/wdy/8AyHR/wg3i3/oG6L/4O5f/AJDoA6T/AIWPaf8APhN/32KP+Fj2n/PhN/32K5vT/C2o/wDCVW2ja9b2tp9qsp7uKayv2uf9U8KFWVoI8Z88EEE9DXSf8K4tP+f+b/vgUAH/AAse0/58Jv8AvsUUf8K4tP8An/m/74FFAHZ1zfxH/wCSWeK/+wLef+iHrpK5v4j/APJLPFf/AGBbz/0Q9ADvH+u2Ph3wFq+oam8AiW1kVI5yu2ZypCx4PBJPGOc15Z4Q8SXng+y0nw74dg0V9OH9nQz3SoS01zOpkmO5XwxEYyD9BzwK91oojo2/T8P+HB6q3r+J8+XXjNvFniqLXGh0RxHbx2dtZ3dqZMR3dwIyszFwHIjjdiBhV3bSGNdhN8T76PTJdQtRpUdpJef2ZbWzrJ5lnN53lhrhgdoG0FtgCt90AnOR6nRT6Jf1/W/3g9W3/X9bHh938Ttf1HS4dl74elR7KOS4ilsXaK6+0XBhhQq02VGwbmyTjOCDWpP8UtThTWJNIstPXTtJtbtBD5LlraWFhHEJCHCjzGztiABCgHdzivXKKNPz/r5B1v8A15/eeUr8SPEcdjKb1dFhuYdXg094kVncho18zZH5gaQiRtvB4AY4bHPqq52jdgnHOBS0UX0/rsIKKKKQwooooAK5ux/5Knrv/YF03/0ffV0lc3Y/8lT13/sC6b/6PvqAOkooooAKKKKACiiigArymw17wV4d+LfjC9u7/RbK58m2Xd5kSTSPhzIo53MxIXIHJOM9q9WooWjuG6seZN8S9UTVdVglgsYIrWO5YpKj77DypFWN59rHcsoYsoCr06kZYYfiLx7qWsfD64stUh063N3HqlpdTyRN5btACEjRS52u4+YZZsbTjd29popSV48vkVGVpc3meCaX8S20Se3t9Nv/AA/tmNhbSzyFmIQ2bMC374DKsgXgAHOOvNdBp3xS1vW9S8MQ2Evh+1i1a2gnuBczKXyxYSKimdGyCmFCrJyfmK459brJvfDOl6hqiahdxztOoUFVu5Uik2nK74lYI+CeNynFXzXld9zJRtHlXa3/AATzn406+62lzolz9jt7NLe2vVkuV+edxdKCIzuAGwDLcE4YdOtaMfxE1m41rUbGCHT4vKS42LKhLWPlyKkck5EmGWUMWX7gwPvEZYel0VK0VvX8f8jS6vf0PNbH4javdeNdF0VLG1ntry0jmluspB5+4NueFXmyQpVcqokyGzuAALelUUU2ydQooopDCiiigAooooA5u+/5KnoX/YF1L/0fY10lc3ff8lT0L/sC6l/6Psa6SgAooooAKKKKACiiigAooooA8u+JE1lpXjjRvEVnLb/2to8fm3VujqJ5rJ3EcmVHzMq7iw7Daaq2mv2Nj428calb3ulnWI1s40e5bzGgRgFZCFO7arMoK5UbsZK5yPW6KForev4g9Xf0/A8KvfitfwodYmGhxata6JesElWQESRXaxldvnfdk2ZA5YFeGYZFa8HxM1bWb/S4bG+00Rr4gexuZreMuk0YgMqKP3nBY/J15YdOqn16inf+vnf/AIAP+vut/wAE8Vh+MuuTWdnc3NvpGlpc6l9kY3boxiBjdirIs+5XRlUHeF3bx8q1qWHxXv8AUX8LzwDTDb6mlqL6FVdnhabzF3B9wVVDx4xhiehKnGfVqKNPy/r5g9dvP/h/keL6X8adSuI7xZV0q/nis7meOOxVgVMNz5W5gZGJUxnzMDnCnBOeNxPiJrieLdC0b7PpeoRX8aytfWkqxw3SM7DdAZJQSVUKzIolPJGRgMfTKKE1pf8ArcHrfz/A8c8XeJpbn4naPBdpaRnSNcEVtbYxcyh7R2D7i2NjsdgAHVOpPA0dP+JGt6h4fvbvdpVu8CQSm6aFjDAXDGS2dTKMyx7QDl05YfKDhT6lRQnZW/r+mD1d/wCuv+ZwXhXx3quv+PNS0e40yK3srRDtdnRJgRt2uYzJ5hRwSQfLUDaOWzx3tFFHRCCiiikMKKKKACiiigAooooA5u+/5KnoX/YF1L/0fY10lc3ff8lT0L/sC6l/6Psa6SgAooooAK5v4j/8ks8V/wDYFvP/AEQ9dJXN/Ef/AJJZ4r/7At5/6IegDpKKKKACiiigAooooAKKKKACiiigAooooAK5ux/5Knrv/YF03/0ffV0lcTc6Daa38U9X+2zahF5Oi6ft+xalcWmcz3ud3kuu7pxnOOcdTQB21Fefadpejaj4q1LQltvF0EunIjy3MviS68pw+dm3bdluQCeVGMc44zu/8IHpH/P54g/8KPUP/j9AHSUVxut+GND0PQr3VbibxLNFZQPPJHD4jvt7KoycbrgDOB3IqPSPDmiazD5sDeKoYmhimSSfX79VkEibhtIuDkjOD6GgDtqK5v8A4QPSP+fzxB/4Ueof/H6yPEmi+H/DGmxXt7J4omikuorb9x4iviUaRwisd1wOMkZxk+1HWwHd0Vzf/CB6R/z+eIP/AAo9Q/8Aj9H/AAgekf8AP54g/wDCj1D/AOP0AdJRXN/8IHpH/P54g/8ACj1D/wCP0f8ACB6R/wA/niD/AMKPUP8A4/QB0lFef694TsrLWvDMFtqHiBIr7U3guF/4SK/O9BZ3MgHM3HzxocjB4x0Jqh8RfDUGg+EpNQ0rVvEME/2q1iB/4SC9YBXnRW4aU9VYj+WDRu0gPT6K8t8SW+meGde0+wZdfu4LyeGKSc+Lb5ZIjNIUTbGJDkAjksV46FiCBkNfN/YD6nD4f1+4H22SyiSDxhqcpaSOSRGyqEvjEYI2o33ucAE0dLjs/wCv68j2mivFzqdtFq1tpVzoXipL5rFLq8jj8S6pKtmzq7IrOG24+TDMSuCRgNgkVfD2t2d7/wAI/Z3+n+Jp7zUrKK8uXsfEOqzJbxyswRuGxj5fm3FQvYvzTs/6+f8AkxdL/wBf1qe5UV4r4XVPEfjBm87XbfTJtD+321p/wk9+xJ85lDM3mAqxUYK8ge9N8MXM2sQaCkunarLPrFnLfBo/Geor5caTIpGC3JCyA4zztxnnNCTf9ev+TB6Nrt/wP8z2yivFG13ShCJl0/xAUlaF7fd4s1JS0L3P2cs43/I4bnZzkfxA5FJLqnmWNo+k+HfEeoXVxc3NuYYvF2psimGfyidyFiAfvZZVUDq2cAiTaugeh7ZRXiuhCL/hYF/oWrXGuzQT6tJZ2rr4mvwbfZaxy7MCQbgcv8xOenHp6N/wgekf8/niD/wo9Q/+P0W0T76h1sF9/wAlT0L/ALAupf8Ao+xrpK87vPBWlr8SdGtxda5sk0m/ck6/fFwVmswMP524D5jkA4PBIO0YyPHmhL4b1TR9RtdV8QrpEEw/tWD+37074XZYw+4zZGxmU8EcZzml1S7h0bPW6K8disUtdY8UGS71y8itZbNbG2m8UXtuqecvQv5pY5JBxhmzwoPArJudfsU0qDW4LPxA0D6FNqX2VvGN+oLRzIjqTknIz8rA4OTlRwQLX+vK4f1+Nj3iivE31CC51DTbSzt9Yilk1qTTrsP4t1JgqJD5xZSH5JXHGOoxnncK9p4n0/ULSxubPRPFAhv7wW9vLdeJ9VgSRWjd1YMxwxHlkMFyBkYZqNlf+v61Df8Ar1/yPdKK8Zh1jSLl/DjwWmum31tIMs3jC/8AMgeZXKDYJDlcxkFiV/2Q2Dilp/ijR7jTpJ72w162l+yxzwoni/UZFYtctb4Zt42KGAJbB4PTjBdne3y+Yf1957nRXkb3Fjb+KtN8P3Wk+Kvt1xEkl4LXxJqdwtqHdkVtyOVK5XJZimARwTkCp4yjisdei0vR59fgW21LT4bu5bxNfFnWeTlFjMh4Kg5bIIPA7kCV2l3dvxsJu1/JXPZ6K8ctdQsL+Ob7Dp+vvK8P2mzSTxZqa+bEJTExkwxKMCrHYockD1yBa0i50XWfGZ0K1tfFMkSRoZr6HxDqckMcjRCUAuH2bSrYDb8k/wAOCDSWuw3oes0Vzf8Awgekf8/niD/wo9Q/+P0f8IHpH/P54g/8KPUP/j9AGtLqsEOv2mkMkhuLq1nukYAbAsTRKwJznOZlxx2PTjN6vO7zwVpa/EnRrcXWubJNJv3JOv3xcFZrMDD+duA+Y5AODwSDtGKnxA8NQaHo1ndaZq3iGGSbVLK2b/ioL1h5bzKrjmU9QcZ7dsU1q0u7S+/QOlz0+ivLdSt9M0nxpp+gONeuIr2byRdf8Jbfb45GR5FBjWThcIRkkH0DcmsZtQk/4RmDVoPDniG5NzM0MMVv4w1OXc6GUOMIS/8AyyGCEI+bkqASF0uHWx7XRXiv9r2f9oX9g+i+KEudPsjNdMviTVXignEHneW0gO0Lg7dxIO7jbjBqvpuu2C/2Zaanp3im4uH0yK+v57DxBqsqQCRGZTw20AhOdzLgsAN2CQbf16/5MP6/L/NHuVFeMeFrf+2NY1+a8m1tLa30u0vrSyXxTfuqeYkjcyCQEkhVzwQDnGepb4Yll1aHRIrrT9Wkl1HS01OSSHxjqPyRmUK2ELDJCsGxnnBGehL5WnZ/1v8A5MV1a/8AXT/NHtNFeJQa9pk62zLp2vgXUlm0OfF2oj/R7mVokdvm+WQMvMfIx0Y9KVdSa7stJfSPDniK+uNQLh0TxfqZjh2zmIneu7jgsS4QY4BJ4os/xsN6OzPbKK8X8LLBceNbzQtWudenSbU72G0nXxLfgwrAsbeWVEgyMOTuJzXon/CB6R/z+eIP/Cj1D/4/S6J99Q6tdjpKK5v/AIQPSP8An88Qf+FHqH/x+j/hA9I/5/PEH/hR6h/8foA6Siub/wCED0j/AJ/PEH/hR6h/8fo/4QPSP+fzxB/4Ueof/H6AC+/5KnoX/YF1L/0fY10lcTbaDaaJ8U9I+xTahL52i6hu+26lcXeMT2WNvnO23rzjGeM9BXbUAFFFFABXN/Ef/klniv8A7At5/wCiHrpK5v4j/wDJLPFf/YFvP/RD0AdJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXN2P/JU9d/7Aum/+j76ukrm7H/kqeu/9gXTf/R99QBlNpXjKy8Ya9qul2OiSRalHDFC0+pSq0QjDAOyC3IJO7O3d261lt8OdbXVdVu1uLCY3UdyvmSyOrX3myKyJPtQELEFKrgtkHooyD18vjbQINQvbK4vmhmsM/afMt5FSLCeZy5Xb93kYPPOOlUrr4meFLO3gmm1CYifhUjsbiR0O/wAvDoqFozvO3DAc8ULpb+rj7nH3Hwq1k+G4tLSXTZ4oH1FYLeaR1ihW4z5UigRkBo8lQoAADHBHSqjfCvxG7Iz2Hh4lbzT7ll+2SYf7PCY5Mn7P1bj8OtdrD8R9FgNwNVvtrC5uo4VhsLnIWABnDAp99RyccEdM1PH8S/Cclu841UqiSBG32synldwfBTJj2/N5n3Mc5xQtde9v+B+InZ6Pz/Hc8yn8DahZX/hay8R6J/bEmm28aD7I0ssDbZmZVDm1ZVwu3ILwA8Asw+71/jj4f6v4h8RPqOnnTpgUs/JN7M6NbGGfzHVNqNxIMZPHKL17dVF410CbxA2ipfN/aCz/AGcxNbyqPM8vzNocrtOU+Yc8gcVvVXM9H53E9W/Sx5jD8M9TF1qjXkljdRXSTBw8hzqJeYSo1xmMgGMDyxkSAr2x8tWPD3w+1jS/H8WuXuoRvax2qRRw2sgjWICIIYdhiLNHkbh+8UA87c816NRSTsN638/6/QKKKKQHN+KP+Ri8Gf8AYak/9N95WtquiaVrtstvrmmWepQI+9Yry3WZVbGMgMCM4J596yfFH/IxeDP+w1J/6b7yq/ia719PFej2mnS3Nppsyu0tzbWQud0qsu2KUbTsjZN/z5XBx8w6E3aQbK5uz6FpFy6Pc6VZTNGqIhkt0YqqNuQDI4AIBA7HmsnWvAOhavoQ0mO0h061Fx9p2WlpblDJgglo5I3jbOe6nnB6gGuF1jxB8RILHWXtotSW4iDkRwab5ohcXKrEkH7o+crw7mY5bae6dKtWHiHxnqEltbzHVrK2/tO6hN+2jEyOqsptw8RiGImUsC4C9BllOctLm/r+v+CF7f15Heaf4T0XT4bFU0+3mm0+IxW1zNAjSxqeoVsfKDn7q4AHAAHFTR+G9Diks3i0XT0ewz9kZbVAbfPXyzj5c98YrzC78R/EhLHXJpobq3khv4ktoLXTpJ5Fj8/DbR9n2vGYeSQ7sCOq52iSz1Pxhqmo6NcXz67bQW0mppK66XsaQr/x7s6GH+JCcEKATx1OKV7rm/rv+oWs7fI9NtPDuiWF+19Y6PYW12wZWuIbVEkIY7mBYDPJ5PqaiTRfDulXdrdR6ZpdncIWhtpVt443UuSSiHAPzEkkDqc151dar4/h+H2mahb3erz6xPaG6ltv7GQFZURN0Ljy8qGO8hdoZieGAABZqU3iiL4hT3Df2xNbNq1kLe2/soTW32cxEs+/yWKFXLDIYEZ5qmrO3y/G36g/hv8AM9Nbw7ojRXsbaPYGO/O68Q2qYuT6yDHz/jmsHW/hl4d1lrbFrFYR27u4itbO2KuXILHEkTbWOB86bW9642fxD8Q4/D97OY9UFyj2hYR6XvaKZpiLiGJBF+8hWPBEnzc9HPQbGga54pv10x786xFs1Ke3ljbSvKNzF5p8uSTdENqiMAkjyxz1J+QpLVf12/z/AKQS0Owg8H+G7bUEv4dA0xb5H8wXf2OPzt56vvxu3Huc5NbNeba7qnjL/hML230g6kdPaC5hQf2eojjlW3V4nR9pLZcsu4ttyNu0EZPVeBo7qLwFoqajJdyXYs4/ON5F5cofbyrLtXGDxyM8c5PNC1V/T8b/AOQPR2/r+tSK+/5KnoX/AGBdS/8AR9jWrdaDpF9eteXulWNxdPCbdp5bZHdoiclCxGdue3Ssq+/5KnoX/YF1L/0fY10lIDI/4RPw59snu/7A0v7TcMGmn+xR75SGDAs2MkhgDz3ANMm8GeF7n/j48N6RL8hj/eWETfIW3FeV6FiTj1Oa2qKOlgMm18KeHbFVFloOmW4WYXAENnGmJQMCTgfeA79ajl8GeF5lYTeG9IkDTGdg9hEcynq5+X7x9etbVFAGTF4U8OwRpHBoGlxpGFCKlnGAoViygADjBYkehJPeorbwV4Vs/M+yeGdHg82IwSeVYRLvjJyUOF5UnqOlbdFAGf8A8I/o3nWUv9k2Pmaeu2zf7Mm62GMYjOPkH0xSX3h7RdUuludS0iwvJ0ACy3FskjKAdwwSM8Hke9aNFAeRnHw7opS8Q6PYFb47rtfsqYuDjGX4+bjjnNSLoulpqa6kmm2a3yReSt0IFEqx/wBwPjO32zirtFABRRRQBzd9/wAlT0L/ALAupf8Ao+xrV1bQtI16GOHXNKstSijbeiXlukyo2MZAYHB96yr7/kqehf8AYF1L/wBH2NVvEF54gXxnptpYSXFrprw+Z50Fn9oSaYOMwzHafKUpnD5XnucbSdUHS5vyaHpM10LmbS7OS4UqRK1uhcFQQpzjPAYgemT61i618PtB1jQ7fSY7SDTrO3mM0cNpZ27RhiCCfKljeM5yedufeuGn8Q/EOPw/ezmPVBco9oWEel72imaYi4hiQRfvIVjwRJ83PRz0F7SNf8aajcaZBef2pY2/2q6je7bSDvmKTDyVlQxjZG8RPzgKN2ORjBdr6f1/X59Afu/1/X/AO8sfC2i2HkPFptq9xBbC1W6khVpjF/cL4zt/2entUsfhzQ4ZbSWLRtPSSyjMVq62qAwIeqocfKPYYryv/hJPiRsEuox3toDq8UUkFlpklw8UJLiT/l22mPaEIZWc5zludobDq3jm9tbXVrhtetbqPw1dFY00r796smAGjMJwzAKwGBntxkUr3V/62b/4HqFteX+t7f15Hq9h4e0XSppJdL0iwspJU2SPb2yRl1yTtJUDIySce9RQ6N4d0e9tZ7fTdLsboqbW2kSCON9py5jQgA4+820e5rh9e1PxpZaDpc+k3Wq3d5JCt5LGNIXkbog0MnyZUgNIQoVXOPvfLhs7zPFVr4qeWRdVuy/iWTy4J9MEkCW/2YiOQSCElBkqu4MMfNn+Knaz/rul+v5iWqv/AFs3+n5Hpn/CN6H9murf+xdP8i8k825i+yptnfOdzjGGOQOTzWFrHwx8O6vdWkot0sY7XdthtbS3Cnc24kFomaNied8ZRu+cgEcYfEXj9LGzeb+2FDXtot06aRukQsH+0xhBCcxIQm2TBzn771v+Eda8Uan/AMI5caz/AGrC0tu8d7bSaaIVMi78ySFowVz8mAGTnorgna7Wfp/kF/6/rr/W50ceheDtN8RW5i0zQ7XWpjJPARBClzIf+WjqcbyeeWHrzXQ143q7eLb7x1DdNDqiXdo2qQ2jRafmG2BiH2crIYyrb8AkuWG7I46VPb+I/GtxEod9diZ9R09Ax0QgiGSIfaODDwqvuJJ5Ugc4IBmN2l8vxdv+HHL3W/n+H+fQ9YiuYJpZooZo5JIGCyojgmNiAQGHY4IPPYipa8autU8Y6TrF3b28+tTD+2Y4572Dw8M3EH2XDSZWAhgJVADc8YGSMU+z8U+ML/UvDg1HVbvRomtbZ9TjbSXUiQsyurlrd1QsVABZ4gAcjdkENK+3l+KuEvd/r5HsVFFFIDm77/kqehf9gXUv/R9jXSVzd9/yVPQv+wLqX/o+xrpKACiiigArm/iP/wAks8V/9gW8/wDRD10lc38R/wDklniv/sC3n/oh6AOkooooAKKKKACiiigAooooAKKKKACiiigArm7H/kqeu/8AYF03/wBH31dJXN2P/JU9d/7Aum/+j76gBLjwJpt7/wAJGt/PdXMHiIILqB2QLHtTYNm1QRwB1J6Vy998L7qyudHXwwbBYdPDES3FvaxskhYHzPLW0ZWOAB8hiY4+9zkem0ULRphucHc/Cewup3ml17WRI893OShtwA1ymyQDMJ4x09M9TVT/AIUj4eknhmvb7UL+SBYki+2RWsqosaCMLsaDaQVABJBPGQQa9HooWm39WD+vv3OLPwy07/hKxry6rqaSi+jvhbqYBCHSLygMeVu27DjG78c12lFFHSwdbhRRRQAUUUUAc34o/wCRi8Gf9hqT/wBN95Wl4i1uDw14dvtZu4Zp7exhM0sduFLlR1wGIHTnrWb4o/5GLwZ/2GpP/TfeVi/EnwNqXjAodPaxlUafdWixX0jKsMsoG2dNqN8wwV6Dhzg9iio2vqd1bTrdWsU8YIWVA6huoBGaezbVLEE4GcAZNeZP4Bv4/Eia9qtlp1zbRWssF5aWzPNLeQm3RfLw6jfh0bCcLgg4DZz0Hg7w2+geDymnRW6X7QtHbS3FsY28pS32dJQPmO1SM55yT0qnbUiN7K5s6Hr8Gure+VbXFrJY3LWs8dwq5DgA8FWZSCCDweM4ODkVoWt1BfWsdzaSrNBKNySKchh6j2rmdA8KSWGj6vDcW9nYvqxZ5LKzkaW2hdk2sV3Kv3j8xG0D9SeR0L4UatpJ0JRNp0P2CG1R57djvtmidml8keWMicEb8lT67+KEk3Z+X/B+4Htdef8AwDu9d8VJoerabp40bWNSkv5Nhk06082O2GQN8zZAReevP3T6VvVxev8AgY6549stcaOKL7LAiRX0N9cRXEJWQsUEany3Rhwc4I77hwO0pL4fMb30CiiigAooooA5u+/5KnoX/YF1L/0fY10lc3ff8lT0L/sC6l/6Psa6SgAooooAKKKKACiiigAooooAKKKKACiiigDm77/kqehf9gXUv/R9jXSVzd9/yVPQv+wLqX/o+xrmPiR8PtZ8V6417o8elANo8tiJbqd45FkaRXR/libhNmRznJ4x1o6jR6XVa0vftc11H9muIPs03lbpo9ol+VW3Ie6/NjPqD6V5HP8ACbXrnQ9Q09bfQrNZLiW5sViuZWW0cxxBSg8pVU7o2JYLuG84PLbrF98MdduZ5JFstBKtr76oI3upAGjaDymU/uPvM3zHgg+p609vu/y/4P3C3/r1/PQ9XN3AL0Wnmr9oMZlEeedoIGfpk1NXj8Hwn8QHTx595p0WpHw9FpX2yJ2d45I5Cchmj5V0O0nqPRqpXnwh8SL9mbTBpRkhsY4Uku74l4ZFuhONpjtVGxQCqgKuAcAYFOyva/8AWv8AkvvFra/9dP8AN/ce20V5Vq/wy1rUL/X7qBdIjOsadd2joZpMSO7q0MkhKEsVAb128BcDgV7P4YeIBbPb6jHo81idQjum0sXcpgmT7OIXDN5IKsGHmKQD83ofmpLVa/1rb/gjem39af0j12iuE8MeBdS0T4gaprl7qLXMF0rLCFnH3DtxG6eVuOzbhWMp6n5Rk57ul0TDqwooooAKoXOhaReapBqd3pVlPf24xDdy26NLF/uuRkfgav0UAFFFFAHN33/JU9C/7Aupf+j7Gukrm77/AJKnoX/YF1L/ANH2NdJQAUUUUAFc38R/+SWeK/8AsC3n/oh66Sub+I//ACSzxX/2Bbz/ANEPQB0lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc3Y/8lT13/sC6b/6Pvq6Subsf+Sp67/2BdN/9H31AHSUUUUAFFFFABRRRQAUUUUAFFFFAHN+KP8AkYvBn/Yak/8ATfeV0lc34o/5GLwZ/wBhqT/033ldJQAUUUUAFFFFABRRRQAUUUUAFFFFAHN33/JU9C/7Aupf+j7Gukrm77/kqehf9gXUv/R9jXSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc3ff8lT0L/sC6l/6Psa6Subvv8Akqehf9gXUv8A0fY10lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzd9/wAlT0L/ALAupf8Ao+xrpK5u+/5KnoX/AGBdS/8AR9jXSUAFFFFABXN/Ef8A5JZ4r/7At5/6Ieukrm/iP/ySzxX/ANgW8/8ARD0AdJRXN/bvG/8A0L3h/wD8H0//AMh0fbvG/wD0L3h//wAH0/8A8h0AdJRXJrrvix9QksU0jwy15FGJJLceIpTIiEkBiv2TIBIOD7VY+3eN/wDoXvD/AP4Pp/8A5DoA6Siub+3eN/8AoXvD/wD4Pp//AJDqpL4j8TwXj2k2m+Fo7lIhM8L+JJQ6xk7Q5X7JkLnjPTNAHX0VzDap4zSVI30Lw6ryZ2KfEEwLYGTgfY+eKf8AbvG//QveH/8AwfT/APyHQB0lFc39u8b/APQveH//AAfT/wDyHR9u8b/9C94f/wDB9P8A/IdAHSUVyU+v+KrWO5kutK8Lwpap5lw0niOVRCuCdzE2nyjAPJ9KeNZ8XmOCQaL4aKXGBCw8QzYlyMjafsnPAJ47UAdVXN2P/JU9d/7Aum/+j76j7d43/wChe8P/APg+n/8AkOufs7zxj/wsnWWXQtDNwdJsA8Z1qYIq+debSG+y5JJLZGBjA5OSAAeiUVzf27xv/wBC94f/APB9P/8AIdH27xv/ANC94f8A/B9P/wDIdAHSUVzf27xv/wBC94f/APB9P/8AIdH27xv/ANC94f8A/B9P/wDIdAHSUVzf27xv/wBC94f/APB9P/8AIdH27xv/ANC94f8A/B9P/wDIdAHSUVzf27xv/wBC94f/APB9P/8AIdH27xv/ANC94f8A/B9P/wDIdAHSUVzf27xv/wBC94f/APB9P/8AIdH27xv/ANC94f8A/B9P/wDIdAB4o/5GLwZ/2GpP/TfeV0led+I7zxide8JmfQtDR11aQwqmtTMHb7DdcMTajaNu45APIAxzkdB9u8b/APQveH//AAfT/wDyHQB0lFc39u8b/wDQveH/APwfT/8AyHR9u8b/APQveH//AAfT/wDyHQB0lFc39u8b/wDQveH/APwfT/8AyHR9u8b/APQveH//AAfT/wDyHQB0lFc39u8b/wDQveH/APwfT/8AyHR9u8b/APQveH//AAfT/wDyHQB0lFc39u8b/wDQveH/APwfT/8AyHR9u8b/APQveH//AAfT/wDyHQB0lFc39u8b/wDQveH/APwfT/8AyHR9u8b/APQveH//AAfT/wDyHQAX3/JU9C/7Aupf+j7Gukrzu8vPGP8AwsnRmbQtDFwNJvwkY1qYoy+dZ7iW+y5BBC4GDnJ5GADuHVPGQnWA6F4cErKXWM+IJtxUEAkD7H0GRz7igDqKK5v7d43/AOhe8P8A/g+n/wDkOj7d43/6F7w//wCD6f8A+Q6AOkorm/t3jf8A6F7w/wD+D6f/AOQ6Pt3jf/oXvD//AIPp/wD5DoA6Siub+3eN/wDoXvD/AP4Pp/8A5Do+3eN/+he8P/8Ag+n/APkOgDpKK5v7d43/AOhe8P8A/g+n/wDkOj7d43/6F7w//wCD6f8A+Q6AOkorm/t3jf8A6F7w/wD+D6f/AOQ6Pt3jf/oXvD//AIPp/wD5DoA6Siub+3eN/wDoXvD/AP4Pp/8A5Do+3eN/+he8P/8Ag+n/APkOgAvv+Sp6F/2BdS/9H2NdJXnd5eeMf+Fk6MzaFoYuBpN+EjGtTFGXzrPcS32XIIIXAwc5PIwAeg+3eN/+he8P/wDg+n/+Q6AOkorm/t3jf/oXvD//AIPp/wD5Do+3eN/+he8P/wDg+n/+Q6AOkorm/t3jf/oXvD//AIPp/wD5Do+3eN/+he8P/wDg+n/+Q6AOkorm/t3jf/oXvD//AIPp/wD5Do+3eN/+he8P/wDg+n/+Q6AOkorm/t3jf/oXvD//AIPp/wD5Do+3eN/+he8P/wDg+n/+Q6AOkorm/t3jf/oXvD//AIPp/wD5Do+3eN/+he8P/wDg+n/+Q6AOkorm/t3jf/oXvD//AIPp/wD5Do+3eN/+he8P/wDg+n/+Q6AOkorm/t3jf/oXvD//AIPp/wD5Do+3eN/+he8P/wDg+n/+Q6AC+/5KnoX/AGBdS/8AR9jXSVxNtPrk3xT0j+3tO0+yxouoeV9iv3ud/wC/ss7t0Me3HGMZzk9Mc9tQAUUUUAFc38R/+SWeK/8AsC3n/oh66Sub+I//ACSzxX/2Bbz/ANEPQBP4zutZsvCV5P4ahM2oqF8tQMkLuAcgbWyQu4j5W5H3W6Hzy28S+NYJIpL+51mby47eTyrfQpnjmzcssisxtEfIh2lsKvIyABwfYKKFox30seQrrHig6mbyaLXY7qW2SO8dNHLfYR5371bf90Vl2qQVyHLckbsbRsWOreKpZ9OTVLjU7SI5aGaLSPNN4omcYuFCfuGaIIR/qwGY56bK9GooWit/X9f07ierb7/1/X4WPKrLXfFlzd20L3HiG3gudSjVZJtIDSR27wvnzCLZUQrIF5wQMglmU1T1DV/EsGsG/kXxAL6KGSIrDojSxwn7TD+7jZYSHVo1J3cnrgg/KPYaKadmn/W1hNXVv63ueU6dd+JNP1ueE6l4gZLu51AET6MZYYMEGCQMkAPKkcFiOMY4xXf+GLq5vNAhlvfthl3Mu+9h8qWQBiAxTYmMj1RT7Vr0UlorDeruFFFFAHkt9Fftp1lLHPqXmx3epDU4rC188vKVk2CRRGzAFcKvT5WXHVabo2veI7JtIsUk15reOSGOXz/D8oVI2tGypIgB2pMqcg55IJI6esLBEk0kyRIssgAdwoDPjpk98ZNSULS/y/AXW/r+P9feYXhK7vbrSpRqL300sM7Rie9t/IaYAD5lTy0IXORyo6HBIwTBY/8AJU9d/wCwLpv/AKPvq6Subsf+Sp67/wBgXTf/AEffU2M0vEc+p23hnUZtBhWfUo7d2tY26NJjgV5mfE3jS38MfaNRuL+3EcN1Ml3Fpju7PGqtHFOJLWLYh/eZcRqDhQHB6+vVBe2NpqVlLZ6jaw3drMNskE8YdHHoVPBpLR3GrXVzze51/wAUafrcsU7a/dWq3UzD7JpSSBoGtA8e1xDtJWUMoyfZs5FZTXvjpriG9hk1ma6trW9jhjlsQscx3xNH5h+zLhjGWIIVfmj2gE7g3sFvbw2ltFb2kMcEEKBI4olCqigYAAHAAHapKbet12t+l/UlXPO9B1jxO9vo8mrT6hM8lwYnhh06RTIhfh5nktYgu1Qc4WIHtkkCvRKZFKs0QkQOAc8OhQ9cdCAafQAV554sfxFZeMbq70mfVTbnToFCW1msyIPPInZP3ZzKqEMFJy391sYrvzcRi3adW3xqCSYwXzjrgDJJ9hUWnahbatpltqFhIZLa5jWWJyhUspGQcMAR9CM0ut+xXSxmeELnU7rQt+rtPI4nkWCa5t/ImmhDfI8ke1djEdRtX1wM4G5RRTEc34o/5GLwZ/2GpP8A033ldJXN+KP+Ri8Gf9hqT/033ldJSAKKKKACiiigAooooAKKKKACiiigDm77/kqehf8AYF1L/wBH2NYXjzWtf03V5YtEl1hYzpvmILPSTdIs4mQD5hC3JQuCpPQAjB5rdvv+Sp6F/wBgXUv/AEfY10JlUTrCQ+5lLAhDtwCBy2MA89M5PPoaOqB6qx41rGp+LGuJb2w1DxQJLG2vorZ00I/6RIHiaIOhtuQwJG4AcJwQd2eivbzxRN4ot9P03Uddit5oikt1Np0flxu8TSRun+jYGGAQ7344BXJ3V6IZEEixl1DsCVUnkgdTj8R+dOp/ZUQ63PKda1jx8ml6ZeaT9vh+1KVnS6s9zW8qKqgMkVtI5R38wk7QCAu10BGR/Eni+G9vltTrV5K091FBBLojLEiqFZHWTyVBIO8LubDYAOTzXq1FF9Q6JdjyubV/GEVk09vd69PaM9zBazNo6Lcy/uA0byReQChEoZQSqqRjIOQT0Ghavrd1cXG/+0LmSSw8+JLqwa1hikwAIyXiVixOSfmbHOQvyg9pVQ6paDWRpRdxeNAbhUMTbSgYKSHxtJBI4znkcc0t/wCvL+n8g21/rp/XzPNbfW/GD/ZQ11rohlurVJpZdEAkid94nj2iHHlJ8hEnTP8AG4zXqaKUjVWdnKgAu2Mt7nGB+VOoptitqFFFFIYUUUUAc3ff8lT0L/sC6l/6Psa6Subvv+Sp6F/2BdS/9H2NdJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc3ff8lT0L/sC6l/6Psa6Subvv8Akqehf9gXUv8A0fY10lABRRRQAVzfxH/5JZ4r/wCwLef+iHrpK5v4j/8AJLPFf/YFvP8A0Q9AHSUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzdj/yVPXf+wLpv/o++rpK5ux/5Knrv/YF03/0ffUAcX44Gt6fda/q873+laSllMizjWGRGlHlmGRf3/7vJDLtVFyTzuDVnXR1P+37azS51oPq8NzJpunDxCBNGu2EpIzeftZd/muAC52EjBA2j1P+17oeIr3TPsKOsFmlzA6T/NMSWUoVKgLyvB3HOe1QaV4jeaDVD4gtoNJk0qTbcv8AavMgCFA4cSMqcbW5yBgg9RySO3y/r53K1v8A18jj10PxZ5eovdJrM4GpKzQxar5bXVsYVEnkETDysyqWAJQheBtyRUMGi+Lbe/sZr21169iRoxdRRayE3jc+wg+euDGuwSADErEHnBJ7+DxNoN1cRwW2t6dNNI5jSOO7jZnYLuKgA8kKQcehzVN/GWkXccsXh3UtN1i/SRYvssF8hKsTj5yu4qAAxPB+6eKGyUedjTfHSQ2x/srxR5qW1smRrUBAkSdjIzZufmJhIHfJxnkAi/p+l+MW1ezWbTdat7S1vZB50+seYZrV5HAVlFzjKqyHcyu3BAIIGey0nxtpN74Zt9W1S+sNLZraO4uIZrxMWwkyF3M23gkEAkDODSah410y0t9K1C2vNOutHvrh4JNRW+URQ7Y3bcGAKsMxkH5hj3p2s7Mbu01/Wi/pnBaL4Y8b6PeaEsY1RLCzhQSwLdC4JdWbzQ2+7Rdrjbtysm3sEOc6WjaPqG7QNMNzd2N19gjh1fTf7UYPapGQUlRYpCq7zGUyCCQ/qCK9AXXtHe9t7NNVsWurqPzreAXKF5k/vKucsvuOKx7Tx3o82sX9rcajpcNrbvDFBdrqCMs8km8eXyAFcNGw2gsT7dKab/r7v1E3e509FQWl7a38byWNzDcokjRO0MgcK6nDKSOhB4I7VPUgc34o/wCRi8Gf9hqT/wBN95XSVzfij/kYvBn/AGGpP/TfeV0lABRRRQAUUUUAFFFFABRRRQAUUUUAc3ff8lT0L/sC6l/6PsawvHlj4ludXlOgWWszQyab5YksdSSBFnEyMpCtMmCFD5OOQQDnoN2+/wCSp6F/2BdS/wDR9jVnxP4lg8N2McjPaPczSKsVtPdCFphuAbZwSxAOcAfiOtHVMHs1/Xc801jwx4qvJJ7m10rxIk0FvfQWDDXVWVGd42hYsLn5l4fhiegBGAtbesaR4nOtCTTLDWhaC0kjk26yS05eByMBrkLGyy4GVXupDhQRXZ/8Jf4a3Ov/AAkOlbo5xbOPtseVmOcRn5uHOD8vXg1o2l7a38byWNzDcokjRO0MgcK6nDKSOhB4I7Ubx5f6/rUNnf8Ar+tDyL+x/G9xa+V/Z3imGRmt18yTW4gBmIpcOdlznBO0gDoeVAOa1bXT/FrWF0bzTtfWbNtLDENVjIkkWHY4LC4BVd43EA4PBw2Sten0U77+ZKilbyPNp9F8TyW+ozmLXBqkdwkyGHV1FrdIs4cLEnmAofKyhVlRWOd27hqp21h4tjeX7T4d1i5KQ30Ucj6tErlJblXiVZRceYCI1x1XoBkDkeq0UX/r8Culvn9x514H0nxPB4hP/CSw6wtvbWuyOabUQ8M0iyyYbyxPI3MboPnzkr8xJANZ+r6J43lh1n7Kmrm7kjuQJYdVVIrgs+bbyFMo8koMbuEyAQd+a9VoouNafh+B5jYab4nfWWS+sPEsWlpdF7Qpq8JliPyHdJ+/PmRkhxsbdjPC9Nuh4N03xdYanrUniOW5uRIjeSjOBDI25ipjf7Q5TKkAgRxDjOM8nvqKXQlKxyPgCz1yxs9QTXoLuBZLhZbWK7uzctEhjXcm9pZGOHDclsHPAHQddRRTbuM5u+/5KnoX/YF1L/0fY10lc3ff8lT0L/sC6l/6Psa6SkAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc3ff8lT0L/sC6l/6Psa6Subvv+Sp6F/2BdS/9H2NdJQAUUUUAFc38R/+SWeK/wDsC3n/AKIeukrm/iP/AMks8V/9gW8/9EPQB0lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc3Y/8lT13/sC6b/6Pvq6Subsf+Sp67/2BdN/9H31AFqTR9R/4Sq41a31C1SGSxFskD2bMyuGLBy/mAEZY/LtH1qtZaDrMXh/UrHUNWsbi6vEdVuYdOeJQzKQXdTMxc9OjKMAAYrD1T4j3+k69caddaJaYhneLeNRbJQxb4ZCPJwA7fu+vDdN1VJPide3NrrKP4ZuBHp8UolmSe4jjLxuElQT+QFB5YoVYk7eQhoUeZW7/APDjd4vmf9dP0Fh+G+uWsaMNd0uUwtaMscWjNGWW3Uqqgm4IBYHqQR7VJ8P/AAvrWnxSy6rbJZSImIRcRFn8wIVB4upgY1BYBVMYGThVpPE/i3WbuLxDpdjo0kNla2NyzatFeTRtEyR5UqViCFt3GFl3DB3AdCtp4p13WNfsvDsllFZIY5VurmLUGMoCxQujofK+9++GVPGQRkjq7uSfnr/X3C5EkrdP0/4cz5fh/wCIPD3g06Zpt9/a4M0MgitrYwvG65DSKWukIyAnCyIQQSDglT08PhnUZ/COjWyzWmm6jpkomh/0UyQrhXQBo/NJPyOc4lPzc7j3pXvj+50jwbo18+my6lqOoSG3WKKOXDugYs2Io5GAIQkYU9Rkgch83xAvLW3vZrvRI4PstvHe+Q906ztbGN3ZzGYhtdShXZnGerDjJ3BXbXd/qV0+FkcUf2OLVmXTpZIriePyP3xmjXAaOUMBGpxyu09wCATS/wDCFanY6bqEM90mq/bbSCyiSzs0tXtzEW8uYs0pHy7gTgZyuVH8NLo3xC1jWr20tIfC/wBnlullZGu557dGCeWdy+ZbqzKRLjO37ykcj5q2vDHia88QyzxXGmw2htAYrsR3bSGG4DsDEMxrn5QG3ccOvGDmizSt/X9dP6QaaSf9f1/XU2tNshp2mwWgcyGJAGkbrI3VmPuTk/jVquDs7Rr3wDNDJqOrebDe3sNqYb+UTu63EixKZN25sYHDNjA+bIFdppwnGmWou5VmuBEolkT7rvj5iPbOaHuwty6f1oYfij/kYvBn/Yak/wDTfeV0lc34o/5GLwZ/2GpP/TfeV0lIAooooAKKKKACiiigAooooAKKKKAObvv+Sp6F/wBgXUv/AEfY1W8UeDbzXb+W60/VorI3FtHbzJcWf2hcRyGRCvzrtO489cjHQgGrN9/yVPQv+wLqX/o+xrpKA6WOCufBepRLq9xe302tXWqwpbAwRiFrcrI7RygvKVUJv52DnaCFJyD2em2Q07TYLQOZDEgDSN1kbqzH3Jyfxq1RR0sD1dwooooAKKKKACiiigAooooAKKKKAObvv+Sp6F/2BdS/9H2NdJXN33/JU9C/7Aupf+j7GukoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAObvv8Akqehf9gXUv8A0fY10lc3ff8AJU9C/wCwLqX/AKPsa6SgAooooAK5v4j/APJLPFf/AGBbz/0Q9dJXN/Ef/klniv8A7At5/wCiHoA6SiiigAooooAKKKKACiiigAooooAKKKKACubsf+Sp67/2BdN/9H31dJXN2P8AyVPXf+wLpv8A6PvqANi40fTLq4ee6060mmfy90kkCszeW25MkjJ2sSR6HkVVu/Cfh2/uLme+0DS7ma7ULcSTWUbtMAQQHJGWAIHX0Feaf8JvH4U8UeJYtLm0q5WfVbjGnRsBcSTLZxvldrc5dSpGwkseueDfPxG1dIoZhqOhXFi1y9t/asNtJ9nlc27SR7f33BWRQjLuO4sACp4o+yn5X+8evNb+tDo4Phj4dj1251O5tYbz7QCDb3FlbFFUrt27hEJGXHG1nZQMccDGkPBXhyEM2naLYadcH7tzZWkUUqcbcqwXIO0lc9QCcVw+h/EvVdY8OXWrNqvhuKG1njSRsEAK0CSkczgFgS6YyOhP8JU3Piffx3Fj4Ytp7mxNpqV2fOsbyE5vF8h2VApdSDu2gdSHZD1GC5Jx0YoWk7rzf3Hcz6BpF3o0ek3mmWl1p0SqqWtxCskYC/d+VgRxUyaZYRSRyR2Nsjxw/Z0ZYVBWLj5AccLwOOnFeY2PxH1EQWUEN/oLRSXFpbrPskCRtKHDWzbpcmaPapJJyQeVUnNdD40Fk2raEJJ9Nn1iG5hkS0fi5lXeAzQfMTGBkliAcqCpIHNNp3172/r5MSenyub9p4R8O6dcR3Gm6DpllcQ7zFPb2USPEWGGKkLwT39e9XNN05dNtTF50tzK7b5riYKHmfAG5tqqucADgAYA4rj/ABt4k1jQPFVkbG4t2tf7MupzZyQszTyI0fQhx90MWwFJ2q/HIIuaD4gbxB4Y1d9T1WyW1gd4F1vTiIoJUMakyxl2cKVLFT8zDKn6CdeW6/rW35j0vZmq/gnwrLYiyk8M6O9qJTMIGsIjH5hGC+3bjcRxnrWvBBDa28dvbRJDDEoSOONQqooGAABwAB2rnPANrb2Xh17ewishZx3Di3ubK2SCO7TAIl2oApJ6Fhw23I4OK6em9BbnN+KP+Ri8Gf8AYak/9N95XSVzfij/AJGLwZ/2GpP/AE33ldJSGFFFFABRRRQAUUUUAFFFFABRRRQBzd9/yVPQv+wLqX/o+xrpK5u+/wCSp6F/2BdS/wDR9jXSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc3ff8AJU9C/wCwLqX/AKPsa6Subvv+Sp6F/wBgXUv/AEfY10lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzd9/yVPQv+wLqX/o+xrpK5u+/5KnoX/YF1L/0fY10lABRRRQAVzfxH/wCSWeK/+wLef+iHrpK5v4j/APJLPFf/AGBbz/0Q9AHSUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzdj/wAlT13/ALAum/8Ao++rpK5ux/5Knrv/AGBdN/8AR99QB0lVNM1S01e0NzYO7xLK8R3xNGQ6MVYFWAPBBHSuE1Sw8ZSeIdXmsLe+Wymj2LGt+B5oWSM5iJl/dM0XmKMJHhuSTwwxF0PxdawFbTR/EUWxrmRFh1iH5ma7EkZbNwAx8suCWBz0O7imtUvMb0T9T14yqJxDh9xUsDsO3AIH3sYzz0zn8qDKonEOH3FSwOw7cAgfexjPPTOfyryk6d4wFveRJpPibCxyrAx1qIsw+1h4sE3OciIkEnqBtJPAqfTNO8WyQ3MN/p/iO2ja2nRGbVIpHI+074VyLnO/yiVLhlOON/ANH9fmJ7v1S/ryPUBIhkZA6l1ALKDyAenH4Gh5ETbvdV3HauTjJ9BXlyeG9eXxZZXbaZrqLctbm9mt9cPkoggdHRlNwCzB9hyFY8EhiepbeHfE11NaTazY6s0cGqx3awJqpDxKYZFcB/tHzAOVOMqNpwEHK0B/l/n/AJfieoRSrNEsiBwrdA6FD+IIBFPry210nxi9rZfarXW0mjt0TP8AayYVFDCSOQCf55X4KyZJBIJZMHMelad4yGiSw3mm+IFuIpbaWJbjVo285xEElDSJc7lTeN2Mkc52NytCV7/1/X9eoj1aigdBnrRSGc34o/5GLwZ/2GpP/TfeV0lc34o/5GLwZ/2GpP8A033ldJQAUUUUAFFFFABRRRQAUUUUAFFFFAHN33/JU9C/7Aupf+j7Gukrm77/AJKnoX/YF1L/ANH2NdJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzd9/wAlT0L/ALAupf8Ao+xrpK5u+/5KnoX/AGBdS/8AR9jXSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN33/JU9C/7Aupf+j7Gukrm77/kqehf9gXUv/R9jXSUAFFFFABXN/Ef/AJJZ4r/7At5/6Ieukrm/iP8A8ks8V/8AYFvP/RD0AdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAdJXN2P/ACVPXf8AsC6b/wCj76j/AIWP4I/6HLw//wCDSD/4qufs/H3g9fiTrN03izQxbyaTYRpKdSh2MyzXhZQd2CQHUkdtw9RQB6JRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAHij/kYvBn/Yak/9N95XSV534j8feD59e8JyQeLNDkS31aSSZk1KEiNfsN0u5iG4G5lGT3YDvXQf8LH8Ef8AQ5eH/wDwaQf/ABVAHSUVzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVQB0lFc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFUAdJRXN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVAHSUVzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVQB0lFc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFUAF9/yVPQv+wLqX/o+xrpK87vPH3g9viTo10vizQzbx6TfxvKNSh2KzTWZVSd2ASEYgd9p9DXQf8LH8Ef8AQ5eH/wDwaQf/ABVAHSUVzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVQB0lFc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFUAdJRXN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVAHSUVzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVQB0lFc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFUAdJRXN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVABff8lT0L/sC6l/6Psa6SvO7zx94Pb4k6NdL4s0M28ek38byjUodis01mVUndgEhGIHfafQ10H/Cx/BH/AEOXh/8A8GkH/wAVQB0lFc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFUAdJRXN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVAHSUVzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVQB0lFc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFUAdJRXN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVAHSUVzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVQB0lFc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFUAF9/yVPQv+wLqX/o+xrpK4m28R6H4g+Kekf2DrOn6n5Gi6h5v2K6Sby909ljdtJxnBxn0NdtQAUUUUAFFFFAFHW9PbVtBv9OSUQtd27wCQruCblIzjIz1rlvEt1caB4t03WTezpYQWpTUoDM/kmIuqiXyydqlGYEsADt3ZJwK7eqM2h6Tc6idQuNMs5b0wmA3MlujSGM9U3EZ289OlC0af9bA9Vb+un+R5v/wmd/4f1bWr24tr7Vby+1CKCzsfMnaOCP7MsoURxpIVOM5Kx5LHkgcjoT48vJNWjsrTRBO09oZok8+RZY5QiMYZlMO2NsOOAzNgZ21uzeD/AA1cG7M/h3SZTeuHut9jGftDA5DPlfmIJJyc05vCvh5pvNbQdMMmFG82cecKu0c47LwPQcUdP67A97nMXXxGu7aVo10mzmK/ZRlNQYDM1w1uwOYQQUdemOeehGKrxfFG9f8AscHwzNI+pQpcmO0ea4aOFmClvkgIyGJOGKjaM7snaOtn8I+G7m3gt7nw/pU0NvH5UMcllGyxJkHaoK4AyAcDjIFOPhTw6bW0tToGlm3smL2sX2OPZbsTklBjCnPORinp+P4A9tDm9E12fX/HaTBXt7G4024EUaX7v5gSdEDtFgCJ8lxxk4IycjAz9J8Zaxpfh9LcaUmpG3s3ukml1N3kkhjlKOXJjZg4GCBltwB5BGK7mDw7oltqjalbaPYQ37Fma6jtUWUlgAxLgZ5AGeecCmSeHrFYroaZGmlTXkgkubixgiSSY553Eoc5HBJGcHgg80ui/rv/AJitq3/XT/I5XxdqN3rfw4l1Gz32xa+h+wyWepzQfaIjOiKzSRhWVXVjwNwAIPJxjI1PRNUsZtHg8jxBNd3Iuy9nY+JrhxEV2+W3myypvUcE7gT8x+XHy16Le6Bo+p6ZFp2p6XZ3tlDt8u3ubdZY12jAwrAjgcU6TQ9Jmv7W+l0uye7s12W1w1uhkgXphGxlR7Ciy6Du7K5w2mTXvh+PxLPqV9fXeoRRWsWBNPcoJ5IhuMUOWxl2J2ouccAdq3/AGpfbfD8tq899cS6fcyW5k1CKWOd0zujZ1lUPkoy8kc4NX28HeGW1Br9vDukteNMJ2uDYxeYZQchy23O4Ek561dt9H0201K51C0060gvbvH2i5igVZJsdN7AZbHvTv3/r+tRW0si5VGLSoIdfu9XVpDcXVrBaupI2BYmlZSBjOczNnnsOnOb1FIYUUUUAFFFFABRRRQAUUUUAFFFFAFG/0qDUb3TLqdpFfTbprqEIQAzGGSHDZHI2yseMcgfQ3qKKACiiigAooooAKKKKACiiigAooooAoy6VBNr9pq7NILi1tZ7VFBGwrK0TMSMZzmFcc9z14xeoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCjLpUE2v2mrs0guLW1ntUUEbCsrRMxIxnOYVxz3PXjF6iigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//2Q==" alt="" width="568" height="793" vspace="0" hspace="0" border="0" style="width:568px;height:793px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><strong>To report any side effect(s):<br />&bull; Saudi Arabia:</strong><br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Sanofi- Pharmacovigilance: KSA_Pharmacovigilance@sanofi.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdosage would cause severe hypotension, bradycardia or asystole.. The half life of adenosine in blood is very short, and side effects (when they occur) would quickly resolve. Administration of IV aminophylline or theophylline may be needed. Pharmacokinetic evaluation indicates that methyl xanthines are competitive antagonists to adenosine, and that therapeutic concentrations of theophylline block its exogenous effects.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other Cardiac Preparations: ATC Code: C01EB 10<br />Endogenous nucleoside with peripheral vasodilator/antiarrhythmic effect<br />Antiarrhythmic drug.</p><p>Adenosine is a purine nucleoside which is present in all cells of the body. Animal pharmacology studies have in several species shown that Adenosine has a negative dromotropic effect on the atrioventricular (AV) node.<br />In man Adenocor (Adenosine) administered by rapid intravenous injection slows conduction through the AV node. This action can interrupt re-entry circuits involving the AV node and restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardias. Once the circuit has been interrupted, the tachycardia stops and normal sinus rhythm is re-established.<br />One acute interruption of the circuit is usually sufficient to arrest the tachycardia.<br />Since atrial fibrillation and atrial flutter do not involve the AV node as part of a re-entry circuit, Adenosine will not terminate these arrhythmias.<br />By transiently slowing AV conduction, atrial activity is easier to evaluate from ECG recordings and therefore the use of Adenosine can aid the diagnosis of broad or narrow complex tachycardias.<br />Adenosine may be useful during electrophysiological studies to determine the site of AV block or to determine in some cases of pre-excitation, whether conduction is occurring by an accessory pathway or via the AV node. Paediatric population<br />No controlled studies have been conducted in paediatric patients with adenosine for the conversion of paroxysmal supraventricular tachycardia (PSVT). However, the safety and efficacy of adenosine in children aged 0 to 18 years with PSVT is considered established based on extensive clinical use and literature data (open label studies, case reports, clinical guidelines).<br />Literature review identified 14 studies where IV adenosine was used for acute termination of supraventricular tachycardia (SVT) in around a total of 450 paediatric patients aged 6 hours to 18 years. Studies were heterogenic in terms of age, and dosing schedules. SVT was terminated in 72 to 100% of cases in most of the published studies. Dosages used varied from 37.5 mcg/kg to 400 mcg/kg. Several studies discussed a lack of response to starting doses less than 100mcg/kg.<br />Depending on the child&#39;s clinical history, symptoms and ECG diagnosis, adenosine has been used in clinical practice under expert supervision in children with stable wide-QRS complex tachycardia and Wolff-Parkinson-White syndrome however the currently available data does not support a paediatric indication. In total 6 cases of adenosine-induced arrhythmias (3 atrial fibrillation, 2 atrial flutter, 1 ventricular fibrillation) have been described in 6 children aged 0 to 16 years with manifest or concealed WPW syndrome, of which 3 spontaneously recovered and 3 needed amiodarone +/- cardioversion (see also section 4.4).<br />Adenosine has been used as an aid to diagnosis of broad or narrow complex supraventricular tachycardias in same doses as for treatment of supraventricular tachycardia. Although adenosine will not convert atrial flutter, atrial fibrillation or ventricular tachycardia to sinus rhythm, the slowing of AV conduction helps diagnosis of atrial activity. However, the currently available data does not support a paediatric indication for the use of adenosine for diagnostic purposes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adenosine is impossible to study via classical ADME protocols. It is present in various forms in all cells of the body where it plays an important role in energy production and utilisation systems. An efficient salvage and recycling system exists in the body, primarily in the erythrocytes and blood vessel endothelial cells. The half life in vitro is estimated to be &lt;10 seconds. The in vivo half life may be even shorter.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium Chloride<br />Water for Injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Compatibility with other medicines is not known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
Any portion of the vial not used at once should be discarded.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C. Do not refrigerate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clear, type I glass vials with chlorobutyl rubber closures secured with aluminium caps. Packs of 6 vials in plastic trays in cardboard cartons.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aventis Pharma Limited
One Onslow Street
Guildford
Surrey
GU1 4YS
UK
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                14 November 2013
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>